Loading...
Header Logo
Keywords
Last Name
Institution

ROBERT COLEMAN

TitleProfessor
InstitutionMD Anderson
DepartmentGynecological Oncology & Reproductive Medicine
vCardDownload vCard

    Collapse ORNG Applications 
    Collapse Verify Publications

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Roh JW, Choi JE, Han HD, Hu W, Matsuo K, Nishimura M, Lee JS, Kwon SY, Cho CH, Kim J, Coleman RL, Lopez-Bernstein G, Sood AK. Clinical and biological significance of EZH2 expression in endometrial cancer. Cancer Biol Ther. 2019 Oct 22; 1-10. PMID: 31640461.
      View in: PubMed
    2. Soliman PT, Westin SN, Iglesias DA, Fellman BM, Ying Y, Zhang Q, Yates MS, Broaddus RR, Slomovitz BM, Lu KH, Coleman RL. Everolimus, letrozole, and metformin in women with advanced or recurrent endometrioid endometrial cancer: A multi-center, single arm, phase II study. Clin Cancer Res. 2019 Oct 18. PMID: 31628143.
      View in: PubMed
    3. Westin SN, Sill MW, Coleman RL, Waggoner S, Moore KN, Mathews CA, Martin LP, Modesitt SC, Lee S, Ju Z, Mills GB, Schilder RJ, Fracasso PM, Birrer MJ, Aghajanian C. Safety lead-in of the MEK inhibitor trametinib in combination with GSK2141795, an AKT inhibitor, in patients with recurrent endometrial cancer: An NRG Oncology/GOG study. Gynecol Oncol. 2019 Oct 15. PMID: 31623857.
      View in: PubMed
    4. Obermair A, Asher R, Pareja R, Frumovitz M, Lopez A, Moretti-Marques R, Rendon G, Ribeiro R, Tsunoda A, Behan V, Buda A, Bernadini MQ, Zhao H, Vieira M, Walker J, Spirtos NM, Yao S, Chetty N, Zhu T, Isla D, Tamura M, Nicklin J, Robledo KP, Gebski V, Coleman RL, Salvo G, Ramirez PT. Incidence of adverse events in minimally invasive versus open radical hysterectomy in early cervical cancer: Results of a randomized controlled trial. Am J Obstet Gynecol. 2019 Oct 03. PMID: 31586602.
      View in: PubMed
    5. Coleman RL, Fleming GF, Brady MF, Swisher EM, Steffensen KD, Friedlander M, Okamoto A, Moore KN, Efrat Ben-Baruch N, Werner TL, Cloven NG, Oaknin A, DiSilvestro PA, Morgan MA, Nam JH, Leath CA, Nicum S, Hagemann AR, Littell RD, Cella D, Baron-Hay S, Garcia-Donas J, Mizuno M, Bell-McGuinn K, Sullivan DM, Bach BA, Bhattacharya S, Ratajczak CK, Ansell PJ, Dinh MH, Aghajanian C, Bookman MA. Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer. N Engl J Med. 2019 Sep 28. PMID: 31562800.
      View in: PubMed
    6. Danson S, Mulvey MR, Turner L, Horsman J, Escott K, Coleman RE, Ahmedzai SH, Bennett MI, Andrew D. An exploratory randomized-controlled trial of the efficacy of the Src-kinase inhibitor saracatinib as a novel analgesic for cancer-induced bone pain. J Bone Oncol. 2019 Dec; 19:100261. PMID: 31667062.
      View in: PubMed
    7. Webber K, Carolus E, Mileshkin L, Sommeijer D, McAlpine J, Bladgen S, Coleman RL, Herzog TJ, Sehouli J, Nasser S, Inci G, Friedlander M. OVQUEST - Life after the diagnosis and treatment of ovarian cancer - An international survey of symptoms and concerns in ovarian cancer survivors. Gynecol Oncol. 2019 10; 155(1):126-134. PMID: 31416612.
      View in: PubMed
    8. Lheureux S, Mirza M, Coleman R. The DNA Repair Pathway as a Target for Novel Drugs in Gynecologic Cancers. J Clin Oncol. 2019 Sep 20; 37(27):2449-2459. PMID: 31403862.
      View in: PubMed
    9. Vergote I, Coleman RL, Pignata S, Bookman MA, Marth C, Herzog TJ, Gonzalez-Martin A, Copeland LJ. Joint ENGOT and GOG Foundation requirements for trials with industry partners. Gynecol Oncol. 2019 08; 154(2):255-258. PMID: 31331494.
      View in: PubMed
    10. Ramondetta LM, Hu W, Thaker PH, Urbauer DL, Chisholm GB, Westin SN, Sun Y, Ramirez PT, Fleming N, Sahai SK, Nick AM, Arevalo JMG, Dizon T, Coleman RL, Cole SW, Sood AK. Prospective pilot trial with combination of propranolol with chemotherapy in patients with epithelial ovarian cancer and evaluation on circulating immune cell gene expression. Gynecol Oncol. 2019 09; 154(3):524-530. PMID: 31353053.
      View in: PubMed
    11. Vergote I, Coleman RL, Pignata S, Bookman MA, Marth C, Herzog TJ, Gonzalez Martin A, Copeland LJ. Joint ENGOT and GOG Foundation requirements for trials with industry partners. Int J Gynecol Cancer. 2019 Sep; 29(7):1094-1097. PMID: 31320391.
      View in: PubMed
    12. Chelariu-Raicu A, Coleman RL, Sood AK. Anti-Angiogenesis Therapy in Ovarian Cancer: Which Patient is It Most Likely to Benefit? Oncology (Williston Park). 2019 Jul 16; 33(7). PMID: 31365748.
      View in: PubMed
    13. Tewari KS, Burger RA, Enserro D, Norquist BM, Swisher EM, Brady MF, Bookman MA, Fleming GF, Huang H, Homesley HD, Fowler JM, Greer BE, Boente M, Liang SX, Ye C, Bais C, Randall LM, Chan JK, Ferriss JS, Coleman RL, Aghajanian C, Herzog TJ, DiSaia PJ, Copeland LJ, Mannel RS, Birrer MJ, Monk BJ. Final Overall Survival of a Randomized Trial of Bevacizumab for Primary Treatment of Ovarian Cancer. J Clin Oncol. 2019 Sep 10; 37(26):2317-2328. PMID: 31216226.
      View in: PubMed
    14. Falchook G, Coleman RL, Schilder RJ. Paclitaxel and Alisertib in Recurrent Ovarian Cancer-In Reply. JAMA Oncol. 2019 Jun 01; 5(6):910-911. PMID: 31021370.
      View in: PubMed
    15. Labrie M, Kim TB, Ju Z, Lee S, Zhao W, Fang Y, Lu Y, Chen K, Ramirez P, Frumovitz M, Meyer L, Fleming ND, Sood AK, Coleman RL, Mills GB, Westin SN. Adaptive responses in a PARP inhibitor window of opportunity trial illustrate limited functional interlesional heterogeneity and potential combination therapy options. Oncotarget. 2019 May 28; 10(37):3533-3546. PMID: 31191824.
      View in: PubMed
    16. Beaver JA, Coleman RL, Arend RC, Armstrong DK, Bala S, Mills GB, Sood AK, Herzog TJ. Advancing Drug Development in Gynecologic Malignancies. Clin Cancer Res. 2019 Aug 15; 25(16):4874-4880. PMID: 31126961.
      View in: PubMed
    17. Hinchcliff E, Westin SN, Dal Molin G, LaFargue CJ, Coleman RL. Poly-ADP-ribose polymerase inhibitor use in ovarian cancer: expanding indications and novel combination strategies. Int J Gynecol Cancer. 2019 May 22. PMID: 31118216.
      View in: PubMed
    18. Halder J, Kamat AA, Landen CN, Han LY, Lutgendorf SK, Lin YG, Merritt WM, Jennings NB, Chavez-Reyes A, Coleman RL, Gershenson DM, Schmandt R, Cole SW, Lopez-Berestein G, Sood AK. Correction: Focal Adhesion Kinase Targeting Using In vivo Short Interfering RNA Delivery in Neutral Liposomes for Ovarian Carcinoma Therapy. Clin Cancer Res. 2019 May 15; 25(10):3194. PMID: 31092618.
      View in: PubMed
    19. Sestak I, Blake GM, Patel R, Coleman RE, Cuzick J, Eastell R. Comparison of risedronate versus placebo in preventing anastrozole-induced bone loss in women at high risk of developing breast cancer with osteopenia. Bone. 2019 Jul; 124:83-88. PMID: 31028957.
      View in: PubMed
    20. Lin R, Coleman RL, Yuan Y. TOP: Time-to-Event Bayesian Optimal Phase II Trial Design for Cancer Immunotherapy. J Natl Cancer Inst. 2019 Mar 29. PMID: 30924863.
      View in: PubMed
    21. Ma S, Pradeep S, Villar-Prados A, Wen Y, Bayraktar E, Mangala LS, Kim MS, Wu SY, Hu W, Rodriguez-Aguayo C, Leuschner C, Liang X, Ram PT, Schlacher K, Coleman RL, Sood AK. GnRH-R-Targeted Lytic Peptide Sensitizes BRCA Wild-type Ovarian Cancer to PARP Inhibition. Mol Cancer Ther. 2019 05; 18(5):969-979. PMID: 30926640.
      View in: PubMed
    22. Kurnit KC, Westin SN, Coleman RL. Microsatellite instability in endometrial cancer: New purpose for an old test. Cancer. 2019 Mar 26. PMID: 30913308.
      View in: PubMed
    23. Konstantinopoulos PA, Barry WT, Birrer M, Westin SN, Cadoo KA, Shapiro GI, Mayer EL, O'Cearbhaill RE, Coleman RL, Kochupurakkal B, Whalen C, Curtis J, Farooq S, Luo W, Eismann J, Buss MK, Aghajanian C, Mills GB, Palakurthi S, Kirschmeier P, Liu J, Cantley LC, Kaufmann SH, Swisher EM, D'Andrea AD, Winer E, Wulf GM, Matulonis UA. Olaparib and a-specific PI3K inhibitor alpelisib for patients with epithelial ovarian cancer: a dose-escalation and dose-expansion phase 1b trial. Lancet Oncol. 2019 Apr; 20(4):570-580. PMID: 30880072.
      View in: PubMed
    24. Bast RC, Matulonis UA, Sood AK, Ahmed AA, Amobi AE, Balkwill FR, Wielgos-Bonvallet M, Bowtell DDL, Brenton JD, Brugge JS, Coleman RL, Draetta GF, Doberstein K, Drapkin RI, Eckert MA, Edwards RP, Elias KM, Ennis D, Futreal A, Gershenson DM, Greenberg RA, Huntsman DG, Ji JXY, Kohn EC, Iavarone C, Lengyel ER, Levine DA, Lord CJ, Lu Z, Mills GB, Modugno F, Nelson BH, Odunsi K, Pilsworth JA, Rottapel RK, Powell DJ, Shen L, Shih IM, Spriggs DR, Walton J, Zhang K, Zhang R, Zou L. Critical questions in ovarian cancer research and treatment: Report of an American Association for Cancer Research Special Conference. Cancer. 2019 Jun 15; 125(12):1963-1972. PMID: 30835824.
      View in: PubMed
    25. Naumann RW, Coleman RL, Brown J, Moore KN. Phase III trials in ovarian cancer: The evolving landscape of front line therapy. Gynecol Oncol. 2019 05; 153(2):436-444. PMID: 30765149.
      View in: PubMed
    26. Gao Q, Yang Z, Xu S, Li X, Yang X, Jin P, Liu Y, Zhou X, Zhang T, Gong C, Wei X, Liu D, Sun C, Chen G, Hu J, Meng L, Zhou J, Sawada K, Fruscio R, Grunt TW, Wischhusen J, Vargas-Hernández VM, Pothuri B, Coleman RL. Heterotypic CAF-tumor spheroids promote early peritoneal metastatis of ovarian cancer. J Exp Med. 2019 Mar 04; 216(3):688-703. PMID: 30710055.
      View in: PubMed
    27. Westbrook JA, Wood SL, Cairns DA, McMahon K, Gahlaut R, Thygesen H, Shires M, Roberts S, Marshall H, Oliva MR, Dunning MJ, Hanby AM, Selby PJ, Speirs V, Mavria G, Coleman RE, Brown JE. Identification and validation of DOCK4 as a potential biomarker for risk of bone metastasis development in patients with early breast cancer. J Pathol. 2019 Mar; 247(3):381-391. PMID: 30426503.
      View in: PubMed
    28. Tulotta C, Lefley DV, Freeman K, Gregory WM, Hanby AM, Heath PR, Nutter F, Wilkinson JM, Spicer-Hadlington AR, Liu X, Bradbury SMJ, Hambley L, Cookson V, Allocca G, Kruithof de Julio M, Coleman RE, Brown JE, Holen I, Ottewell PD. Endogenous Production of IL1B by Breast Cancer Cells Drives Metastasis and Colonization of the Bone Microenvironment. Clin Cancer Res. 2019 May 01; 25(9):2769-2782. PMID: 30670488.
      View in: PubMed
    29. Uccella S, Fagotti A, Zannoni GF, Coleman RL. Presumed early ovarian cancer with isolated tumor cells in para-aortic sentinel nodes. Int J Gynecol Cancer. 2019 01; 29(1):216-220. PMID: 30640707.
      View in: PubMed
    30. Falchook G, Coleman RL, Roszak A, Behbakht K, Matulonis U, Ray-Coquard I, Sawrycki P, Duska LR, Tew W, Ghamande S, Lesoin A, Schwartz PE, Buscema J, Fabbro M, Lortholary A, Goff B, Kurzrock R, Martin LP, Gray HJ, Fu S, Sheldon-Waniga E, Lin HM, Venkatakrishnan K, Zhou X, Leonard EJ, Schilder RJ. Alisertib in Combination With Weekly Paclitaxel in Patients With Advanced Breast Cancer or Recurrent Ovarian Cancer: A Randomized Clinical Trial. JAMA Oncol. 2019 Jan 01; 5(1):e183773. PMID: 30347019.
      View in: PubMed
    31. LaFargue CJ, Dal Molin GZ, Sood AK, Coleman RL. Exploring and comparing adverse events between PARP inhibitors. Lancet Oncol. 2019 Jan; 20(1):e15-e28. PMID: 30614472.
      View in: PubMed
    32. Armbruster S, Coleman RL, Rauh-Hain JA. Management and Treatment of Recurrent Epithelial Ovarian Cancer. Hematol Oncol Clin North Am. 2018 12; 32(6):965-982. PMID: 30390768.
      View in: PubMed
    33. Slomovitz BM, Taub MC, Huang M, Levenback C, Coleman RL. A randomized phase II study of letrozole vs. observation in patients with newly diagnosed uterine leiomyosarcoma (uLMS). Gynecol Oncol Rep. 2019 Feb; 27:1-4. PMID: 30519622.
      View in: PubMed
    34. Kurnit KC, Coleman RL, Westin SN. Using PARP Inhibitors in the Treatment of Patients With Ovarian Cancer. Curr Treat Options Oncol. 2018 11 15; 19(12):1. PMID: 30535808.
      View in: PubMed
    35. Lin KK, Harrell MI, Oza AM, Oaknin A, Ray-Coquard I, Tinker AV, Helman E, Radke MR, Say C, Vo LT, Mann E, Isaacson JD, Maloney L, O'Malley DM, Chambers SK, Kaufmann SH, Scott CL, Konecny GE, Coleman RL, Sun JX, Giordano H, Brenton JD, Harding TC, McNeish IA, Swisher EM. BRCA Reversion Mutations in Circulating Tumor DNA Predict Primary and Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma. Cancer Discov. 2019 02; 9(2):210-219. PMID: 30425037.
      View in: PubMed
    36. D'Oronzo S, Coleman R, Brown J, Silvestris F. Metastatic bone disease: Pathogenesis and therapeutic options: Up-date on bone metastasis management. J Bone Oncol. 2019 Apr; 15:004-4. PMID: 30937279.
      View in: PubMed
    37. Dood RL, Zhao Y, Armbruster SD, Coleman RL, Tworoger S, Sood AK, Baggerly KA. Defining Survivorship Trajectories Across Patients With Solid Tumors: An Evidence-Based Approach. JAMA Oncol. 2018 11 01; 4(11):1519-1526. PMID: 29860375.
      View in: PubMed
    38. Ramirez PT, Frumovitz M, Pareja R, Lopez A, Vieira M, Ribeiro R, Buda A, Yan X, Shuzhong Y, Chetty N, Isla D, Tamura M, Zhu T, Robledo KP, Gebski V, Asher R, Behan V, Nicklin JL, Coleman RL, Obermair A. Minimally Invasive versus Abdominal Radical Hysterectomy for Cervical Cancer. N Engl J Med. 2018 Nov 15; 379(20):1895-1904. PMID: 30380365.
      View in: PubMed
    39. Hansen JM, Sood AK, Coleman RL, Westin SN, Soliman PT, Ramirez PT, Fellman BM, Schmeler KM, Fleming ND. Concordance of a laparoscopic scoring algorithm with primary surgery findings in advanced stage ovarian cancer. Gynecol Oncol. 2018 12; 151(3):428-432. PMID: 30366647.
      View in: PubMed
    40. Dood RL, Fleming ND, Coleman RL, Westin SN, Lara OD, LaFargue CJ, Liu J, Sood AK. When Ovarian Cancer Is Not: Characterizing Nonovarian Cancer Pathology in a Laparoscopy-Based Triage System. Int J Gynecol Cancer. 2018 10; 28(8):1485-1490. PMID: 30036226.
      View in: PubMed
    41. Jazaeri A, Coleman RL, Sood AK, Frumovitz MM, Soliman PT, Shafer A, Cutrera JJ, Klinger M, Sharafi SE, Johnson CAL, Villanueva VF, Hinchcliff EM, Dickens A, Cain KE, Anderson JE, Lu KH, Westin SN. A practical guide for the safe implementation of early phase drug development and immunotherapy program in gynecologic oncology practice. Gynecol Oncol. 2018 11; 151(2):374-380. PMID: 30213435.
      View in: PubMed
    42. Richardson DL, Coleman RL, Sill MW. Paclitaxel and Pazopanib in Ovarian Cancer-Reply. JAMA Oncol. 2018 09 01; 4(9):1299. PMID: 29978183.
      View in: PubMed
    43. Fleming ND, Nick AM, Coleman RL, Westin SN, Ramirez PT, Soliman PT, Fellman B, Meyer LA, Schmeler KM, Lu KH, Sood AK. Laparoscopic Surgical Algorithm to Triage the Timing of Tumor Reductive Surgery in Advanced Ovarian Cancer. Obstet Gynecol. 2018 09; 132(3):545-554. PMID: 30095787.
      View in: PubMed
    44. Handforth C, Burkinshaw R, Freeman J, Brown JE, Snowden JA, Coleman RE, Greenfield DM. Comprehensive geriatric assessment and decision-making in older men with incurable but manageable (chronic) cancer. Support Care Cancer. 2019 May; 27(5):1755-1763. PMID: 30143894.
      View in: PubMed
    45. Zibetti Dal Molin G, Abrahão CM, Coleman RL, Maluf FC. Response to pembrolizumab in a heavily treated patient with metastatic ovarian carcinosarcoma. Gynecol Oncol Res Pract. 2018; 5:6. PMID: 30147940.
      View in: PubMed
    46. Nishio S, Matsuo K, Yonemoto K, Shimokawa M, Hosaka M, Kodama M, Miyake TM, Ushijima K, Kamura T, Westin SN, Soliman PT, Coleman RL. Race and nodal disease status are prognostic factors in patients with stage IVB cervical cancer. Oncotarget. 2018 Aug 17; 9(64):32321-32330. PMID: 30190789.
      View in: PubMed
    47. Dal Molin GZ, Westin SN, Coleman RL. Rucaparib in ovarian cancer: extending the use of PARP inhibitors in the recurrent disease. Future Oncol. 2018 Dec; 14(30):3101-3110. PMID: 30105925.
      View in: PubMed
    48. Brown J, Rathbone E, Hinsley S, Gregory W, Gossiel F, Marshall H, Burkinshaw R, Shulver H, Thandar H, Bertelli G, Maccon K, Bowman A, Hanby A, Bell R, Cameron D, Coleman R. Associations Between Serum Bone Biomarkers in Early Breast Cancer and Development of Bone Metastasis: Results From the AZURE (BIG01/04) Trial. J Natl Cancer Inst. 2018 08 01; 110(8):871-879. PMID: 29425304.
      View in: PubMed
    49. Ubellacker JM, Baryawno N, Severe N, DeCristo MJ, Sceneay J, Hutchinson JN, Haider MT, Rhee CS, Qin Y, Gregory WM, Garrido-Castro AC, Holen I, Brown JE, Coleman RE, Scadden DT, McAllister SS. Modulating Bone Marrow Hematopoietic Lineage Potential to Prevent Bone Metastasis in Breast Cancer. Cancer Res. 2018 09 15; 78(18):5300-5314. PMID: 30065048.
      View in: PubMed
    50. Dal Molin GZ, Omatsu K, Sood AK, Coleman RL. Rucaparib in ovarian cancer: an update on safety, efficacy and place in therapy. Ther Adv Med Oncol. 2018; 10:1758835918778483. PMID: 29977351.
      View in: PubMed
    51. Chan JK, Chow S, Bhowmik S, Mann A, Kapp DS, Coleman RL. Metastatic gynecologic malignancies: advances in treatment and management. Clin Exp Metastasis. 2018 08; 35(5-6):521-533. PMID: 29931499.
      View in: PubMed
    52. Francis PA, Pagani O, Fleming GF, Walley BA, Colleoni M, Láng I, Gómez HL, Tondini C, Ciruelos E, Burstein HJ, Bonnefoi HR, Bellet M, Martino S, Geyer CE, Goetz MP, Stearns V, Pinotti G, Puglisi F, Spazzapan S, Climent MA, Pavesi L, Ruhstaller T, Davidson NE, Coleman R, Debled M, Buchholz S, Ingle JN, Winer EP, Maibach R, Rabaglio-Poretti M, Ruepp B, Di Leo A, Coates AS, Gelber RD, Goldhirsch A, Regan MM. Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer. N Engl J Med. 2018 Jul 12; 379(2):122-137. PMID: 29863451.
      View in: PubMed
    53. Abraham J, Coleman R, Elias A, Holmes FA, Kalinsky K, Kittaneh M, Lower E, Mahtani R, Terry Mamounas E, Pegram M, Vogel C. Use of cyclin-dependent kinase (CDK) 4/6 inhibitors for hormone receptor-positive, human epidermal growth factor receptor 2-negative, metastatic breast cancer: a roundtable discussion by The Breast Cancer Therapy Expert Group (BCTEG). Breast Cancer Res Treat. 2018 Aug; 171(1):11-20. PMID: 29725889.
      View in: PubMed
    54. Brown J, Naumann RW, Brady WE, Coleman RL, Moore KN, Gershenson DM. Clinical trial methodology in rare gynecologic tumor research: Strategies for success. Gynecol Oncol. 2018 06; 149(3):605-611. PMID: 29699802.
      View in: PubMed
    55. Carvajal LA, Neriah DB, Senecal A, Benard L, Thiruthuvanathan V, Yatsenko T, Narayanagari SR, Wheat JC, Todorova TI, Mitchell K, Kenworthy C, Guerlavais V, Annis DA, Bartholdy B, Will B, Anampa JD, Mantzaris I, Aivado M, Singer RH, Coleman RA, Verma A, Steidl U. Dual inhibition of MDMX and MDM2 as a therapeutic strategy in leukemia. Sci Transl Med. 2018 04 11; 10(436). PMID: 29643228.
      View in: PubMed
    56. Rachner TD, Coleman R, Hadji P, Hofbauer LC. Bone health during endocrine therapy for cancer. Lancet Diabetes Endocrinol. 2018 11; 6(11):901-910. PMID: 29572126.
      View in: PubMed
    57. Ma S, Pradeep S, Hu W, Zhang D, Coleman R, Sood A. The role of tumor microenvironment in resistance to anti-angiogenic therapy. F1000Res. 2018; 7:326. PMID: 29560266.
      View in: PubMed
    58. Holmes AM, Emmans CJ, Coleman R, Smith TE, Hosie CA. Effects of transportation, transport medium and re-housing on Xenopus laevis (Daudin). Gen Comp Endocrinol. 2018 09 15; 266:21-28. PMID: 29545087.
      View in: PubMed
    59. Logothetis C, Morris MJ, Den R, Coleman RE. Current perspectives on bone metastases in castrate-resistant prostate cancer. Cancer Metastasis Rev. 2018 03; 37(1):189-196. PMID: 29380085.
      View in: PubMed
    60. Richardson DL, Sill MW, Coleman RL, Sood AK, Pearl ML, Kehoe SM, Carney ME, Hanjani P, Van Le L, Zhou XC, Alvarez Secord A, Gray HJ, Landrum LM, Lankes HA, Hu W, Aghajanian C. Paclitaxel With and Without Pazopanib for Persistent or Recurrent Ovarian Cancer: A Randomized Clinical Trial. JAMA Oncol. 2018 Feb 01; 4(2):196-202. PMID: 29242937.
      View in: PubMed
    61. Handforth C, D'Oronzo S, Coleman R, Brown J. Cancer Treatment and Bone Health. Calcif Tissue Int. 2018 02; 102(2):251-264. PMID: 29353450.
      View in: PubMed
    62. Abraham J, Caldera H, Coleman R, Elias A, Goetz MP, Kittaneh M, Lower E, Mahtani R, Terry Mamounas E, Pegram M, Rugo H, Schwartzberg L, Traina T, Vogel C. Endocrine therapy and related issues in hormone receptor-positive early breast cancer: a roundtable discussion by the breast cancer therapy expert group (BCTEG). Breast Cancer Res Treat. 2018 May; 169(1):1-7. PMID: 29352368.
      View in: PubMed
    63. Squires H, Pandor A, Thokala P, Stevens JW, Kaltenthaler E, Clowes M, Coleman R, Wyld L. Pertuzumab for the Neoadjuvant Treatment of Early-Stage HER2-Positive Breast Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. Pharmacoeconomics. 2018 01; 36(1):29-38. PMID: 28770452.
      View in: PubMed
    64. Huang Y, Hu W, Huang J, Shen F, Sun Y, Ivan C, Pradeep S, Dood R, Haemmerle M, Jiang D, Mangala LS, Noh K, Hansen JM, Dalton HJ, Previs RA, Nagaraja AS, McGuire M, Jennings NB, Broaddus R, Coleman RL, Sood AK. Inhibiting Nuclear Phospho-Progesterone Receptor Enhances Antitumor Activity of Onapristone in Uterine Cancer. Mol Cancer Ther. 2018 02; 17(2):464-473. PMID: 29237804.
      View in: PubMed
    65. Noh K, Mangala LS, Han HD, Zhang N, Pradeep S, Wu SY, Ma S, Mora E, Rupaimoole R, Jiang D, Wen Y, Shahzad MMK, Lyons Y, Cho M, Hu W, Nagaraja AS, Haemmerle M, Mak CSL, Chen X, Gharpure KM, Deng H, Xiong W, Kingsley CV, Liu J, Jennings N, Birrer MJ, Bouchard RR, Lopez-Berestein G, Coleman RL, An Z, Sood AK. Differential Effects of EGFL6 on Tumor versus Wound Angiogenesis. Cell Rep. 2017 Dec 05; 21(10):2785-2795. PMID: 29212026.
      View in: PubMed
    66. Le TN, Harvey RE, Kim CK, Brown J, Coleman RL, Smith JA. A retrospective evaluation of activity of gemcitabine/platinum regimens in the treatment of recurrent ovarian cancer. Gynecol Oncol Res Pract. 2017; 4:16. PMID: 29158911.
      View in: PubMed
    67. Niu H, Shin H, Gao F, Zhang J, Bahamon B, Danaee H, Melichar B, Schilder RJ, Coleman RL, Falchook G, Adenis A, Behbakht K, DeMichele A, Dees EC, Perez K, Matulonis U, Sawrycki P, Huebner D, Ecsedy J. Aurora A Functional Single Nucleotide Polymorphism (SNP) Correlates With Clinical Outcome in Patients With Advanced Solid Tumors Treated With Alisertib, an Investigational Aurora A Kinase Inhibitor. EBioMedicine. 2017 Nov; 25:50-57. PMID: 29122619.
      View in: PubMed
    68. Coleman R, Hall A, Albanell J, Hanby A, Bell R, Cameron D, Dodwell D, Marshall H, Jean-Mairet J, Tercero JC, Rojo F, Gregory W, Gomis RR. Effect of MAF amplification on treatment outcomes with adjuvant zoledronic acid in early breast cancer: a secondary analysis of the international, open-label, randomised, controlled, phase 3 AZURE (BIG 01/04) trial. Lancet Oncol. 2017 11; 18(11):1543-1552. PMID: 29037984.
      View in: PubMed
    69. Liu WL, Coleman RA, Singh SK. A new era of studying p53-mediated transcription activation. Transcription. 2018; 9(2):102-107. PMID: 28795863.
      View in: PubMed
    70. Baselga J, Coleman RE, Cortés J, Janni W. Advances in the management of HER2-positive early breast cancer. Crit Rev Oncol Hematol. 2017 Nov; 119:113-122. PMID: 29042085.
      View in: PubMed
    71. Coleman RL, Oza AM, Lorusso D, Aghajanian C, Oaknin A, Dean A, Colombo N, Weberpals JI, Clamp A, Scambia G, Leary A, Holloway RW, Gancedo MA, Fong PC, Goh JC, O'Malley DM, Armstrong DK, Garcia-Donas J, Swisher EM, Floquet A, Konecny GE, McNeish IA, Scott CL, Cameron T, Maloney L, Isaacson J, Goble S, Grace C, Harding TC, Raponi M, Sun J, Lin KK, Giordano H, Ledermann JA. Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017 Oct 28; 390(10106):1949-1961. PMID: 28916367.
      View in: PubMed
    72. D'Oronzo S, Brown J, Coleman R. The role of biomarkers in the management of bone-homing malignancies. J Bone Oncol. 2017 Nov; 9:1-9. PMID: 28948139.
      View in: PubMed
    73. Oza AM, Tinker AV, Oaknin A, Shapira-Frommer R, McNeish IA, Swisher EM, Ray-Coquard I, Bell-McGuinn K, Coleman RL, O'Malley DM, Leary A, Chen LM, Provencher D, Ma L, Brenton JD, Konecny GE, Castro CM, Giordano H, Maloney L, Goble S, Lin KK, Sun J, Raponi M, Rolfe L, Kristeleit RS. Antitumor activity and safety of the PARP inhibitor rucaparib in patients with high-grade ovarian carcinoma and a germline or somatic BRCA1 or BRCA2 mutation: Integrated analysis of data from Study 10 and ARIEL2. Gynecol Oncol. 2017 11; 147(2):267-275. PMID: 28882436.
      View in: PubMed
    74. Dalton HJ, Pradeep S, McGuire M, Hailemichael Y, Ma S, Lyons Y, Armaiz-Pena GN, Previs RA, Hansen JM, Rupaimoole R, Gonzalez-Villasana V, Cho MS, Wu SY, Mangala LS, Jennings NB, Hu W, Langley R, Mu H, Andreeff M, Bar-Eli M, Overwijk W, Ram P, Lopez-Berestein G, Coleman RL, Sood AK. Macrophages Facilitate Resistance to Anti-VEGF Therapy by Altered VEGFR Expression. Clin Cancer Res. 2017 Nov 15; 23(22):7034-7046. PMID: 28855350.
      View in: PubMed
    75. Lyons YA, Pradeep S, Wu SY, Haemmerle M, Hansen JM, Wagner MJ, Villar-Prados A, Nagaraja AS, Dood RL, Previs RA, Hu W, Zhao Y, Mak DH, Xiao Z, Melendez BD, Lizee GA, Mercado-Uribe I, Baggerly KA, Hwu P, Liu J, Overwijk WW, Coleman RL, Sood AK. Macrophage depletion through colony stimulating factor 1 receptor pathway blockade overcomes adaptive resistance to anti-VEGF therapy. Oncotarget. 2017 Nov 14; 8(57):96496-96505. PMID: 29228548.
      View in: PubMed
    76. Herzog TJ, Ison G, Alvarez RD, Balasubramaniam S, Armstrong DK, Beaver JA, Ellis A, Tang S, Ford P, McKee A, Gershenson DM, Kim G, Monk BJ, Pazdur R, Coleman RL. FDA ovarian cancer clinical trial endpoints workshop: A Society of Gynecologic Oncology White Paper. Gynecol Oncol. 2017 10; 147(1):3-10. PMID: 28844539.
      View in: PubMed
    77. Fleming ND, Coleman RL, Tung C, Westin SN, Hu W, Sun Y, Bhosale P, Munsell MF, Sood AK. Phase II trial of bevacizumab with dose-dense paclitaxel as first-line treatment in patients with advanced ovarian cancer. Gynecol Oncol. 2017 10; 147(1):41-46. PMID: 28774461.
      View in: PubMed
    78. Parker CC, Coleman RE, Sartor O, Vogelzang NJ, Bottomley D, Heinrich D, Helle SI, O'Sullivan JM, Fosså SD, Chodacki A, Wiechno P, Logue J, Seke M, Widmark A, Johannessen DC, Hoskin P, James ND, Solberg A, Syndikus I, Kliment J, Wedel S, Boehmer S, Dall'Oglio M, Franzén L, Bruland ØS, Petrenciuc O, Staudacher K, Li R, Nilsson S. Three-year Safety of Radium-223 Dichloride in Patients with Castration-resistant Prostate Cancer and Symptomatic Bone Metastases from Phase 3 Randomized Alpharadin in Symptomatic Prostate Cancer Trial. Eur Urol. 2017 Jul 10. PMID: 28705540.
      View in: PubMed
    79. D'Oronzo S, Brown J, Coleman R. The value of biomarkers in bone metastasis. Eur J Cancer Care (Engl). 2017 Nov; 26(6). PMID: 28653449.
      View in: PubMed
    80. Randall LM, Pothuri B, Swisher EM, Diaz JP, Buchanan A, Witkop CT, Bethan Powell C, Smith EB, Robson ME, Boyd J, Coleman RL, Lu K. Multi-disciplinary summit on genetics services for women with gynecologic cancers: A Society of Gynecologic Oncology White Paper. Gynecol Oncol. 2017 08; 146(2):217-224. PMID: 28596016.
      View in: PubMed
    81. Cameron D, Morden JP, Canney P, Velikova G, Coleman R, Bartlett J, Agrawal R, Banerji J, Bertelli G, Bloomfield D, Brunt AM, Earl H, Ellis P, Gaunt C, Gillman A, Hearfield N, Laing R, Murray N, Couper N, Stein RC, Verrill M, Wardley A, Barrett-Lee P, Bliss JM. Accelerated versus standard epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil or capecitabine as adjuvant therapy for breast cancer in the randomised UK TACT2 trial (CRUK/05/19): a multicentre, phase 3, open-label, randomised, controlled trial. Lancet Oncol. 2017 07; 18(7):929-945. PMID: 28600210.
      View in: PubMed
    82. Kondrashova O, Nguyen M, Shield-Artin K, Tinker AV, Teng NNH, Harrell MI, Kuiper MJ, Ho GY, Barker H, Jasin M, Prakash R, Kass EM, Sullivan MR, Brunette GJ, Bernstein KA, Coleman RL, Floquet A, Friedlander M, Kichenadasse G, O'Malley DM, Oza A, Sun J, Robillard L, Maloney L, Bowtell D, Giordano H, Wakefield MJ, Kaufmann SH, Simmons AD, Harding TC, Raponi M, McNeish IA, Swisher EM, Lin KK, Scott CL. Secondary Somatic Mutations Restoring RAD51C and RAD51D Associated with Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma. Cancer Discov. 2017 09; 7(9):984-998. PMID: 28588062.
      View in: PubMed
    83. Earl HM, Hiller L, Howard HC, Dunn JA, Young J, Bowden SJ, McDermaid M, Waterhouse AK, Wilson G, Agrawal R, O'Reilly S, Bowman A, Ritchie DM, Goodman A, Hickish T, McAdam K, Cameron D, Dodwell D, Rea DW, Caldas C, Provenzano E, Abraham JE, Canney P, Crown JP, Kennedy MJ, Coleman R, Leonard RC, Carmichael JA, Wardley AM, Poole CJ. Addition of gemcitabine to paclitaxel, epirubicin, and cyclophosphamide adjuvant chemotherapy for women with early-stage breast cancer (tAnGo): final 10-year follow-up of an open-label, randomised, phase 3 trial. Lancet Oncol. 2017 06; 18(6):755-769. PMID: 28479233.
      View in: PubMed
    84. Morden JP, Alvarez I, Bertelli G, Coates AS, Coleman R, Fallowfield L, Jassem J, Jones S, Kilburn L, Lønning PE, Ortmann O, Snowdon C, van de Velde C, Andersen J, Del Mastro L, Dodwell D, Holmberg S, Nicholas H, Paridaens R, Bliss JM, Coombes RC. Long-Term Follow-Up of the Intergroup Exemestane Study. J Clin Oncol. 2017 Aug 01; 35(22):2507-2514. PMID: 28467729.
      View in: PubMed
    85. Coleman RL, Brady MF, Herzog TJ, Sabbatini P, Armstrong DK, Walker JL, Kim BG, Fujiwara K, Tewari KS, O'Malley DM, Davidson SA, Rubin SC, DiSilvestro P, Basen-Engquist K, Huang H, Chan JK, Spirtos NM, Ashfaq R, Mannel RS. Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2017 06; 18(6):779-791. PMID: 28438473.
      View in: PubMed
    86. Hadji P, Aapro MS, Body JJ, Gnant M, Brandi ML, Reginster JY, Zillikens MC, Glüer CC, de Villiers T, Baber R, Roodman GD, Cooper C, Langdahl B, Palacios S, Kanis J, Al-Daghri N, Nogues X, Eriksen EF, Kurth A, Rizzoli R, Coleman RE. Management of Aromatase Inhibitor-Associated Bone Loss (AIBL) in postmenopausal women with hormone sensitive breast cancer: Joint position statement of the IOF, CABS, ECTS, IEG, ESCEO IMS, and SIOG. J Bone Oncol. 2017 Jun; 7:1-12. PMID: 28413771.
      View in: PubMed
    87. Wagner MJ, Mitra R, McArthur MJ, Baze W, Barnhart K, Wu SY, Rodriguez-Aguayo C, Zhang X, Coleman RL, Lopez-Berestein G, Sood AK. Preclinical Mammalian Safety Studies of EPHARNA (DOPC Nanoliposomal EphA2-Targeted siRNA). Mol Cancer Ther. 2017 06; 16(6):1114-1123. PMID: 28265009.
      View in: PubMed
    88. Gershenson DM, Bodurka DC, Coleman RL, Lu KH, Malpica A, Sun CC. Hormonal Maintenance Therapy for Women With Low-Grade Serous Cancer of the Ovary or Peritoneum. J Clin Oncol. 2017 Apr 01; 35(10):1103-1111. PMID: 28221866.
      View in: PubMed
    89. Suidan RS, Ramirez PT, Sarasohn DM, Teitcher JB, Iyer RB, Zhou Q, Iasonos A, Denesopolis J, Zivanovic O, Long Roche KC, Sonoda Y, Coleman RL, Abu-Rustum NR, Hricak H, Chi DS. A multicenter assessment of the ability of preoperative computed tomography scan and CA-125 to predict gross residual disease at primary debulking for advanced epithelial ovarian cancer. Gynecol Oncol. 2017 Apr; 145(1):27-31. PMID: 28209497.
      View in: PubMed
    90. Ng CS, Zhang Z, Lee SI, Marques HS, Burgers K, Su F, Bauza J, Mannel RS, Walker JL, Huh WK, Rubin SC, DiSilvestro P, Martin LP, Chan JK, Bookman MA, Coleman RL, Lee TY. CT Perfusion as an Early Biomarker of Treatment Efficacy in Advanced Ovarian Cancer: An ACRIN and GOG Study. Clin Cancer Res. 2017 Jul 15; 23(14):3684-3691. PMID: 28174234.
      View in: PubMed
    91. Westin SN, Coleman RL. Individualized Medicine in Ovarian Cancer: Are We There Yet? Gynecol Oncol. 2017 02; 144(2):229-231. PMID: 28089051.
      View in: PubMed
    92. Smith JA, Mathew L, Burney M, Nyshadham P, Coleman RL. Corrigendum to 'Equivalency challenge: evaluation of Lipodox® as the generic equivalent for Doxil® in a human ovarian cancer orthotropic mouse model' [Gynecol. Oncol. 141 (2016) 357-363]. Gynecol Oncol. 2017 02; 144(2):448. PMID: 28089052.
      View in: PubMed
    93. Coleman RA, Liang C, Patel R, Ali S, Mukherjee J. Brain and Brown Adipose Tissue Metabolism in Transgenic Tg2576 Mice Models of Alzheimer Disease Assessed Using 18F-FDG PET Imaging. Mol Imaging. 2017 01 01; 16:1536012117704557. PMID: 28654383.
      View in: PubMed
    94. Parker C, Zhan L, Cislo P, Reuning-Scherer J, Vogelzang NJ, Nilsson S, Sartor O, O'Sullivan JM, Coleman RE. Effect of radium-223 dichloride (Ra-223) on hospitalisation: An analysis from the phase 3 randomised Alpharadin in Symptomatic Prostate Cancer Patients (ALSYMPCA) trial. Eur J Cancer. 2017 01; 71:1-6. PMID: 27930924.
      View in: PubMed
    95. Swisher EM, Lin KK, Oza AM, Scott CL, Giordano H, Sun J, Konecny GE, Coleman RL, Tinker AV, O'Malley DM, Kristeleit RS, Ma L, Bell-McGuinn KM, Brenton JD, Cragun JM, Oaknin A, Ray-Coquard I, Harrell MI, Mann E, Kaufmann SH, Floquet A, Leary A, Harding TC, Goble S, Maloney L, Isaacson J, Allen AR, Rolfe L, Yelensky R, Raponi M, McNeish IA. Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial. Lancet Oncol. 2017 01; 18(1):75-87. PMID: 27908594.
      View in: PubMed
    96. Singh SK, Qiao Z, Song L, Jani V, Rice W, Eng E, Coleman RA, Liu WL. Structural visualization of the p53/RNA polymerase II assembly. Genes Dev. 2016 11 15; 30(22):2527-2537. PMID: 27920087.
      View in: PubMed
    97. Holen I, Lefley DV, Francis SE, Rennicks S, Bradbury S, Coleman RE, Ottewell P. IL-1 drives breast cancer growth and bone metastasis in vivo. Oncotarget. 2016 Nov 15; 7(46):75571-75584. PMID: 27765923.
      View in: PubMed
    98. Wilson C, Hinsley S, Marshall H, Cameron D, Bell R, Dodwell D, Coleman RE. Reproductive hormone analyses and effects of adjuvant zoledronic acid in early breast cancer - An AZURE (BIG 01/04) sub-study. J Bone Oncol. 2017 Nov; 9:48-54. PMID: 29234591.
      View in: PubMed
    99. Liu JF, Ray-Coquard I, Selle F, Poveda AM, Cibula D, Hirte H, Hilpert F, Raspagliesi F, Gladieff L, Harter P, Siena S, Del Campo JM, Tabah-Fisch I, Pearlberg J, Moyo V, Riahi K, Nering R, Kubasek W, Adiwijaya B, Czibere A, Naumann RW, Coleman RL, Vergote I, MacBeath G, Pujade-Lauraine E. Randomized Phase II Trial of Seribantumab in Combination With Paclitaxel in Patients With Advanced Platinum-Resistant or -Refractory Ovarian Cancer. J Clin Oncol. 2016 12 20; 34(36):4345-4353. PMID: 27998236.
      View in: PubMed
    100. Monk BJ, Poveda A, Vergote I, Raspagliesi F, Fujiwara K, Bae DS, Oaknin A, Ray-Coquard I, Provencher DM, Karlan BY, Lhommé C, Richardson G, Rincón DG, Coleman RL, Marth C, Brize A, Fabbro M, Redondo A, Bamias A, Ma H, Vogl FD, Bach BA, Oza AM. Final results of a phase 3 study of trebananib plus weekly paclitaxel in recurrent ovarian cancer (TRINOVA-1): Long-term survival, impact of ascites, and progression-free survival-2. Gynecol Oncol. 2016 Oct; 143(1):27-34. PMID: 27546885.
      View in: PubMed
    101. Wright AA, Bohlke K, Armstrong DK, Bookman MA, Cliby WA, Coleman RL, Dizon DS, Kash JJ, Meyer LA, Moore KN, Olawaiye AB, Oldham J, Salani R, Sparacio D, Tew WP, Vergote I, Edelson MI. Neoadjuvant Chemotherapy for Newly Diagnosed, Advanced Ovarian Cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2016 10 01; 34(28):3460-73. PMID: 27502591.
      View in: PubMed
    102. Vogelzang NJ, Coleman RE, Michalski JM, Nilsson S, O'Sullivan JM, Parker C, Widmark A, Thuresson M, Xu L, Germino J, Sartor O. Hematologic Safety of Radium-223 Dichloride: Baseline Prognostic Factors Associated With Myelosuppression in the ALSYMPCA Trial. Clin Genitourin Cancer. 2017 02; 15(1):42-52.e8. PMID: 27613490.
      View in: PubMed
    103. Wright AA, Bohlke K, Armstrong DK, Bookman MA, Cliby WA, Coleman RL, Dizon DS, Kash JJ, Meyer LA, Moore KN, Olawaiye AB, Oldham J, Salani R, Sparacio D, Tew WP, Vergote I, Edelson MI. Neoadjuvant chemotherapy for newly diagnosed, advanced ovarian cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology Clinical Practice Guideline. Gynecol Oncol. 2016 10; 143(1):3-15. PMID: 27650684.
      View in: PubMed
    104. Coleman RE. Impact of Bone-Targeted Treatments on Skeletal Morbidity and Survival in Breast Cancer. Oncology (Williston Park). 2016 08; 30(8):695-702. PMID: 27528238.
      View in: PubMed
    105. Macdonald MC, Hancock BW, Winter MC, Coleman RE, Tidy JA. Management and Outcomes of Patients with Stage I and IlIl Low-Risk Gestational Trophoblastic Neoplasia Treated in Sheffield, UK, from 1997-2006. J Reprod Med. 2016 Aug; 61(7-8):341-346. PMID: 30408379.
      View in: PubMed
    106. Frumovitz M, Burzawa JK, Byers LA, Lyons YA, Ramalingam P, Coleman RL, Brown J. Corrigendum to "Sequencing of mutational hotspots in cancer-related genes in small cell neuroendocrine cervical cancer" [Gynecol. Oncol. 141 (2016) 588-591]. Gynecol Oncol. 2016 10; 143(1):224. PMID: 27477189.
      View in: PubMed
    107. Coleman RL, Monk BJ. Saving the best treatment for last? Ann Oncol. 2016 09; 27(9):1656-8. PMID: 27456298.
      View in: PubMed
    108. Chuang LT, Randall TC, Denny L, Johnston CM, Schmeler KM, Covens AL, Cibula D, Bookman MA, Rawal S, DePetrillo D, Nam JH, Goodman A, Naik R, Manchanda R, Gaffney DK, Small W, Creutzberg C, Rattray C, Kesic V, Paraja R, Eiken M, Belleson K, Coleman RL, Barakat RR, Trimble EL, Quinn M. Sister Society Meeting on Global Education Development and Collaboration: Meeting Report. Int J Gynecol Cancer. 2016 07; 26(6):1186-8. PMID: 27327155.
      View in: PubMed
    109. Parker C, Finkelstein SE, Michalski JM, O'Sullivan JM, Bruland Ø, Vogelzang NJ, Coleman RE, Nilsson S, Sartor O, Li R, Seger MA, Bottomley D. Efficacy and Safety of Radium-223 Dichloride in Symptomatic Castration-resistant Prostate Cancer Patients With or Without Baseline Opioid Use From the Phase 3 ALSYMPCA Trial. Eur Urol. 2016 11; 70(5):875-883. PMID: 27344296.
      View in: PubMed
    110. Hou MM, Wang Z, Janku F, Piha-Paul S, Naing A, Hong D, Westin S, Coleman RL, Sood AK, Tsimberidou AM, Subbiah V, Wheler J, Zinner R, Lu K, Meric-Bernstam F, Fu S. Continuous anti-angiogenic therapy after tumor progression in patients with recurrent high-grade epithelial ovarian cancer: phase I trial experience. Oncotarget. 2016 Jun 07; 7(23):35132-43. PMID: 27147567.
      View in: PubMed
    111. Schmidt N, Jacob L, Coleman R, Kostev K, Hadji P. Erratum to: The impact of treatment compliance on fracture risk in women with breast cancer treated with aromatase inhibitors in the United Kingdom. Breast Cancer Res Treat. 2016 06; 157(2):401. PMID: 27165143.
      View in: PubMed
    112. Coleman RL. Foreword. Gynecol Oncol. 2016 06; 141 Suppl 1:1. PMID: 27267443.
      View in: PubMed
    113. Meyer L, Suidan R, Sun C, Westin S, Coleman RL, Mills GB. The management of malignant ascites and impact on quality of life outcomes in women with ovarian cancer. Expert Rev Qual Life Cancer Care. 2016; 1(3):231-238. PMID: 30906877.
      View in: PubMed
    114. Monk BJ, Sill MW, Walker JL, Darus CJ, Sutton G, Tewari KS, Martin LP, Schilder JM, Coleman RL, Balkissoon J, Aghajanian C. Randomized Phase II Evaluation of Bevacizumab Versus Bevacizumab Plus Fosbretabulin in Recurrent Ovarian, Tubal, or Peritoneal Carcinoma: An NRG Oncology/Gynecologic Oncology Group Study. J Clin Oncol. 2016 07 01; 34(19):2279-86. PMID: 27217446.
      View in: PubMed
    115. Takekuma M, Wong KK, Coleman RL. A long-term surviving patient with recurrent low-grade serous ovarian carcinoma treated with the MEK1/2 inhibitor, selumetinib. Gynecol Oncol Res Pract. 2016; 3:5. PMID: 27231576.
      View in: PubMed
    116. Di Guilmi J, Salvo G, Mehran R, Sood AK, Coleman RL, Lu KH, Vaporciyan A, Ramirez PT. Role of Video-Assisted Thoracoscopy in Advanced Ovarian Cancer: A Literature Review. Int J Gynecol Cancer. 2016 May; 26(4):801-6. PMID: 26937753.
      View in: PubMed
    117. Coleman R. Bone targeted treatments in cancer - The story so far. J Bone Oncol. 2016 Sep; 5(3):90-92. PMID: 27761363.
      View in: PubMed
    118. Jenner ZB, Sood AK, Coleman RL. Evaluation of rucaparib and companion diagnostics in the PARP inhibitor landscape for recurrent ovarian cancer therapy. Future Oncol. 2016 Jun; 12(12):1439-56. PMID: 27087632.
      View in: PubMed
    119. Frumovitz M, Burzawa JK, Byers LA, Lyons YA, Ramalingam P, Coleman RL, Brown J. Sequencing of mutational hotspots in cancer-related genes in small cell neuroendocrine cervical cancer. Gynecol Oncol. 2016 06; 141(3):588-591. PMID: 27079212.
      View in: PubMed
    120. Alvarez RD, Matulonis UA, Herzog TJ, Coleman RL, Monk BJ, Markman M. Moving beyond the platinum sensitive/resistant paradigm for patients with recurrent ovarian cancer. Gynecol Oncol. 2016 06; 141(3):405-409. PMID: 27049967.
      View in: PubMed
    121. Wilson C, Coleman R. Adjuvant Bone-Targeted Therapies for Postmenopausal Breast Cancer. JAMA Oncol. 2016 Apr; 2(4):423-4. PMID: 26794938.
      View in: PubMed
    122. Coleman RL, Matulonis UA. Precision medicine. Gynecol Oncol. 2016 Apr; 141(1):1. PMID: 27016221.
      View in: PubMed
    123. Sartor O, Hoskin P, Coleman RE, Nilsson S, Vogelzang NJ, Petrenciuc O, Staudacher K, Thuresson M, Parker C. Chemotherapy following radium-223 dichloride treatment in ALSYMPCA. Prostate. 2016 07; 76(10):905-16. PMID: 27004570.
      View in: PubMed
    124. Huang J, Hu W, Hu L, Previs RA, Dalton HJ, Yang XY, Sun Y, McGuire M, Rupaimoole R, Nagaraja AS, Kang Y, Liu T, Nick AM, Jennings NB, Coleman RL, Jaffe RB, Sood AK. Dll4 Inhibition plus Aflibercept Markedly Reduces Ovarian Tumor Growth. Mol Cancer Ther. 2016 06; 15(6):1344-52. PMID: 27009216.
      View in: PubMed
    125. Dao F, Schlappe BA, Tseng J, Lester J, Nick AM, Lutgendorf SK, McMeekin S, Coleman RL, Moore KN, Karlan BY, Sood AK, Levine DA. Characteristics of 10-year survivors of high-grade serous ovarian carcinoma. Gynecol Oncol. 2016 May; 141(2):260-263. PMID: 26968641.
      View in: PubMed
    126. Coleman RL, Herzog TJ, Chan DW, Munroe DG, Pappas TC, Smith A, Zhang Z, Wolf J. Validation of a second-generation multivariate index assay for malignancy risk of adnexal masses. Am J Obstet Gynecol. 2016 Jul; 215(1):82.e1-82.e11. PMID: 26970494.
      View in: PubMed
    127. Smith JA, Mathew L, Burney M, Nyshadham P, Coleman RL. Equivalency challenge: Evaluation of Lipodox® as the generic equivalent for Doxil® in a human ovarian cancer orthotropic mouse model. Gynecol Oncol. 2016 05; 141(2):357-363. PMID: 26946092.
      View in: PubMed
    128. Coleman R. Treatment of Metastatic Bone Disease and the Emerging Role of Radium-223. Semin Nucl Med. 2016 Mar; 46(2):99-104. PMID: 26897713.
      View in: PubMed
    129. Wilson C, Gossiel F, Leonard R, Anderson RA, Adamson DJ, Thomas G, Coleman RE. Goserelin, as an ovarian protector during (neo)adjuvant breast cancer chemotherapy, prevents long term altered bone turnover. J Bone Oncol. 2016 Mar; 5(1):43-9. PMID: 26998426.
      View in: PubMed
    130. Yardley DA, Brufsky A, Coleman RE, Conte PF, Cortes J, Glück S, Nabholtz JM, O'Shaughnessy J, Beck RM, Ko A, Renschler MF, Barton D, Harbeck N. Erratum to: 'Phase II/III weekly nab-paclitaxel plus gemcitabine or carboplatin versus gemcitabine/carboplatin as first-line treatment of patients with metastatic triple-negative breast cancer (the tnAcity study): study protocol for a randomized controlled trial. Trials. 2016 Feb 03; 17:63. PMID: 26841937.
      View in: PubMed
    131. Hansen JM, Coleman RL, Sood AK. Targeting the tumour microenvironment in ovarian cancer. Eur J Cancer. 2016 Mar; 56:131-143. PMID: 26849037.
      View in: PubMed
    132. Gregory WM, Twelves CJ, Bell R, Smye SW, Howard DR, Coleman RE, Cameron DA. Characterizing and quantifying the effects of breast cancer therapy using mathematical modeling. Breast Cancer Res Treat. 2016 Jan; 155(2):303-11. PMID: 26783036.
      View in: PubMed
    133. Alazzam M, Tidy J, Osborne R, Coleman R, Hancock BW, Lawrie TA. Chemotherapy for resistant or recurrent gestational trophoblastic neoplasia. Cochrane Database Syst Rev. 2016 Jan 13; (1):CD008891. PMID: 26760424.
      View in: PubMed
    134. Coleman RA, Liu Z, Darzacq X, Tjian R, Singer RH, Lionnet T. Imaging Transcription: Past, Present, and Future. Cold Spring Harb Symp Quant Biol. 2015; 80:1-8. PMID: 26763984.
      View in: PubMed
    135. Westbrook JA, Cairns DA, Peng J, Speirs V, Hanby AM, Holen I, Wood SL, Ottewell PD, Marshall H, Banks RE, Selby PJ, Coleman RE, Brown JE. CAPG and GIPC1: Breast Cancer Biomarkers for Bone Metastasis Development and Treatment. J Natl Cancer Inst. 2016 Apr; 108(4). PMID: 26757732.
      View in: PubMed
    136. Coleman RL. Ovarian cancer in 2015: Insights into strategies for optimizing ovarian cancer care. Nat Rev Clin Oncol. 2016 Feb; 13(2):71-2. PMID: 26718108.
      View in: PubMed
    137. Schmidt N, Jacob L, Coleman R, Kostev K, Hadji P. The impact of treatment compliance on fracture risk in women with breast cancer treated with aromatase inhibitors in the United Kingdom. Breast Cancer Res Treat. 2016 01; 155(1):151-7. PMID: 26687384.
      View in: PubMed
    138. Yardley DA, Brufsky A, Coleman RE, Conte PF, Cortes J, Glück S, Nabholtz JM, O'Shaughnessy J, Beck RM, Ko A, Renschler MF, Barton D, Harbeck N. Phase II/III weekly nab-paclitaxel plus gemcitabine or carboplatin versus gemcitabine/carboplatin as first-line treatment of patients with metastatic triple-negative breast cancer (the tnAcity study): study protocol for a randomized controlled trial. Trials. 2015 Dec 16; 16:575. PMID: 26673577.
      View in: PubMed
    139. Forbes JF, Sestak I, Howell A, Bonanni B, Bundred N, Levy C, von Minckwitz G, Eiermann W, Neven P, Stierer M, Holcombe C, Coleman RE, Jones L, Ellis I, Cuzick J. Anastrozole versus tamoxifen for the prevention of locoregional and contralateral breast cancer in postmenopausal women with locally excised ductal carcinoma in situ (IBIS-II DCIS): a double-blind, randomised controlled trial. Lancet. 2016 Feb 27; 387(10021):866-73. PMID: 26686313.
      View in: PubMed
    140. Minion LE, Coleman RL, Alvarez RD, Herzog TJ. Endpoints in clinical trials: What do patients consider important? A survey of the Ovarian Cancer National Alliance. Gynecol Oncol. 2016 Feb; 140(2):193-8. PMID: 26631607.
      View in: PubMed
    141. Archibald K, Drake T, Coleman R. Barriers to the Uptake of Human-based Test Methods, and How to Overcome Them. Altern Lab Anim. 2015 Nov; 43(5):301-8. PMID: 26551287.
      View in: PubMed
    142. Previs RA, Armaiz-Pena GN, Lin YG, Davis AN, Pradeep S, Dalton HJ, Hansen JM, Merritt WM, Nick AM, Langley RR, Coleman RL, Sood AK. Dual Metronomic Chemotherapy with Nab-Paclitaxel and Topotecan Has Potent Antiangiogenic Activity in Ovarian Cancer. Mol Cancer Ther. 2015 Dec; 14(12):2677-86. PMID: 26516159.
      View in: PubMed
    143. Pradeep S, Huang J, Mora EM, Nick AM, Cho MS, Wu SY, Noh K, Pecot CV, Rupaimoole R, Stein MA, Brock S, Wen Y, Xiong C, Gharpure K, Hansen JM, Nagaraja AS, Previs RA, Vivas-Mejia P, Han HD, Hu W, Mangala LS, Zand B, Stagg LJ, Ladbury JE, Ozpolat B, Alpay SN, Nishimura M, Stone RL, Matsuo K, Armaiz-Peña GN, Dalton HJ, Danes C, Goodman B, Rodriguez-Aguayo C, Kruger C, Schneider A, Haghpeykar S, Jaladurgam P, Hung MC, Coleman RL, Liu J, Li C, Urbauer D, Lopez-Berestein G, Jackson DB, Sood AK. Erythropoietin Stimulates Tumor Growth via EphB4. Cancer Cell. 2015 Nov 09; 28(5):610-622. PMID: 26481148.
      View in: PubMed
    144. Pavlovic M, Arnal-Estapé A, Rojo F, Bellmunt A, Tarragona M, Guiu M, Planet E, Garcia-Albéniz X, Morales M, Urosevic J, Gawrzak S, Rovira A, Prat A, Nonell L, Lluch A, Jean-Mairet J, Coleman R, Albanell J, Gomis RR. Enhanced MAF Oncogene Expression and Breast Cancer Bone Metastasis. J Natl Cancer Inst. 2015 Dec; 107(12):djv256. PMID: 26376684.
      View in: PubMed
    145. Greenfield DM, Blewitt A, Coleman RE, Walsh JS, Snowden JA, Ross RJM, Han TS. Evaluation of adipocytokines and traditional cardiometabolic risk factors in young male cancer survivors: an age-matched control study. Clin Endocrinol (Oxf). 2016 Feb; 84(2):296-304. PMID: 26248973.
      View in: PubMed
    146. Castro MP, Whitcomb BP, Zajchowski DA, Coleman RL. Successful use of next generation genomic sequencing (NGS)-directed therapy of clear cell carcinoma of the ovary (CCCO) with trametinib and metformin in a patient with chemotherapy-refractory disease. Gynecol Oncol Res Pract. 2015; 2:4. PMID: 27231564.
      View in: PubMed
    147. Watkins JL, Thaker PH, Nick AM, Ramondetta LM, Kumar S, Urbauer DL, Matsuo K, Squires KC, Coleman RL, Lutgendorf SK, Ramirez PT, Sood AK. Clinical impact of selective and nonselective beta-blockers on survival in patients with ovarian cancer. Cancer. 2015 Oct 01; 121(19):3444-51. PMID: 26301456.
      View in: PubMed
    148. Slomovitz BM, Coleman RL. Reply to G. Bogani et al. J Clin Oncol. 2015 Oct 20; 33(30):3516. PMID: 26240222.
      View in: PubMed
    149. Smith JA, Costales AB, Jaffari M, Urbauer DL, Frumovitz M, Kutac CK, Tran H, Coleman RL. Is it equivalent? Evaluation of the clinical activity of single agent Lipodox® compared to single agent Doxil® in ovarian cancer treatment. J Oncol Pharm Pract. 2016 Aug; 22(4):599-604. PMID: 26183293.
      View in: PubMed
    150. Graybill W, Sood AK, Monk BJ, Coleman RL. State of the science: Emerging therapeutic strategies for targeting angiogenesis in ovarian cancer. Gynecol Oncol. 2015 Aug; 138(2):223-6. PMID: 26166806.
      View in: PubMed
    151. Gartrell BA, Coleman R, Efstathiou E, Fizazi K, Logothetis CJ, Smith MR, Sonpavde G, Sartor O, Saad F. Metastatic Prostate Cancer and the Bone: Significance and Therapeutic Options. Eur Urol. 2015 Nov; 68(5):850-8. PMID: 26153564.
      View in: PubMed
    152. Bonneterre J, Hutt E, Bosq J, Graham JD, Powell MA, Leblanc E, Fujiwara K, Herzog TJ, Coleman RL, Clarke CL, Gilles EM, Zukiwski AA, Monk BJ. Development of a technique to detect the activated form of the progesterone receptor and correlation with clinical and histopathological characteristics of endometrioid adenocarcinoma of the uterine corpus. Gynecol Oncol. 2015 Sep; 138(3):663-7. PMID: 26142884.
      View in: PubMed
    153. Coleman R, Hadji P. Denosumab and fracture risk in women with breast cancer. Lancet. 2015 Aug 01; 386(9992):409-10. PMID: 26040500.
      View in: PubMed
    154. Previs R, Leath CA, Coleman RL, Herzog TJ, Krivak TC, Brower SL, Tian C, Secord AA. Evaluation of in vitro chemoresponse profiles in women with Type I and Type II epithelial ovarian cancers: An observational study ancillary analysis. Gynecol Oncol. 2015 Aug; 138(2):267-71. PMID: 26037898.
      View in: PubMed
    155. Slomovitz BM, Coleman RL, Oonk MH, van der Zee A, Levenback C. Update on sentinel lymph node biopsy for early-stage vulvar cancer. Gynecol Oncol. 2015 Aug; 138(2):472-7. PMID: 26022527.
      View in: PubMed
    156. Westin SN, Ju Z, Broaddus RR, Krakstad C, Li J, Pal N, Lu KH, Coleman RL, Hennessy BT, Klempner SJ, Werner HM, Salvesen HB, Cantley LC, Mills GB, Myers AP. PTEN loss is a context-dependent outcome determinant in obese and non-obese endometrioid endometrial cancer patients. Mol Oncol. 2015 Oct; 9(8):1694-703. PMID: 26045339.
      View in: PubMed
    157. Coleman R, King T, Nicoara CD, Bader M, McCarthy L, Chandran H, Parashar K. Combined creatinine velocity and nadir creatinine: A reliable predictor of renal outcome in neonatally diagnosed posterior urethral valves. J Pediatr Urol. 2015 Aug; 11(4):214.e1-3. PMID: 26062970.
      View in: PubMed
    158. Miyake T, Pradeep S, Wu SY, Rupaimoole R, Zand B, Wen Y, Gharpure KM, Nagaraja AS, Hu W, Cho MS, Dalton HJ, Previs RA, Taylor ML, Hisamatsu T, Kang Y, Liu T, Shacham S, McCauley D, Hawke DH, Wiktorowicz JE, Coleman RL, Sood AK. XPO1/CRM1 Inhibition Causes Antitumor Effects by Mitochondrial Accumulation of eIF5A. Clin Cancer Res. 2015 Jul 15; 21(14):3286-97. PMID: 25878333.
      View in: PubMed
    159. Coleman RL, Sill MW, Thaker PH, Bender DP, Street D, McGuire WP, Johnston CM, Rotmensch J. A phase II evaluation of selumetinib (AZD6244, ARRY-142886), a selective MEK-1/2 inhibitor in the treatment of recurrent or persistent endometrial cancer: an NRG Oncology/Gynecologic Oncology Group study. Gynecol Oncol. 2015 Jul; 138(1):30-5. PMID: 25887099.
      View in: PubMed
    160. Thanapprapasr D, Previs RA, Hu W, Ivan C, Armaiz-Pena GN, Dorniak PL, Hansen JM, Rupaimoole R, Huang J, Dalton HJ, Ali-Fehmi R, Coleman RL, Sood AK. PTEN Expression as a Predictor of Response to Focal Adhesion Kinase Inhibition in Uterine Cancer. Mol Cancer Ther. 2015 Jun; 14(6):1466-1475. PMID: 25833835.
      View in: PubMed
    161. Gómez-Hidalgo NR, Martinez-Cannon BA, Nick AM, Lu KH, Sood AK, Coleman RL, Ramirez PT. Predictors of optimal cytoreduction in patients with newly diagnosed advanced-stage epithelial ovarian cancer: Time to incorporate laparoscopic assessment into the standard of care. Gynecol Oncol. 2015 Jun; 137(3):553-8. PMID: 25827290.
      View in: PubMed
    162. Coleman RL, Sill MW, Bell-McGuinn K, Aghajanian C, Gray HJ, Tewari KS, Rubin SC, Rutherford TJ, Chan JK, Chen A, Swisher EM. A phase II evaluation of the potent, highly selective PARP inhibitor veliparib in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who carry a germline BRCA1 or BRCA2 mutation - An NRG Oncology/Gynecologic Oncology Group study. Gynecol Oncol. 2015 Jun; 137(3):386-91. PMID: 25818403.
      View in: PubMed
    163. Gelmon KA, Boyle FM, Kaufman B, Huntsman DG, Manikhas A, Di Leo A, Martin M, Schwartzberg LS, Lemieux J, Aparicio S, Shepherd LE, Dent S, Ellard SL, Tonkin K, Pritchard KI, Whelan TJ, Nomikos D, Nusch A, Coleman RE, Mukai H, Tjulandin S, Khasanov R, Rizel S, Connor AP, Santillana SL, Chapman JA, Parulekar WR. Lapatinib or Trastuzumab Plus Taxane Therapy for Human Epidermal Growth Factor Receptor 2-Positive Advanced Breast Cancer: Final Results of NCIC CTG MA.31. J Clin Oncol. 2015 May 10; 33(14):1574-83. PMID: 25779558.
      View in: PubMed
    164. Secord AA, Coleman RL, Havrilesky LJ, Abernethy AP, Samsa GP, Cella D. Patient-reported outcomes as end points and outcome indicators in solid tumours. Nat Rev Clin Oncol. 2015 Jun; 12(6):358-70. PMID: 25754949.
      View in: PubMed
    165. Herzog TJ, Coleman RL, Monk BJ, Armstrong DK, Alvarez RD. In assessing surrogate clinical trial end points: drug safety is a requisite. J Clin Oncol. 2015 May 01; 33(13):1511-2. PMID: 25732164.
      View in: PubMed
    166. Vergote IB, Marth C, Coleman RL. Role of the folate receptor in ovarian cancer treatment: evidence, mechanism, and clinical implications. Cancer Metastasis Rev. 2015 Mar; 34(1):41-52. PMID: 25564455.
      View in: PubMed
    167. Choi HJ, Armaiz Pena GN, Pradeep S, Cho MS, Coleman RL, Sood AK. Anti-vascular therapies in ovarian cancer: moving beyond anti-VEGF approaches. Cancer Metastasis Rev. 2015 Mar; 34(1):19-40. PMID: 25544368.
      View in: PubMed
    168. Nick AM, Coleman RL, Ramirez PT, Sood AK. A framework for a personalized surgical approach to ovarian cancer. Nat Rev Clin Oncol. 2015 Apr; 12(4):239-45. PMID: 25707631.
      View in: PubMed
    169. Wilson C, Ottewell P, Coleman RE, Holen I. The differential anti-tumour effects of zoledronic acid in breast cancer - evidence for a role of the activin signaling pathway. BMC Cancer. 2015 Feb 14; 15:55. PMID: 25884855.
      View in: PubMed
    170. Ozcan G, Ozpolat B, Coleman RL, Sood AK, Lopez-Berestein G. Preclinical and clinical development of siRNA-based therapeutics. Adv Drug Deliv Rev. 2015 Jun 29; 87:108-19. PMID: 25666164.
      View in: PubMed
    171. Yang X, Shen F, Hu W, Coleman RL, Sood AK. New ways to successfully target tumor vasculature in ovarian cancer. Curr Opin Obstet Gynecol. 2015 Feb; 27(1):58-65. PMID: 25502429.
      View in: PubMed
    172. Prue RL, Vari F, Radford KJ, Tong H, Hardy MY, D'Rozario R, Waterhouse NJ, Rossetti T, Coleman R, Tracey C, Goossen H, Gounder V, Crosbie G, Hancock S, Diaz-Guilas S, Mainwaring P, Swindle P, Hart DN. A phase I clinical trial of CD1c (BDCA-1)+ dendritic cells pulsed with HLA-A*0201 peptides for immunotherapy of metastatic hormone refractory prostate cancer. J Immunother. 2015 Feb-Mar; 38(2):71-6. PMID: 25658616.
      View in: PubMed
    173. Slomovitz BM, Jiang Y, Yates MS, Soliman PT, Johnston T, Nowakowski M, Levenback C, Zhang Q, Ring K, Munsell MF, Gershenson DM, Lu KH, Coleman RL. Phase II study of everolimus and letrozole in patients with recurrent endometrial carcinoma. J Clin Oncol. 2015 Mar 10; 33(8):930-6. PMID: 25624430.
      View in: PubMed
    174. Francis PA, Regan MM, Fleming GF, Láng I, Ciruelos E, Bellet M, Bonnefoi HR, Climent MA, Da Prada GA, Burstein HJ, Martino S, Davidson NE, Geyer CE, Walley BA, Coleman R, Kerbrat P, Buchholz S, Ingle JN, Winer EP, Rabaglio-Poretti M, Maibach R, Ruepp B, Giobbie-Hurder A, Price KN, Colleoni M, Viale G, Coates AS, Goldhirsch A, Gelber RD. Adjuvant ovarian suppression in premenopausal breast cancer. N Engl J Med. 2015 Jan 29; 372(5):436-46. PMID: 25495490.
      View in: PubMed
    175. Hou MM, Liu X, Wheler J, Naing A, Hong D, Coleman RL, Tsimberidou A, Janku F, Zinner R, Lu K, Kurzrock R, Fu S. Targeted PI3K/AKT/mTOR therapy for metastatic carcinomas of the cervix: A phase I clinical experience. Oncotarget. 2014 Nov 30; 5(22):11168-79. PMID: 25426553.
      View in: PubMed
    176. Plamadeala V, Kelley JL, Chan JK, Krivak TC, Gabrin MJ, Brower SL, Powell MA, Rutherford TJ, Coleman RL. A cost-effectiveness analysis of a chemoresponse assay for treatment of patients with recurrent epithelial ovarian cancer. Gynecol Oncol. 2015 Jan; 136(1):94-8. PMID: 25462203.
      View in: PubMed
    177. Wen Y, Graybill WS, Previs RA, Hu W, Ivan C, Mangala LS, Zand B, Nick AM, Jennings NB, Dalton HJ, Sehgal V, Ram P, Lee JS, Vivas-Mejia PE, Coleman RL, Sood AK. Immunotherapy targeting folate receptor induces cell death associated with autophagy in ovarian cancer. Clin Cancer Res. 2015 Jan 15; 21(2):448-59. PMID: 25416196.
      View in: PubMed
    178. Previs RA, Coleman RL, Harris AL, Sood AK. Molecular pathways: translational and therapeutic implications of the Notch signaling pathway in cancer. Clin Cancer Res. 2015 Mar 01; 21(5):955-61. PMID: 25388163.
      View in: PubMed
    179. Coleman RL, Herzog TJ, Monk BJ, Dooner P. Gynecologic Oncology Research and Practice: a new journal to meet the needs of a growing field. Gynecol Oncol Res Pract. 2014; 1:1. PMID: 27231554.
      View in: PubMed
    180. Goyal A, Dodwell D, Reed MW, Coleman RE. Axillary treatment in women with one or two sentinel nodes with macrometastases: more evidence is needed to inform practice. J Clin Oncol. 2014 Dec 01; 32(34):3902. PMID: 25245444.
      View in: PubMed
    181. Herzog TJ, Alvarez RD, Secord A, Goff BA, Mannel RS, Monk BJ, Coleman RL. SGO guidance document for clinical trial designs in ovarian cancer: a changing paradigm. Gynecol Oncol. 2014 Oct; 135(1):3-7. PMID: 25124162.
      View in: PubMed
    182. Kaur J, Khararjian A, Coleman RA, Constantinescu CC, Pan ML, Mukherjee J. Spinal cord dopamine D2/D3 receptors: in vivo and ex vivo imaging in the rat using (18)F/(11)C-fallypride. Nucl Med Biol. 2014 Nov-Dec; 41(10):841-7. PMID: 25199843.
      View in: PubMed
    183. Coleman R, Cameron D, Dodwell D, Bell R, Wilson C, Rathbone E, Keane M, Gil M, Burkinshaw R, Grieve R, Barrett-Lee P, Ritchie D, Liversedge V, Hinsley S, Marshall H. Adjuvant zoledronic acid in patients with early breast cancer: final efficacy analysis of the AZURE (BIG 01/04) randomised open-label phase 3 trial. Lancet Oncol. 2014 Aug; 15(9):997-1006. PMID: 25035292.
      View in: PubMed
    184. Pradeep S, Kim SW, Wu SY, Nishimura M, Chaluvally-Raghavan P, Miyake T, Pecot CV, Kim SJ, Choi HJ, Bischoff FZ, Mayer JA, Huang L, Nick AM, Hall CS, Rodriguez-Aguayo C, Zand B, Dalton HJ, Arumugam T, Lee HJ, Han HD, Cho MS, Rupaimoole R, Mangala LS, Sehgal V, Oh SC, Liu J, Lee JS, Coleman RL, Ram P, Lopez-Berestein G, Fidler IJ, Sood AK. Hematogenous metastasis of ovarian cancer: rethinking mode of spread. Cancer Cell. 2014 Jul 14; 26(1):77-91. PMID: 25026212.
      View in: PubMed
    185. Tian C, Sargent DJ, Krivak TC, Powell MA, Gabrin MJ, Brower SL, Coleman RL. Evaluation of a chemoresponse assay as a predictive marker in the treatment of recurrent ovarian cancer: further analysis of a prospective study. Br J Cancer. 2014 Aug 26; 111(5):843-50. PMID: 25003664.
      View in: PubMed
    186. Abu-Rustum N, Chi D, Coleman RL, del Campo JM, Fotopoulou C, Frumovitz M, Gershenson DM, Gonzalez A, Jhingran A, Ledermann J, Mariani A, Mirza M, Oaknin A, Ramirez PT, Schmeler KM, Sood AK. Summary of the 2014 MD Anderson International Meeting in Gynecologic Oncology: emerging therapies in gynecologic cancer. Gynecol Oncol. 2014 Jul; 134(1):6-9. PMID: 24952408.
      View in: PubMed
    187. Monk BJ, Poveda A, Vergote I, Raspagliesi F, Fujiwara K, Bae DS, Oaknin A, Ray-Coquard I, Provencher DM, Karlan BY, Lhommé C, Richardson G, Rincón DG, Coleman RL, Herzog TJ, Marth C, Brize A, Fabbro M, Redondo A, Bamias A, Tassoudji M, Navale L, Warner DJ, Oza AM. Anti-angiopoietin therapy with trebananib for recurrent ovarian cancer (TRINOVA-1): a randomised, multicentre, double-blind, placebo-controlled phase 3 trial. Lancet Oncol. 2014 Jul; 15(8):799-808. PMID: 24950985.
      View in: PubMed
    188. Sartor O, Coleman R, Nilsson S, Heinrich D, Helle SI, O'Sullivan JM, Fosså SD, Chodacki A, Wiechno P, Logue J, Widmark A, Johannessen DC, Hoskin P, James ND, Solberg A, Syndikus I, Vogelzang NJ, O'Bryan-Tear CG, Shan M, Bruland ØS, Parker C. Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: results from a phase 3, double-blind, randomised trial. Lancet Oncol. 2014 Jun; 15(7):738-46. PMID: 24836273.
      View in: PubMed
    189. Meyer LA, Slomovitz BM, Djordjevic B, Westin SN, Iglesias DA, Munsell MF, Jiang Y, Schmandt R, Broaddus RR, Coleman RL, Galbincea JM, Lu KH. The search continues: looking for predictive biomarkers for response to mammalian target of rapamycin inhibition in endometrial cancer. Int J Gynecol Cancer. 2014 May; 24(4):713-7. PMID: 24651628.
      View in: PubMed
    190. Ireson J, Singh K, Gillett S, Hills A, Everard J, Winter M, Coleman RE, Tidy J, Hancock BW. Evolution of a specialist gestational trophoblastic disease service with a major nursing component: the Sheffield, United Kingdom, experience. J Reprod Med. 2014 May-Jun; 59(5-6):195-8. PMID: 24937956.
      View in: PubMed
    191. Stone RL, Baggerly KA, Armaiz-Pena GN, Kang Y, Sanguino AM, Thanapprapasr D, Dalton HJ, Bottsford-Miller J, Zand B, Akbani R, Diao L, Nick AM, DeGeest K, Lopez-Berestein G, Coleman RL, Lutgendorf S, Sood AK. Focal adhesion kinase: an alternative focus for anti-angiogenesis therapy in ovarian cancer. Cancer Biol Ther. 2014 Jul; 15(7):919-29. PMID: 24755674.
      View in: PubMed
    192. Tucker SL, Gharpure K, Herbrich SM, Unruh AK, Nick AM, Crane EK, Coleman RL, Guenthoer J, Dalton HJ, Wu SY, Rupaimoole R, Lopez-Berestein G, Ozpolat B, Ivan C, Hu W, Baggerly KA, Sood AK. Molecular biomarkers of residual disease after surgical debulking of high-grade serous ovarian cancer. Clin Cancer Res. 2014 Jun 15; 20(12):3280-8. PMID: 24756370.
      View in: PubMed
    193. Hu W, Liu T, Ivan C, Sun Y, Huang J, Mangala LS, Miyake T, Dalton HJ, Pradeep S, Rupaimoole R, Previs RA, Han HD, Bottsford-Miller J, Zand B, Kang Y, Pecot CV, Nick AM, Wu SY, Lee JS, Sehgal V, Ram P, Liu J, Tucker SL, Lopez-Berestein G, Baggerly KA, Coleman RL, Sood AK. Notch3 pathway alterations in ovarian cancer. Cancer Res. 2014 Jun 15; 74(12):3282-93. PMID: 24743243.
      View in: PubMed
    194. Saxton JM, Scott EJ, Daley AJ, Woodroofe M, Mutrie N, Crank H, Powers HJ, Coleman RE. Effects of an exercise and hypocaloric healthy eating intervention on indices of psychological health status, hypothalamic-pituitary-adrenal axis regulation and immune function after early-stage breast cancer: a randomised controlled trial. Breast Cancer Res. 2014 Apr 14; 16(2):R39. PMID: 24731917.
      View in: PubMed
    195. Coleman R, Aksnes AK, Naume B, Garcia C, Jerusalem G, Piccart M, Vobecky N, Thuresson M, Flamen P. A phase IIa, nonrandomized study of radium-223 dichloride in advanced breast cancer patients with bone-dominant disease. Breast Cancer Res Treat. 2014 Jun; 145(2):411-8. PMID: 24728613.
      View in: PubMed
    196. Coleman RL, Moon J, Sood AK, Hu W, Delmore JE, Bonebrake AJ, Anderson GL, Chambers SK, Markman M. Randomised phase II study of docetaxel plus vandetanib versus docetaxel followed by vandetanib in patients with persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma: SWOG S0904. Eur J Cancer. 2014 Jun; 50(9):1638-48. PMID: 24709487.
      View in: PubMed
    197. Wen Y, Zand B, Ozpolat B, Szczepanski MJ, Lu C, Yuca E, Carroll AR, Alpay N, Bartholomeusz C, Tekedereli I, Kang Y, Rupaimoole R, Pecot CV, Dalton HJ, Hernandez A, Lokshin A, Lutgendorf SK, Liu J, Hittelman WN, Chen WY, Lopez-Berestein G, Szajnik M, Ueno NT, Coleman RL, Sood AK. Antagonism of tumoral prolactin receptor promotes autophagy-related cell death. Cell Rep. 2014 Apr 24; 7(2):488-500. PMID: 24703838.
      View in: PubMed
    198. Roh JW, Huang J, Hu W, Yang X, Jennings NB, Sehgal V, Sohn BH, Han HD, Lee SJ, Thanapprapasr D, Bottsford-Miller J, Zand B, Dalton HJ, Previs RA, Davis AN, Matsuo K, Lee JS, Ram P, Coleman RL, Sood AK. Biologic effects of platelet-derived growth factor receptor a blockade in uterine cancer. Clin Cancer Res. 2014 May 15; 20(10):2740-50. PMID: 24634380.
      View in: PubMed
    199. Nutter F, Holen I, Brown HK, Cross SS, Evans CA, Walker M, Coleman RE, Westbrook JA, Selby PJ, Brown JE, Ottewell PD. Different molecular profiles are associated with breast cancer cell homing compared with colonisation of bone: evidence using a novel bone-seeking cell line. Endocr Relat Cancer. 2014 Apr; 21(2):327-41. PMID: 24413608.
      View in: PubMed
    200. George SC, Smith TE, Mac Cana PS, Coleman R, Montgomery WI. Physiological stress in the Eurasian badger (Meles meles): effects of host, disease and environment. Gen Comp Endocrinol. 2014 May 01; 200:54-60. PMID: 24607571.
      View in: PubMed
    201. Graybill WS, Coleman RL. Vintafolide: a novel targeted agent for epithelial ovarian cancer. Future Oncol. 2014 Mar; 10(4):541-8. PMID: 24754586.
      View in: PubMed
    202. Takeuchi S, Lucchini M, Schmeler KM, Coleman RL, Gershenson DM, Munsell MF, Macapinlac HA, Ramirez PT. Utility of 18F-FDG PET/CT in follow-up of patients with low-grade serous carcinoma of the ovary. Gynecol Oncol. 2014 Apr; 133(1):100-4. PMID: 24534359.
      View in: PubMed
    203. Huang J, Hu W, Bottsford-Miller J, Liu T, Han HD, Zand B, Pradeep S, Roh JW, Thanapprapasr D, Dalton HJ, Pecot CV, Rupaimoole R, Lu C, Fellman B, Urbauer D, Kang Y, Jennings NB, Huang L, Deavers MT, Broaddus R, Coleman RL, Sood AK. Cross-talk between EphA2 and BRaf/CRaf is a key determinant of response to Dasatinib. Clin Cancer Res. 2014 Apr 01; 20(7):1846-55. PMID: 24486585.
      View in: PubMed
    204. Pandey S, Venugopal A, Kant R, Coleman R, Mukherjee J. ¹²4I-Epidepride: a PET radiotracer for extended imaging of dopamine D2/D3 receptors. Nucl Med Biol. 2014 May-Jun; 41(5):426-31. PMID: 24602412.
      View in: PubMed
    205. Hofbauer LC, Rachner TD, Coleman RE, Jakob F. Endocrine aspects of bone metastases. Lancet Diabetes Endocrinol. 2014 Jun; 2(6):500-12. PMID: 24880565.
      View in: PubMed
    206. Agarwal R, Alifrangis C, Everard J, Savage PM, Short D, Tidy J, Fisher RA, Sebire NJ, Harvey R, Hancock BW, Coleman RE, Seckl MJ. Management and survival of patients with FIGO high-risk gestational trophoblastic neoplasia: the U.K. experience, 1995-2010. J Reprod Med. 2014 Jan-Feb; 59(1-2):7-12. PMID: 24597279.
      View in: PubMed
    207. Pandey SK, Kaur J, Easwaramoorthy B, Shah A, Coleman R, Mukherjee J. Multimodality imaging probe for positron emission tomography and fluorescence imaging studies. Mol Imaging. 2014; 13:1-7. PMID: 24824856.
      View in: PubMed
    208. Barrett-Lee P, Casbard A, Abraham J, Hood K, Coleman R, Simmonds P, Timmins H, Wheatley D, Grieve R, Griffiths G, Murray N. Oral ibandronic acid versus intravenous zoledronic acid in treatment of bone metastases from breast cancer: a randomised, open label, non-inferiority phase 3 trial. Lancet Oncol. 2014 Jan; 15(1):114-22. PMID: 24332514.
      View in: PubMed
    209. Frumovitz M, Coleman RC, Soliman PT, Ramirez PT, Levenback CF. A case for caution in the pursuit of the sentinel node in women with endometrial carcinoma. Gynecol Oncol. 2014 Feb; 132(2):275-9. PMID: 24291694.
      View in: PubMed
    210. Herzog TJ, Armstrong DK, Brady MF, Coleman RL, Einstein MH, Monk BJ, Mannel RS, Thigpen JT, Umpierre SA, Villella JA, Alvarez RD. Ovarian cancer clinical trial endpoints: Society of Gynecologic Oncology white paper. Gynecol Oncol. 2014 Jan; 132(1):8-17. PMID: 24239753.
      View in: PubMed
    211. Matsuo K, Nishimura M, Komurov K, Shahzad MM, Ali-Fehmi R, Roh JW, Lu C, Cody DD, Ram PT, Loizos N, Coleman RL, Sood AK. Platelet-derived growth factor receptor alpha (PDGFRa) targeting and relevant biomarkers in ovarian carcinoma. Gynecol Oncol. 2014 Jan; 132(1):166-75. PMID: 24183729.
      View in: PubMed
    212. Naumann RW, Coleman RL, Burger RA, Sausville EA, Kutarska E, Ghamande SA, Gabrail NY, Depasquale SE, Nowara E, Gilbert L, Gersh RH, Teneriello MG, Harb WA, Konstantinopoulos PA, Penson RT, Symanowski JT, Lovejoy CD, Leamon CP, Morgenstern DE, Messmann RA. PRECEDENT: a randomized phase II trial comparing vintafolide (EC145) and pegylated liposomal doxorubicin (PLD) in combination versus PLD alone in patients with platinum-resistant ovarian cancer. J Clin Oncol. 2013 Dec 10; 31(35):4400-6. PMID: 24127448.
      View in: PubMed
    213. Liu T, Hu W, Dalton HJ, Choi HJ, Huang J, Kang Y, Pradeep S, Miyake T, Song JH, Wen Y, Lu C, Pecot CV, Bottsford-Miller J, Zand B, Jennings NB, Ivan C, Gallick GE, Baggerly KA, Hangauer DG, Coleman RL, Frumovitz M, Sood AK. Targeting SRC and tubulin in mucinous ovarian carcinoma. Clin Cancer Res. 2013 Dec 01; 19(23):6532-43. PMID: 24100628.
      View in: PubMed
    214. Awada A, Garcia AA, Chan S, Jerusalem GH, Coleman RE, Huizing MT, Mehdi A, O'Reilly SM, Hamm JT, Barrett-Lee PJ, Cocquyt V, Sideras K, Young DE, Zhao C, Chia YL, Hoch U, Hannah AL, Perez EA. Two schedules of etirinotecan pegol (NKTR-102) in patients with previously treated metastatic breast cancer: a randomised phase 2 study. Lancet Oncol. 2013 Nov; 14(12):1216-25. PMID: 24095299.
      View in: PubMed
    215. Hadji P, Coleman R, Gnant M. Bone effects of mammalian target of rapamycin (mTOR) inhibition with everolimus. Crit Rev Oncol Hematol. 2013 Aug; 87(2):101-11. PMID: 23838481.
      View in: PubMed
    216. Galic V, Coleman RL, Herzog TJ. Unmet needs in ovarian cancer: dividing histologic subtypes to exploit novel targets and pathways. Curr Cancer Drug Targets. 2013 Jul; 13(6):698-707. PMID: 23675882.
      View in: PubMed
    217. Rathbone EJ, Brown JE, Marshall HC, Collinson M, Liversedge V, Murden GA, Cameron D, Bell R, Spensley S, Agrawal R, Jyothirmayi R, Chakraborti P, Yuille F, Coleman RE. Osteonecrosis of the jaw and oral health-related quality of life after adjuvant zoledronic acid: an adjuvant zoledronic acid to reduce recurrence trial subprotocol (BIG01/04). J Clin Oncol. 2013 Jul 20; 31(21):2685-91. PMID: 23796998.
      View in: PubMed
    218. Craig CD, Iglesias DA, Watkins J, Coleman RL, Kilgore L, Ramirez PT. Extensive cutaneous metastases of ovarian cancer after prolonged response to liposomal doxorubicin. Gynecol Oncol Case Rep. 2013; 5:64-6. PMID: 24371701.
      View in: PubMed
    219. Gartrell BA, Coleman RE, Fizazi K, Miller K, Saad F, Sternberg CN, Galsky MD. Toxicities following treatment with bisphosphonates and receptor activator of nuclear factor-?B ligand inhibitors in patients with advanced prostate cancer. Eur Urol. 2014 Feb; 65(2):278-86. PMID: 23706567.
      View in: PubMed
    220. Young RJ, Coleman RE. Zoledronic acid to prevent and treat cancer metastasis: new prospects for an old drug. Future Oncol. 2013 May; 9(5):633-43. PMID: 23647292.
      View in: PubMed
    221. Saigal N, Bajwa AK, Faheem SS, Coleman RA, Pandey SK, Constantinescu CC, Fong V, Mukherjee J. Evaluation of serotonin 5-HT(1A) receptors in rodent models using [¹8F]mefway PET. Synapse. 2013 Sep; 67(9):596-608. PMID: 23504990.
      View in: PubMed
    222. Pithia N, Gulati N, Pandey S, Coleman R, Kant R, Mukherjee J. Synthesis and biological evaluation of 18F-Norfallypride in the rodent brain using PET imaging. Nucl Med Biol. 2013 Jul; 40(5):697-704. PMID: 23562464.
      View in: PubMed
    223. Winter MC, Wilson C, Syddall SP, Cross SS, Evans A, Ingram CE, Jolley IJ, Hatton MQ, Freeman JV, Mori S, Holen I, Coleman RE. Neoadjuvant chemotherapy with or without zoledronic acid in early breast cancer--a randomized biomarker pilot study. Clin Cancer Res. 2013 May 15; 19(10):2755-65. PMID: 23515409.
      View in: PubMed
    224. Coleman RE, Rathbone E, Brown JE. Management of cancer treatment-induced bone loss. Nat Rev Rheumatol. 2013 Jun; 9(6):365-74. PMID: 23507900.
      View in: PubMed
    225. Coleman R, Hadji P. JBO-Launched and flying ahead. J Bone Oncol. 2013 Feb; 2(1):1. PMID: 26909266.
      View in: PubMed
    226. Armstrong DK, White AJ, Weil SC, Phillips M, Coleman RL. Farletuzumab (a monoclonal antibody against folate receptor alpha) in relapsed platinum-sensitive ovarian cancer. Gynecol Oncol. 2013 Jun; 129(3):452-8. PMID: 23474348.
      View in: PubMed
    227. Valachis A, Polyzos NP, Coleman RE, Gnant M, Eidtmann H, Brufsky AM, Aft R, Tevaarwerk AJ, Swenson K, Lind P, Mauri D. Adjuvant therapy with zoledronic acid in patients with breast cancer: a systematic review and meta-analysis. Oncologist. 2013; 18(4):353-61. PMID: 23404816.
      View in: PubMed
    228. Coleman RE, Lipton A, Costa L, Cook RJ, Lee KA, Saad F, Brown JE, Terpos E, Major PP, Kohno N, Smith M, Body JJ. Possible survival benefits from zoledronic acid treatment in patients with bone metastases from solid tumours and poor prognostic features-An exploratory analysis of placebo-controlled trials. J Bone Oncol. 2013 Jun; 2(2):70-6. PMID: 26909273.
      View in: PubMed
    229. Coleman RL, Monk BJ, Sood AK, Herzog TJ. Latest research and treatment of advanced-stage epithelial ovarian cancer. Nat Rev Clin Oncol. 2013 Apr; 10(4):211-24. PMID: 23381004.
      View in: PubMed
    230. Julius JM, Tanyi JL, Nogueras-Gonzalez GM, Watkins JL, Coleman RL, Wolf JK, Smith JA. Evaluation of pegylated liposomal doxorubicin dose on the adverse drug event profile and outcomes in treatment of recurrent endometrial cancer. Int J Gynecol Cancer. 2013 Feb; 23(2):348-54. PMID: 23295941.
      View in: PubMed
    231. Farley J, Brady WE, Vathipadiekal V, Lankes HA, Coleman R, Morgan MA, Mannel R, Yamada SD, Mutch D, Rodgers WH, Birrer M, Gershenson DM. Selumetinib in women with recurrent low-grade serous carcinoma of the ovary or peritoneum: an open-label, single-arm, phase 2 study. Lancet Oncol. 2013 Feb; 14(2):134-40. PMID: 23261356.
      View in: PubMed
    232. Mackey JR, Martin M, Pienkowski T, Rolski J, Guastalla JP, Sami A, Glaspy J, Juhos E, Wardley A, Fornander T, Hainsworth J, Coleman R, Modiano MR, Vinholes J, Pinter T, Rodríguez-Lescure A, Colwell B, Whitlock P, Provencher L, Laing K, Walde D, Price C, Hugh JC, Childs BH, Bassi K, Lindsay MA, Wilson V, Rupin M, Houé V, Vogel C. Adjuvant docetaxel, doxorubicin, and cyclophosphamide in node-positive breast cancer: 10-year follow-up of the phase 3 randomised BCIRG 001 trial. Lancet Oncol. 2013 Jan; 14(1):72-80. PMID: 23246022.
      View in: PubMed
    233. Alazzam M, Tidy J, Osborne R, Coleman R, Hancock BW, Lawrie TA. Chemotherapy for resistant or recurrent gestational trophoblastic neoplasia. Cochrane Database Syst Rev. 2012 Dec 12; 12:CD008891. PMID: 23235667.
      View in: PubMed
    234. Miyake TM, Sood AK, Coleman RL. Contemporary use of bevacizumab in ovarian cancer. Expert Opin Biol Ther. 2013 Feb; 13(2):283-94. PMID: 23190436.
      View in: PubMed
    235. Coleman RL, Ali S, Levenback CF, Gold MA, Fowler JM, Judson PL, Bell MC, De Geest K, Spirtos NM, Potkul RK, Leitao MM, Bakkum-Gamez JN, Rossi EC, Lentz SS, Burke JJ, Van Le L, Trimble CL. Is bilateral lymphadenectomy for midline squamous carcinoma of the vulva always necessary? An analysis from Gynecologic Oncology Group (GOG) 173. Gynecol Oncol. 2013 Feb; 128(2):155-9. PMID: 23201592.
      View in: PubMed
    236. Ivan C, Hu W, Bottsford-Miller J, Zand B, Dalton HJ, Liu T, Huang J, Nick AM, Lopez-Berestein G, Coleman RL, Baggerly KA, Sood AK. Epigenetic analysis of the Notch superfamily in high-grade serous ovarian cancer. Gynecol Oncol. 2013 Mar; 128(3):506-11. PMID: 23200915.
      View in: PubMed
    237. Schmeler KM, Wilson GL, Cain K, Munsell MF, Ramirez PT, Soliman PT, Nick AM, Frumovitz M, Coleman RL, Kroll MH, Levenback CF. Venous thromboembolism (VTE) rates following the implementation of extended duration prophylaxis for patients undergoing surgery for gynecologic malignancies. Gynecol Oncol. 2013 Feb; 128(2):204-8. PMID: 23200912.
      View in: PubMed
    238. Slomovitz BM, Coleman RL. The PI3K/AKT/mTOR pathway as a therapeutic target in endometrial cancer. Clin Cancer Res. 2012 Nov 01; 18(21):5856-64. PMID: 23082003.
      View in: PubMed
    239. Bottsford-Miller JN, Coleman RL, Sood AK. Resistance and escape from antiangiogenesis therapy: clinical implications and future strategies. J Clin Oncol. 2012 Nov 10; 30(32):4026-34. PMID: 23008289.
      View in: PubMed
    240. Brown JE, Cook RJ, Lipton A, Coleman RE. Serum lactate dehydrogenase is prognostic for survival in patients with bone metastases from breast cancer: a retrospective analysis in bisphosphonate-treated patients. Clin Cancer Res. 2012 Nov 15; 18(22):6348-55. PMID: 22952345.
      View in: PubMed
    241. Coleman RE. Adjuvant bone-targeted therapy to prevent metastasis: lessons from the AZURE study. Curr Opin Support Palliat Care. 2012 Sep; 6(3):322-9. PMID: 22801464.
      View in: PubMed
    242. Coleman RL, Sill MW, Lankes HA, Fader AN, Finkler NJ, Hoffman JS, Rose PG, Sutton GP, Drescher CW, McMeekin DS, Hu W, Deavers M, Godwin AK, Alpaugh RK, Sood AK. A phase II evaluation of aflibercept in the treatment of recurrent or persistent endometrial cancer: a Gynecologic Oncology Group study. Gynecol Oncol. 2012 Dec; 127(3):538-43. PMID: 22922531.
      View in: PubMed
    243. Revyakin A, Zhang Z, Coleman RA, Li Y, Inouye C, Lucas JK, Park SR, Chu S, Tjian R. Transcription initiation by human RNA polymerase II visualized at single-molecule resolution. Genes Dev. 2012 Aug 01; 26(15):1691-702. PMID: 22810624.
      View in: PubMed
    244. Coleman R, Gnant M, Morgan G, Clezardin P. Effects of bone-targeted agents on cancer progression and mortality. J Natl Cancer Inst. 2012 Jul 18; 104(14):1059-67. PMID: 22752060.
      View in: PubMed
    245. Levenback CF, Ali S, Coleman RL, Gold MA, Fowler JM, Judson PL, Bell MC, De Geest K, Spirtos NM, Potkul RK, Leitao MM, Bakkum-Gamez JN, Rossi EC, Lentz SS, Burke JJ, Van Le L, Trimble CL. Lymphatic mapping and sentinel lymph node biopsy in women with squamous cell carcinoma of the vulva: a gynecologic oncology group study. J Clin Oncol. 2012 Nov 01; 30(31):3786-91. PMID: 22753905.
      View in: PubMed
    246. Kingdon SJ, Coleman RE, Ellis L, Hancock BW. Deaths from gestational trophoblastic neoplasia: any lessons to be learned? J Reprod Med. 2012 Jul-Aug; 57(7-8):293-6. PMID: 22838243.
      View in: PubMed
    247. Westin SN, Herzog TJ, Coleman RL. Investigational agents in development for the treatment of ovarian cancer. Invest New Drugs. 2013 Feb; 31(1):213-29. PMID: 22661305.
      View in: PubMed
    248. Zand B, Coleman RL, Sood AK. Targeting angiogenesis in gynecologic cancers. Hematol Oncol Clin North Am. 2012 Jun; 26(3):543-63, viii. PMID: 22520979.
      View in: PubMed
    249. Coleman R, Hadji P. Bone Oncology-An emerging multi-disciplinary specialty. J Bone Oncol. 2012 Jun; 1(1):1. PMID: 26909247.
      View in: PubMed
    250. Jassam N, Gopaul S, McShane P, McHugh A, Coleman R, Thompson D, Barth JH. Calcium adjustment equations in neonates and children. Ann Clin Biochem. 2012 Jul; 49(Pt 4):352-8. PMID: 22535865.
      View in: PubMed
    251. Berruti A, Cook R, Saad F, Buttigliero C, Lipton A, Tampellini M, Lee KA, Coleman RE, Smith MR. Prognostic role of serum parathyroid hormone levels in advanced prostate cancer patients undergoing zoledronic acid administration. Oncologist. 2012; 17(5):645-52. PMID: 22523198.
      View in: PubMed
    252. Fu S, Hennessy BT, Ng CS, Ju Z, Coombes KR, Wolf JK, Sood AK, Levenback CF, Coleman RL, Kavanagh JJ, Gershenson DM, Markman M, Dice K, Howard A, Li J, Li Y, Stemke-Hale K, Dyer M, Atkinson E, Jackson E, Kundra V, Kurzrock R, Bast RC, Mills GB. Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer. Gynecol Oncol. 2012 Jul; 126(1):47-53. PMID: 22487539.
      View in: PubMed
    253. Nihira MA, Drake NL, Corton MM, Wai CY, Coleman RL, Quiroz LH. Reported cystoscopic experience correlates poorly with objective assessment of cystoscopic skills. Female Pelvic Med Reconstr Surg. 2012 Mar-Apr; 18(2):97-102. PMID: 22453320.
      View in: PubMed
    254. Annunziata CM, Kohn EC, LoRusso P, Houston ND, Coleman RL, Buzoianu M, Robbie G, Lechleider R. Phase 1, open-label study of MEDI-547 in patients with relapsed or refractory solid tumors. Invest New Drugs. 2013 Feb; 31(1):77-84. PMID: 22370972.
      View in: PubMed
    255. Noguera IR, Sun CC, Broaddus RR, Branham D, Levenback CF, Ramirez PT, Sood AK, Coleman RL, Gershenson DM. Phase II trial of imatinib mesylate in patients with recurrent platinum- and taxane-resistant low-grade serous carcinoma of the ovary, peritoneum, or fallopian tube. Gynecol Oncol. 2012 Jun; 125(3):640-5. PMID: 22387451.
      View in: PubMed
    256. Milam MR, Java J, Walker JL, Metzinger DS, Parker LP, Coleman RL. Nodal metastasis risk in endometrioid endometrial cancer. Obstet Gynecol. 2012 Feb; 119(2 Pt 1):286-92. PMID: 22270280.
      View in: PubMed
    257. Brown JE, Coleman RE. Denosumab in patients with cancer-a surgical strike against the osteoclast. Nat Rev Clin Oncol. 2012 Jan 10; 9(2):110-8. PMID: 22231759.
      View in: PubMed
    258. Thanapprapasr D, Hu W, Sood AK, Coleman RL. Moving beyond VEGF for anti-angiogenesis strategies in gynecologic cancer. Curr Pharm Des. 2012; 18(19):2713-9. PMID: 22390757.
      View in: PubMed
    259. Schmeler KM, Sood AK, Bell-McGuinn KM, Coleman RL, Frumovitz M, Sonoda Y, Ramirez PT, Gershenson DM, Barakat RR, Gardner GJ. Proceedings from the 9th International Conference on Ovarian Cancer. Gynecol Oncol. 2012 Apr; 125(1):5-7. PMID: 22210309.
      View in: PubMed
    260. Coleman RE. Bone cancer in 2011: Prevention and treatment of bone metastases. Nat Rev Clin Oncol. 2011 Dec 20; 9(2):76-8. PMID: 22182971.
      View in: PubMed
    261. Sood AK, Coleman RL, Ellis LM. Moving beyond anti-vascular endothelial growth factor therapy in ovarian cancer. J Clin Oncol. 2012 Feb 01; 30(4):345-7. PMID: 22184398.
      View in: PubMed
    262. Amir E, Clemons M, Purdie CA, Miller N, Quinlan P, Geddie W, Coleman RE, Freedman OC, Jordan LB, Thompson AM. Tissue confirmation of disease recurrence in breast cancer patients: pooled analysis of multi-centre, multi-disciplinary prospective studies. Cancer Treat Rev. 2012 Oct; 38(6):708-14. PMID: 22178456.
      View in: PubMed
    263. Julius JM, Gaikwad A, Lowry A, Lewis RE, Lozano RD, Dalrymple JL, Coleman RL, Smith JA. Defining the role of echinocandin catechol functional groups in the development of secondary hepatocellular carcinoma. J Antimicrob Chemother. 2012 Feb; 67(2):422-9. PMID: 22129592.
      View in: PubMed
    264. Smith MR, Saad F, Coleman R, Shore N, Fizazi K, Tombal B, Miller K, Sieber P, Karsh L, Damião R, Tammela TL, Egerdie B, Van Poppel H, Chin J, Morote J, Gómez-Veiga F, Borkowski T, Ye Z, Kupic A, Dansey R, Goessl C. Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial. Lancet. 2012 Jan 07; 379(9810):39-46. PMID: 22093187.
      View in: PubMed
    265. Bodurka DC, Deavers MT, Tian C, Sun CC, Malpica A, Coleman RL, Lu KH, Sood AK, Birrer MJ, Ozols R, Baergen R, Emerson RE, Steinhoff M, Behmaram B, Rasty G, Gershenson DM. Reclassification of serous ovarian carcinoma by a 2-tier system: a Gynecologic Oncology Group Study. Cancer. 2012 Jun 15; 118(12):3087-94. PMID: 22072418.
      View in: PubMed
    266. Coleman R. Early management and long-term outcomes in primary vesico-ureteric reflux. BJU Int. 2011 Nov; 108 Suppl 2:3-8. PMID: 22085118.
      View in: PubMed
    267. Bliss JM, Kilburn LS, Coleman RE, Forbes JF, Coates AS, Jones SE, Jassem J, Delozier T, Andersen J, Paridaens R, van de Velde CJ, Lønning PE, Morden J, Reise J, Cisar L, Menschik T, Coombes RC. Disease-related outcomes with long-term follow-up: an updated analysis of the intergroup exemestane study. J Clin Oncol. 2012 Mar 01; 30(7):709-17. PMID: 22042946.
      View in: PubMed
    268. Coleman RL, Duska LR, Ramirez PT, Heymach JV, Kamat AA, Modesitt SC, Schmeler KM, Iyer RB, Garcia ME, Miller DL, Jackson EF, Ng CS, Kundra V, Jaffe R, Sood AK. Phase 1-2 study of docetaxel plus aflibercept in patients with recurrent ovarian, primary peritoneal, or fallopian tube cancer. Lancet Oncol. 2011 Nov; 12(12):1109-17. PMID: 21992853.
      View in: PubMed
    269. Ottewell PD, Brown HK, Jones M, Rogers TL, Cross SS, Brown NJ, Coleman RE, Holen I. Combination therapy inhibits development and progression of mammary tumours in immunocompetent mice. Breast Cancer Res Treat. 2012 Jun; 133(2):523-36. PMID: 21956211.
      View in: PubMed
    270. Aapro MS, Coleman RE. Bone health management in patients with breast cancer: current standards and emerging strategies. Breast. 2012 Feb; 21(1):8-19. PMID: 21958673.
      View in: PubMed
    271. Nick AM, Stone RL, Armaiz-Pena G, Ozpolat B, Tekedereli I, Graybill WS, Landen CN, Villares G, Vivas-Mejia P, Bottsford-Miller J, Kim HS, Lee JS, Kim SM, Baggerly KA, Ram PT, Deavers MT, Coleman RL, Lopez-Berestein G, Sood AK. Silencing of p130cas in ovarian carcinoma: a novel mechanism for tumor cell death. J Natl Cancer Inst. 2011 Nov 02; 103(21):1596-612. PMID: 21957230.
      View in: PubMed
    272. Coleman RE, Marshall H, Cameron D, Dodwell D, Burkinshaw R, Keane M, Gil M, Houston SJ, Grieve RJ, Barrett-Lee PJ, Ritchie D, Pugh J, Gaunt C, Rea U, Peterson J, Davies C, Hiley V, Gregory W, Bell R. Breast-cancer adjuvant therapy with zoledronic acid. N Engl J Med. 2011 Oct 13; 365(15):1396-405. PMID: 21995387.
      View in: PubMed
    273. Moroney JW, Schlumbrecht MP, Helgason T, Coleman RL, Moulder S, Naing A, Bodurka DC, Janku F, Hong DS, Kurzrock R. A phase I trial of liposomal doxorubicin, bevacizumab, and temsirolimus in patients with advanced gynecologic and breast malignancies. Clin Cancer Res. 2011 Nov 01; 17(21):6840-6. PMID: 21890452.
      View in: PubMed
    274. Alazzam M, Young T, Coleman R, Hancock B, Drew D, Wilson P, Tidy J. Predicting gestational trophoblastic neoplasia (GTN): is urine hCG the answer? Gynecol Oncol. 2011 Sep; 122(3):595-9. PMID: 21684585.
      View in: PubMed
    275. Naumann RW, Coleman RL. Management strategies for recurrent platinum-resistant ovarian cancer. Drugs. 2011 Jul 30; 71(11):1397-412. PMID: 21812505.
      View in: PubMed
    276. Hu W, Lu C, Dong HH, Huang J, Shen DY, Stone RL, Nick AM, Shahzad MM, Mora E, Jennings NB, Lee SJ, Roh JW, Matsuo K, Nishimura M, Goodman BW, Jaffe RB, Langley RR, Deavers MT, Lopez-Berestein G, Coleman RL, Sood AK. Biological roles of the Delta family Notch ligand Dll4 in tumor and endothelial cells in ovarian cancer. Cancer Res. 2011 Sep 15; 71(18):6030-9. PMID: 21795478.
      View in: PubMed
    277. Coombes RC, Bliss JM, Espie M, Erdkamp F, Wals J, Tres A, Marty M, Coleman RE, Tubiana-Mathieu N, den Boer MO, Wardley A, Kilburn LS, Cooper D, Thomas MW, Reise JA, Wilkinson K, Hupperets P. Randomized, phase III trial of sequential epirubicin and docetaxel versus epirubicin alone in postmenopausal patients with node-positive breast cancer. J Clin Oncol. 2011 Aug 20; 29(24):3247-54. PMID: 21768453.
      View in: PubMed
    278. Steg AD, Katre AA, Goodman B, Han HD, Nick AM, Stone RL, Coleman RL, Alvarez RD, Lopez-Berestein G, Sood AK, Landen CN. Targeting the notch ligand JAGGED1 in both tumor cells and stroma in ovarian cancer. Clin Cancer Res. 2011 Sep 01; 17(17):5674-85. PMID: 21753153.
      View in: PubMed
    279. Frederick PJ, Ramirez PT, McQuinn L, Milam MR, Weber DM, Coleman RL, Gershenson DM, Landen CN. Preoperative factors predicting survival after secondary cytoreduction for recurrent ovarian cancer. Int J Gynecol Cancer. 2011 Jul; 21(5):831-6. PMID: 21613957.
      View in: PubMed
    280. Archibald K, Coleman R, Foster C. Open letter to UK Prime Minister David Cameron and Health Secretary Andrew Lansley on safety of medicines. Lancet. 2011 Jun 04; 377(9781):1915. PMID: 21641471.
      View in: PubMed
    281. Coleman R. Prostate cancer: targeted therapy for prostate cancer metastases to bone. Nat Rev Urol. 2011 May 17; 8(6):296-8. PMID: 21587226.
      View in: PubMed
    282. Coleman RL, Brady WE, McMeekin DS, Rose PG, Soper JT, Lentz SS, Hoffman JS, Shahin MS. A phase II evaluation of nanoparticle, albumin-bound (nab) paclitaxel in the treatment of recurrent or persistent platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer: a Gynecologic Oncology Group study. Gynecol Oncol. 2011 Jul; 122(1):111-5. PMID: 21497382.
      View in: PubMed
    283. Armstrong DK, Coleman RL, Penson RT. Emerging therapeutic options for platinum-sensitive ovarian cancer patients. Clin Adv Hematol Oncol. 2011 Apr; 9(4 Suppl 5):1-16. PMID: 21558997.
      View in: PubMed
    284. Lacour RA, Euscher E, Atkinson EN, Sun CC, Ramirez PT, Coleman RL, Brown J, Gano JB, Burke TW, Ramondetta LM. A phase II trial of paclitaxel and carboplatin in women with advanced or recurrent uterine carcinosarcoma. Int J Gynecol Cancer. 2011 Apr; 21(3):517-22. PMID: 21436700.
      View in: PubMed
    285. Constantinescu CC, Coleman RA, Pan ML, Mukherjee J. Striatal and extrastriatal microPET imaging of D2/D3 dopamine receptors in rat brain with [¹8F]fallypride and [¹8F]desmethoxyfallypride. Synapse. 2011 Aug; 65(8):778-87. PMID: 21218455.
      View in: PubMed
    286. Coleman R, Costa L, Saad F, Cook R, Hadji P, Terpos E, Garnero P, Brown J, Body JJ, Smith M, Lee KA, Major P, Dimopoulos M, Lipton A. Consensus on the utility of bone markers in the malignant bone disease setting. Crit Rev Oncol Hematol. 2011 Dec; 80(3):411-32. PMID: 21411334.
      View in: PubMed
    287. Brown HK, Ottewell PD, Coleman RE, Holen I. The kinetochore protein Cenp-F is a potential novel target for zoledronic acid in breast cancer cells. J Cell Mol Med. 2011 Mar; 15(3):501-13. PMID: 20015195.
      View in: PubMed
    288. Slomovitz BM, Worley MJ, Markman M, Coleman RL. Emerging therapeutics for primary peritoneal cancer. Expert Opin Emerg Drugs. 2011 Mar; 16(1):71-84. PMID: 21352070.
      View in: PubMed
    289. Coleman RE, McCloskey EV. Bisphosphonates in oncology. Bone. 2011 Jul; 49(1):71-6. PMID: 21320652.
      View in: PubMed
    290. Farley J, Sill MW, Birrer M, Walker J, Schilder RJ, Thigpen JT, Coleman RL, Miller BE, Rose PG, Lankes HA. Phase II study of cisplatin plus cetuximab in advanced, recurrent, and previously treated cancers of the cervix and evaluation of epidermal growth factor receptor immunohistochemical expression: a Gynecologic Oncology Group study. Gynecol Oncol. 2011 May 01; 121(2):303-8. PMID: 21329967.
      View in: PubMed
    291. Morgan MA, Sill MW, Fujiwara K, Greer B, Rubin SC, Degeest K, Yamada SD, Waggoner S, Coleman RL, Walker JL, Mannel RS. A phase I study with an expanded cohort to assess the feasibility of intraperitoneal carboplatin and intravenous paclitaxel in untreated ovarian, fallopian tube, and primary peritoneal carcinoma: A Gynecologic Oncology Group study. Gynecol Oncol. 2011 May 01; 121(2):264-8. PMID: 21277623.
      View in: PubMed
    292. Costa L, Harper P, Coleman RE, Lipton A. Anticancer evidence for zoledronic acid across the cancer continuum. Crit Rev Oncol Hematol. 2011 Feb; 77 Suppl 1:S31-7. PMID: 21353179.
      View in: PubMed
    293. Oliver RT, Mead GM, Rustin GJ, Joffe JK, Aass N, Coleman R, Gabe R, Pollock P, Stenning SP. Randomized trial of carboplatin versus radiotherapy for stage I seminoma: mature results on relapse and contralateral testis cancer rates in MRC TE19/EORTC 30982 study (ISRCTN27163214). J Clin Oncol. 2011 Mar 10; 29(8):957-62. PMID: 21282539.
      View in: PubMed
    294. Cheng X, Yang G, Schmeler KM, Coleman RL, Tu X, Liu J, Kavanagh JJ. Recurrence patterns and prognosis of endometrial stromal sarcoma and the potential of tyrosine kinase-inhibiting therapy. Gynecol Oncol. 2011 May 01; 121(2):323-7. PMID: 21277011.
      View in: PubMed
    295. Milam MR, Tao X, Coleman RL, Harrell R, Bassett R, Dos Reis R, Ramirez PT. Neoadjuvant chemotherapy is associated with prolonged primary treatment intervals in patients with advanced epithelial ovarian cancer. Int J Gynecol Cancer. 2011 Jan; 21(1):66-71. PMID: 21178571.
      View in: PubMed
    296. Lipton A, Costa L, Coleman RE. Bone turnover markers: tools for prognosis and monitoring response to bisphosphonates? Breast Dis. 2011; 33(2):59-69. PMID: 22142664.
      View in: PubMed
    297. Coleman R, Cook R, Hirsh V, Major P, Lipton A. Zoledronic acid use in cancer patients: more than just supportive care? Cancer. 2011 Jan 01; 117(1):11-23. PMID: 21235033.
      View in: PubMed
    298. Carroll AR, Coleman RL, Sood AK. Therapeutic advances in women's cancers. Front Biosci (Schol Ed). 2011 Jan 01; 3:82-97. PMID: 21196359.
      View in: PubMed
    299. Ito K, Tsubamoto H, Itani Y, Kuroboshi H, Fujita H, Nobunaga T, Coleman RL. A feasibility study of carboplatin and weekly paclitaxel combination chemotherapy in endometrial cancer: a Kansai Clinical Oncology Group study (KCOG0015 trial). Gynecol Oncol. 2011 Feb; 120(2):193-7. PMID: 21075434.
      View in: PubMed
    300. Pecot CV, Calin GA, Coleman RL, Lopez-Berestein G, Sood AK. RNA interference in the clinic: challenges and future directions. Nat Rev Cancer. 2011 Jan; 11(1):59-67. PMID: 21160526.
      View in: PubMed
    301. Holen I, Coleman RE. Anti-tumour activity of bisphosphonates in preclinical models of breast cancer. Breast Cancer Res. 2010; 12(6):214. PMID: 21176176.
      View in: PubMed
    302. Merritt WM, Kamat AA, Hwang JY, Bottsford-Miller J, Lu C, Lin YG, Coffey D, Spannuth WA, Nugent E, Han LY, Landen CN, Nick AM, Stone RL, Coffman K, Bruckheimer E, Broaddus RR, Gershenson DM, Coleman RL, Sood AK. Clinical and biological impact of EphA2 overexpression and angiogenesis in endometrial cancer. Cancer Biol Ther. 2010 Dec 15; 10(12):1306-14. PMID: 20948320.
      View in: PubMed
    303. Coleman R, Burkinshaw R, Winter M, Neville-Webbe H, Lester J, Woodward E, Brown J. Zoledronic acid. Expert Opin Drug Saf. 2011 Jan; 10(1):133-45. PMID: 21114419.
      View in: PubMed
    304. Ramirez PT, Jhingran A, Macapinlac HA, Euscher ED, Munsell MF, Coleman RL, Soliman PT, Schmeler KM, Frumovitz M, Ramondetta LM. Laparoscopic extraperitoneal para-aortic lymphadenectomy in locally advanced cervical cancer: a prospective correlation of surgical findings with positron emission tomography/computed tomography findings. Cancer. 2011 May 01; 117(9):1928-34. PMID: 21509770.
      View in: PubMed
    305. Fu S, Hu W, Iyer R, Kavanagh JJ, Coleman RL, Levenback CF, Sood AK, Wolf JK, Gershenson DM, Markman M, Hennessy BT, Kurzrock R, Bast RC. Phase 1b-2a study to reverse platinum resistance through use of a hypomethylating agent, azacitidine, in patients with platinum-resistant or platinum-refractory epithelial ovarian cancer. Cancer. 2011 Apr 15; 117(8):1661-9. PMID: 21472713.
      View in: PubMed
    306. Guise TA, Brufsky A, Coleman RE. Understanding and optimizing bone health in breast cancer. Curr Med Res Opin. 2010 Dec; 26 Suppl 3:3-20. PMID: 21050131.
      View in: PubMed
    307. Gehlert S, Coleman R. Using community-based participatory research to ameliorate cancer disparities. Health Soc Work. 2010 Nov; 35(4):302-9. PMID: 21171537.
      View in: PubMed
    308. Brown J, Smith JA, Ramondetta LM, Sood AK, Ramirez PT, Coleman RL, Levenback CF, Munsell MF, Jung M, Wolf JK. Combination of gemcitabine and cisplatin is highly active in women with endometrial carcinoma: results of a prospective phase 2 trial. Cancer. 2010 Nov 01; 116(21):4973-9. PMID: 20665499.
      View in: PubMed
    309. Nick AM, Schmeler KM, Frumovitz MM, Soliman PT, Spannuth WA, Burzawa JK, Coleman RL, Wei C, dos Reis R, Ramirez PT. Risk of thromboembolic disease in patients undergoing laparoscopic gynecologic surgery. Obstet Gynecol. 2010 Oct; 116(4):956-61. PMID: 20859161.
      View in: PubMed
    310. Trimble EL, Birrer MJ, Hoskins WJ, Marth C, Petryshyn R, Quinn M, Thomas GM, Kitchener HC, Aghajanian C, Alberts DS, Armstrong D, Brown J, Coleman RL, Colombo N, Eisenhauer E, Friedlander M, Fujiwara K, Hunsberger S, Kaye S, Ledermann JA, Lee S, Look K, Mannel R, McNeish IA, Minasian L, Oza A, Paul J, Poveda A, Pujade-Lauraine E, Schoenfeldt M, Swart AM, von Gruenigen V, Wenzel L. Current academic clinical trials in ovarian cancer: Gynecologic Cancer Intergroup and US National Cancer Institute Clinical Trials Planning Meeting, May 2009. Int J Gynecol Cancer. 2010 Oct; 20(7):1290-8. PMID: 21151709.
      View in: PubMed
    311. Landen CN, Goodman B, Katre AA, Steg AD, Nick AM, Stone RL, Miller LD, Mejia PV, Jennings NB, Gershenson DM, Bast RC, Coleman RL, Lopez-Berestein G, Sood AK. Targeting aldehyde dehydrogenase cancer stem cells in ovarian cancer. Mol Cancer Ther. 2010 Dec; 9(12):3186-99. PMID: 20889728.
      View in: PubMed
    312. Coleman R. The use of bisphosphonates in cancer treatment. Ann N Y Acad Sci. 2011 Feb; 1218:3-14. PMID: 20946581.
      View in: PubMed
    313. Hadji P, Gnant M, Aapro M, Lipton A, Coleman R. Dosing of zoledronic acid throughout the treatment continuum in breast cancer. Crit Rev Oncol Hematol. 2011 Aug; 79(2):175-88. PMID: 20846875.
      View in: PubMed
    314. Zand B, Euscher ED, Soliman PT, Schmeler KM, Coleman RL, Frumovitz M, Jhingran A, Ramondetta LM, Ramirez PT. Rate of para-aortic lymph node micrometastasis in patients with locally advanced cervical cancer. Gynecol Oncol. 2010 Dec; 119(3):422-5. PMID: 20837355.
      View in: PubMed
    315. Coleman RE, Banks LM, Girgis SI, Vrdoljak E, Fox J, Cawthorn SJ, Patel A, Bliss JM, Coombes RC, Kilburn LS. Reversal of skeletal effects of endocrine treatments in the Intergroup Exemestane Study. Breast Cancer Res Treat. 2010 Nov; 124(1):153-61. PMID: 20730486.
      View in: PubMed
    316. Smith AL, Frumovitz M, Schmeler KM, dos Reis R, Nick AM, Coleman RL, Ramirez PT. Conservative surgery in early-stage cervical cancer: what percentage of patients may be eligible for conization and lymphadenectomy? Gynecol Oncol. 2010 Nov; 119(2):183-6. PMID: 20708227.
      View in: PubMed
    317. Lu C, Han HD, Mangala LS, Ali-Fehmi R, Newton CS, Ozbun L, Armaiz-Pena GN, Hu W, Stone RL, Munkarah A, Ravoori MK, Shahzad MM, Lee JW, Mora E, Langley RR, Carroll AR, Matsuo K, Spannuth WA, Schmandt R, Jennings NB, Goodman BW, Jaffe RB, Nick AM, Kim HS, Guven EO, Chen YH, Li LY, Hsu MC, Coleman RL, Calin GA, Denkbas EB, Lim JY, Lee JS, Kundra V, Birrer MJ, Hung MC, Lopez-Berestein G, Sood AK. Regulation of tumor angiogenesis by EZH2. Cancer Cell. 2010 Aug 09; 18(2):185-97. PMID: 20708159.
      View in: PubMed
    318. Schorge JO, Modesitt SC, Coleman RL, Cohn DE, Kauff ND, Duska LR, Herzog TJ. SGO White Paper on ovarian cancer: etiology, screening and surveillance. Gynecol Oncol. 2010 Oct; 119(1):7-17. PMID: 20692025.
      View in: PubMed
    319. Spannuth WA, Mangala LS, Stone RL, Carroll AR, Nishimura M, Shahzad MM, Lee SJ, Moreno-Smith M, Nick AM, Liu R, Jennings NB, Lin YG, Merritt WM, Coleman RL, Vivas-Mejia PE, Zhou Y, Krasnoperov V, Lopez-Berestein G, Gill PS, Sood AK. Converging evidence for efficacy from parallel EphB4-targeted approaches in ovarian carcinoma. Mol Cancer Ther. 2010 Aug; 9(8):2377-88. PMID: 20682653.
      View in: PubMed
    320. Slomovitz BM, Lu KH, Johnston T, Coleman RL, Munsell M, Broaddus RR, Walker C, Ramondetta LM, Burke TW, Gershenson DM, Wolf J. A phase 2 study of the oral mammalian target of rapamycin inhibitor, everolimus, in patients with recurrent endometrial carcinoma. Cancer. 2010 Dec 01; 116(23):5415-9. PMID: 20681032.
      View in: PubMed
    321. Price JM, Hancock BW, Tidy J, Everard J, Coleman RE. Screening for central nervous system disease in metastatic gestational trophoblastic neoplasia. J Reprod Med. 2010 Jul-Aug; 55(7-8):301-4. PMID: 20795342.
      View in: PubMed
    322. Brown JE, Cook RJ, Lipton A, Costa L, Coleman RE. Prognostic factors for skeletal complications from metastatic bone disease in breast cancer. Breast Cancer Res Treat. 2010 Oct; 123(3):767-79. PMID: 20574672.
      View in: PubMed
    323. Mansi JL, Yellowlees A, Lipscombe J, Earl HM, Cameron DA, Coleman RE, Perren T, Gallagher CJ, Quigley M, Crown J, Jones AL, Highley M, Leonard RC, Evans TR. Five-year outcome for women randomised in a phase III trial comparing doxorubicin and cyclophosphamide with doxorubicin and docetaxel as primary medical therapy in early breast cancer: an Anglo-Celtic Cooperative Oncology Group study. Breast Cancer Res Treat. 2010 Aug; 122(3):787-94. PMID: 20559708.
      View in: PubMed
    324. Neville-Webbe HL, Gnant M, Coleman RE. Potential anticancer properties of bisphosphonates. Semin Oncol. 2010 Jun; 37 Suppl 1:S53-65. PMID: 20682373.
      View in: PubMed
    325. Betsou F, Rimm DL, Watson PH, Womack C, Hubel A, Coleman RA, Horn L, Terry SF, Zeps N, Clark BJ, Miranda LB, Hewitt RE, Elliott GD. What are the biggest challenges and opportunities for biorepositories in the next three to five years? Biopreserv Biobank. 2010 Jun; 8(2):81-8. PMID: 24845936.
      View in: PubMed
    326. Coleman RE, Lipton A, Roodman GD, Guise TA, Boyce BF, Brufsky AM, Clézardin P, Croucher PI, Gralow JR, Hadji P, Holen I, Mundy GR, Smith MR, Suva LJ. Metastasis and bone loss: advancing treatment and prevention. Cancer Treat Rev. 2010 Dec; 36(8):615-20. PMID: 20478658.
      View in: PubMed
    327. Michailidou M, Brown HK, Lefley DV, Evans A, Cross SS, Coleman RE, Brown NJ, Holen I. Microvascular endothelial cell responses in vitro and in vivo: modulation by zoledronic acid and paclitaxel? J Vasc Res. 2010; 47(6):481-93. PMID: 20431297.
      View in: PubMed
    328. Kamat AA, Baldwin M, Urbauer D, Dang D, Han LY, Godwin A, Karlan BY, Simpson JL, Gershenson DM, Coleman RL, Bischoff FZ, Sood AK. Plasma cell-free DNA in ovarian cancer: an independent prognostic biomarker. Cancer. 2010 Apr 15; 116(8):1918-25. PMID: 20166213.
      View in: PubMed
    329. Lee JW, Stone RL, Lee SJ, Nam EJ, Roh JW, Nick AM, Han HD, Shahzad MM, Kim HS, Mangala LS, Jennings NB, Mao S, Gooya J, Jackson D, Coleman RL, Sood AK. EphA2 targeted chemotherapy using an antibody drug conjugate in endometrial carcinoma. Clin Cancer Res. 2010 May 01; 16(9):2562-70. PMID: 20388851.
      View in: PubMed
    330. Merritt WM, Nick AM, Carroll AR, Lu C, Matsuo K, Dumble M, Jennings N, Zhang S, Lin YG, Spannuth WA, Kamat AA, Stone RL, Shahzad MM, Coleman RL, Kumar R, Sood AK. Bridging the gap between cytotoxic and biologic therapy with metronomic topotecan and pazopanib in ovarian cancer. Mol Cancer Ther. 2010 Apr; 9(4):985-95. PMID: 20371710.
      View in: PubMed
    331. Bhattacharya A, Watts NB, Davis K, Kotowski S, Shukla R, Dwivedi AK, Coleman R. Dynamic bone quality: a noninvasive measure of bone's biomechanical property in osteoporosis. J Clin Densitom. 2010 Apr-Jun; 13(2):228-36. PMID: 20347363.
      View in: PubMed
    332. Moroney J, Wheler J, Hong D, Naing A, Falchook G, Bodurka D, Coleman R, Lu K, Xiao L, Kurzrock R. Phase I clinical trials in 85 patients with gynecologic cancer: the M. D. Anderson Cancer Center experience. Gynecol Oncol. 2010 Jun; 117(3):467-72. PMID: 20347123.
      View in: PubMed
    333. Greenfield DM, Walters SJ, Coleman RE, Hancock BW, Snowden JA, Shalet SM, DeRogatis LR, Ross RJ. Quality of life, self-esteem, fatigue, and sexual function in young men after cancer: a controlled cross-sectional study. Cancer. 2010 Mar 15; 116(6):1592-601. PMID: 20186765.
      View in: PubMed
    334. Herzog TJ, Krivak TC, Fader AN, Coleman RL. Chemosensitivity testing with ChemoFx and overall survival in primary ovarian cancer. Am J Obstet Gynecol. 2010 Jul; 203(1):68.e1-6. PMID: 20227055.
      View in: PubMed
    335. Stone RL, Sood AK, Coleman RL. Collateral damage: toxic effects of targeted antiangiogenic therapies in ovarian cancer. Lancet Oncol. 2010 May; 11(5):465-75. PMID: 20226736.
      View in: PubMed
    336. Spannuth WA, Sood AK, Coleman RL. Farletuzumab in epithelial ovarian carcinoma. Expert Opin Biol Ther. 2010 Mar; 10(3):431-7. PMID: 20092424.
      View in: PubMed
    337. Brown JE, Coleman RE. Biomarkers of bone turnover in oncology: applications in diagnosis and treatment. Expert Opin Med Diagn. 2010 Mar; 4(2):125-38. PMID: 23484446.
      View in: PubMed
    338. Din OS, Dodwell D, Wakefield RJ, Coleman RE. Aromatase inhibitor-induced arthralgia in early breast cancer: what do we know and how can we find out more? Breast Cancer Res Treat. 2010 Apr; 120(3):525-38. PMID: 20157776.
      View in: PubMed
    339. Lu C, Shahzad MM, Moreno-Smith M, Lin YG, Jennings NB, Allen JK, Landen CN, Mangala LS, Armaiz-Pena GN, Schmandt R, Nick AM, Stone RL, Jaffe RB, Coleman RL, Sood AK. Targeting pericytes with a PDGF-B aptamer in human ovarian carcinoma models. Cancer Biol Ther. 2010 Feb; 9(3):176-82. PMID: 20009575.
      View in: PubMed
    340. Sood AK, Coleman RL. Targeted therapy in gynecologic oncology: biology, strategy, and assessment. Gynecol Oncol. 2010 Feb; 116(2):155-6. PMID: 20109724.
      View in: PubMed
    341. Ottewell PD, Lefley DV, Cross SS, Evans CA, Coleman RE, Holen I. Sustained inhibition of tumor growth and prolonged survival following sequential administration of doxorubicin and zoledronic acid in a breast cancer model. Int J Cancer. 2010 Jan 15; 126(2):522-32. PMID: 19621384.
      View in: PubMed
    342. Holen I, Coleman RE. Bisphosphonates as treatment of bone metastases. Curr Pharm Des. 2010; 16(11):1262-71. PMID: 20166976.
      View in: PubMed
    343. Coleman RE, Walsh JS. Bone: causes of low bone mass in breast cancer-time for action? Nat Rev Endocrinol. 2010 Jan; 6(1):10-2. PMID: 20010963.
      View in: PubMed
    344. Kim TJ, Landen CN, Lin YG, Mangala LS, Lu C, Nick AM, Stone RL, Merritt WM, Armaiz-Pena G, Jennings NB, Coleman RL, Tice DA, Sood AK. Combined anti-angiogenic therapy against VEGF and integrin alphaVbeta3 in an orthotopic model of ovarian cancer. Cancer Biol Ther. 2009 Dec; 8(23):2263-72. PMID: 19829059.
      View in: PubMed
    345. Monk BJ, Coleman RL. Changing the paradigm in the treatment of platinum-sensitive recurrent ovarian cancer: from platinum doublets to nonplatinum doublets and adding antiangiogenesis compounds. Int J Gynecol Cancer. 2009 Dec; 19 Suppl 2:S63-7. PMID: 19955917.
      View in: PubMed
    346. Lester JE, Brown JE, Hannon RA, Ellis SP, Horsman JM, Purohit OP, Coleman RE. The use of a point of care device for monitoring the bone resorption biomarker urinary N-telopeptide in cancer patients with bone metastases. Bone. 2010 Mar; 46(3):801-5. PMID: 19931437.
      View in: PubMed
    347. Coleman RL. Emergence of truly "individualized" therapy: the poly (adenosine diphosphate-ribose) polymerase inhibitors. Curr Oncol Rep. 2009 Nov; 11(6):414-6. PMID: 19840517.
      View in: PubMed
    348. Winter MC, Coleman RE. Bisphosphonates in breast cancer: teaching an old dog new tricks. Curr Opin Oncol. 2009 Nov; 21(6):499-506. PMID: 19730102.
      View in: PubMed
    349. Ottewell PD, Woodward JK, Lefley DV, Evans CA, Coleman RE, Holen I. Anticancer mechanisms of doxorubicin and zoledronic acid in breast cancer tumor growth in bone. Mol Cancer Ther. 2009 Oct; 8(10):2821-32. PMID: 19789217.
      View in: PubMed
    350. Hennessy BT, Coleman RL, Markman M. Ovarian cancer. Lancet. 2009 Oct 17; 374(9698):1371-82. PMID: 19793610.
      View in: PubMed
    351. Coleman R, Gnant M. New results from the use of bisphosphonates in cancer patients. Curr Opin Support Palliat Care. 2009 Sep; 3(3):213-8. PMID: 19561507.
      View in: PubMed
    352. Biganzoli L, Bonnefoi H, Cardoso F, Coleman R, Thürlimann B. ASCO 2009: What's New in Breast Cancer Therapy? Breast Care (Basel). 2009; 4(4):268-271. PMID: 20877666.
      View in: PubMed
    353. Merritt WM, Danes CG, Shahzad MM, Lin YG, Kamat AA, Han LY, Spannuth WA, Nick AM, Mangala LS, Stone RL, Kim HS, Gershenson DM, Jaffe RB, Coleman RL, Chandra J, Sood AK. Anti-angiogenic properties of metronomic topotecan in ovarian carcinoma. Cancer Biol Ther. 2009 Aug; 8(16):1596-603. PMID: 19738426.
      View in: PubMed
    354. Major PP, Cook RJ, Lipton A, Smith MR, Terpos E, Coleman RE. Natural history of malignant bone disease in breast cancer and the use of cumulative mean functions to measure skeletal morbidity. BMC Cancer. 2009 Aug 06; 9:272. PMID: 19660124.
      View in: PubMed
    355. Dodwell D, Thorpe H, Coleman R. Refining systemic therapy for early breast cancer: difficulties with subtraction. Lancet Oncol. 2009 Aug; 10(8):738-9. PMID: 19647192.
      View in: PubMed
    356. Levenback CF, van der Zee AG, Rob L, Plante M, Covens A, Schneider A, Coleman R, Solima E, Hertel H, Barranger E, Obermair A, Roy M. Sentinel lymph node biopsy in patients with gynecologic cancers Expert panel statement from the International Sentinel Node Society Meeting, February 21, 2008. Gynecol Oncol. 2009 Aug; 114(2):151-6. PMID: 19457548.
      View in: PubMed
    357. Lee JW, Han HD, Shahzad MM, Kim SW, Mangala LS, Nick AM, Lu C, Langley RR, Schmandt R, Kim HS, Mao S, Gooya J, Fazenbaker C, Jackson D, Tice DA, Landen CN, Coleman RL, Sood AK. EphA2 immunoconjugate as molecularly targeted chemotherapy for ovarian carcinoma. J Natl Cancer Inst. 2009 Sep 02; 101(17):1193-205. PMID: 19641174.
      View in: PubMed
    358. Liu WL, Coleman RA, Ma E, Grob P, Yang JL, Zhang Y, Dailey G, Nogales E, Tjian R. Structures of three distinct activator-TFIID complexes. Genes Dev. 2009 Jul 01; 23(13):1510-21. PMID: 19571180.
      View in: PubMed
    359. Shahzad MM, Lu C, Lee JW, Stone RL, Mitra R, Mangala LS, Lu Y, Baggerly KA, Danes CG, Nick AM, Halder J, Kim HS, Vivas-Mejia P, Landen CN, Lopez-Berestein G, Coleman RL, Sood AK. Dual targeting of EphA2 and FAK in ovarian carcinoma. Cancer Biol Ther. 2009 Jun; 8(11):1027-34. PMID: 19395869.
      View in: PubMed
    360. Aboumarzouk OM, Coleman R, Goepel JR, Shorthouse AJ. PNET/Ewing's sarcoma of the rectum: a case report and review of the literature. BMJ Case Rep. 2009; 2009. PMID: 21691396.
      View in: PubMed
    361. Kamat AA, Coffey D, Merritt WM, Nugent E, Urbauer D, Lin YG, Edwards C, Broaddus R, Coleman RL, Sood AK. EphA2 overexpression is associated with lack of hormone receptor expression and poor outcome in endometrial cancer. Cancer. 2009 Jun 15; 115(12):2684-92. PMID: 19396818.
      View in: PubMed
    362. Tao X, Sood AK, Deavers MT, Schmeler KM, Nick AM, Coleman RL, Milojevic L, Gershenson DM, Brown J. Anti-angiogenesis therapy with bevacizumab for patients with ovarian granulosa cell tumors. Gynecol Oncol. 2009 Sep; 114(3):431-6. PMID: 19524286.
      View in: PubMed
    363. Dranitsaris G, Coleman R, Gradishar W. nab-Paclitaxel weekly or every 3 weeks compared to standard docetaxel as first-line therapy in patients with metastatic breast cancer: an economic analysis of a prospective randomized trial. Breast Cancer Res Treat. 2010 Feb; 119(3):717-24. PMID: 19495958.
      View in: PubMed
    364. Moroney JW, Sood AK, Coleman RL. Aflibercept in epithelial ovarian carcinoma. Future Oncol. 2009 Jun; 5(5):591-600. PMID: 19519199.
      View in: PubMed
    365. Mangala LS, Zuzel V, Schmandt R, Leshane ES, Halder JB, Armaiz-Pena GN, Spannuth WA, Tanaka T, Shahzad MM, Lin YG, Nick AM, Danes CG, Lee JW, Jennings NB, Vivas-Mejia PE, Wolf JK, Coleman RL, Siddik ZH, Lopez-Berestein G, Lutsenko S, Sood AK. Therapeutic Targeting of ATP7B in Ovarian Carcinoma. Clin Cancer Res. 2009 Jun 01; 15(11):3770-80. PMID: 19470734.
      View in: PubMed
    366. Ellis P, Barrett-Lee P, Johnson L, Cameron D, Wardley A, O'Reilly S, Verrill M, Smith I, Yarnold J, Coleman R, Earl H, Canney P, Twelves C, Poole C, Bloomfield D, Hopwood P, Johnston S, Dowsett M, Bartlett JM, Ellis I, Peckitt C, Hall E, Bliss JM. Sequential docetaxel as adjuvant chemotherapy for early breast cancer (TACT): an open-label, phase III, randomised controlled trial. Lancet. 2009 May 16; 373(9676):1681-92. PMID: 19447249.
      View in: PubMed
    367. Gershenson DM, Sun CC, Bodurka D, Coleman RL, Lu KH, Sood AK, Deavers M, Malpica AL, Kavanagh JJ. Recurrent low-grade serous ovarian carcinoma is relatively chemoresistant. Gynecol Oncol. 2009 Jul; 114(1):48-52. PMID: 19361839.
      View in: PubMed
    368. Santoso JT, Azadi A, Wan J, Handorf C, Coleman RL, Tillmanns TD. Lymph node counts in uterine cancer: a randomized double blind trial. Gynecol Oncol. 2009 May; 113(2):159-62. PMID: 19268343.
      View in: PubMed
    369. Khalifeh I, Deavers MT, Cristofanilli M, Coleman RL, Malpica A, Gilcrease MZ. Primary peritoneal serous carcinoma presenting as inflammatory breast cancer. Breast J. 2009 Mar-Apr; 15(2):176-81. PMID: 19292804.
      View in: PubMed
    370. Spannuth WA, Nick AM, Jennings NB, Armaiz-Pena GN, Mangala LS, Danes CG, Lin YG, Merritt WM, Thaker PH, Kamat AA, Han LY, Tonra JR, Coleman RL, Ellis LM, Sood AK. Functional significance of VEGFR-2 on ovarian cancer cells. Int J Cancer. 2009 Mar 01; 124(5):1045-53. PMID: 19058181.
      View in: PubMed
    371. Kamat AA, Coleman RL. Erythropoeisis-stimulating agents (ESAs) in cervix cancer: The "black box" paradox. Cancer Biol Ther. 2009 Jan; 8(1):18-20. PMID: 19127119.
      View in: PubMed
    372. Merritt WM, Lin YG, Han LY, Kamat AA, Spannuth WA, Schmandt R, Urbauer D, Pennacchio LA, Cheng JF, Nick AM, Deavers MT, Mourad-Zeidan A, Wang H, Mueller P, Lenburg ME, Gray JW, Mok S, Birrer MJ, Lopez-Berestein G, Coleman RL, Bar-Eli M, Sood AK. Dicer, Drosha, and outcomes in patients with ovarian cancer. N Engl J Med. 2008 Dec 18; 359(25):2641-50. PMID: 19092150.
      View in: PubMed
    373. Coleman RE. Zoledronic acid ameliorates the effects of endocrine therapy on bone health in women with early-stage breast cancer. Nat Clin Pract Endocrinol Metab. 2009 Feb; 5(2):72-3. PMID: 19065127.
      View in: PubMed
    374. Jandial DD, Soliman PT, Slomovitz BM, Schmeler KM, Levenback C, Coleman RL, Ramirez PT. Laparoscopic colostomy in gynecologic cancer. J Minim Invasive Gynecol. 2008 Nov-Dec; 15(6):723-8. PMID: 18971136.
      View in: PubMed
    375. Coleman RL. Lymphatic mapping for vulvar cancer: ready for "prime-time?". Curr Oncol Rep. 2008 Nov; 10(6):493-6. PMID: 18928663.
      View in: PubMed
    376. Lipton A, Steger GG, Figueroa J, Alvarado C, Solal-Celigny P, Body JJ, de Boer R, Berardi R, Gascon P, Tonkin KS, Coleman RE, Paterson AH, Gao GM, Kinsey AC, Peterson MC, Jun S. Extended efficacy and safety of denosumab in breast cancer patients with bone metastases not receiving prior bisphosphonate therapy. Clin Cancer Res. 2008 Oct 15; 14(20):6690-6. PMID: 18927312.
      View in: PubMed
    377. Coleman RE, Guise TA, Lipton A, Roodman GD, Berenson JR, Body JJ, Boyce BF, Calvi LM, Hadji P, McCloskey EV, Saad F, Smith MR, Suva LJ, Taichman RS, Vessella RL, Weilbaecher KN. Advancing treatment for metastatic bone cancer: consensus recommendations from the Second Cambridge Conference. Clin Cancer Res. 2008 Oct 15; 14(20):6387-95. PMID: 18927277.
      View in: PubMed
    378. Lester JE, Dodwell D, Purohit OP, Gutcher SA, Ellis SP, Thorpe R, Horsman JM, Brown JE, Hannon RA, Coleman RE. Prevention of anastrozole-induced bone loss with monthly oral ibandronate during adjuvant aromatase inhibitor therapy for breast cancer. Clin Cancer Res. 2008 Oct 01; 14(19):6336-42. PMID: 18829518.
      View in: PubMed
    379. Herzog TJ, Powell MA, Rader JS, Gibb RK, Lippmann L, Coleman RL, Mutch DG. Phase II evaluation of topotecan and navelbine in patients with recurrent ovarian, fallopian tube or primary peritoneal cancer. Gynecol Oncol. 2008 Dec; 111(3):467-73. PMID: 18834619.
      View in: PubMed
    380. Lin YG, Immaneni A, Merritt WM, Mangala LS, Kim SW, Shahzad MM, Tsang YT, Armaiz-Pena GN, Lu C, Kamat AA, Han LY, Spannuth WA, Nick AM, Landen CN, Wong KK, Gray MJ, Coleman RL, Bodurka DC, Brinkley WR, Sood AK. Targeting aurora kinase with MK-0457 inhibits ovarian cancer growth. Clin Cancer Res. 2008 Sep 01; 14(17):5437-46. PMID: 18765535.
      View in: PubMed
    381. Coleman RL, Kohn EC. Rationale for combination use of targeted agents in ovarian cancer: do we have one? Cancer. 2008 Aug 15; 113(4):665-7. PMID: 18623195.
      View in: PubMed
    382. Ottewell PD, Mönkkönen H, Jones M, Lefley DV, Coleman RE, Holen I. Antitumor effects of doxorubicin followed by zoledronic acid in a mouse model of breast cancer. J Natl Cancer Inst. 2008 Aug 20; 100(16):1167-78. PMID: 18695136.
      View in: PubMed
    383. Coleman RL, Levine DA. 44th Annual Meeting of the American Society of Clinical Oncology. Gynecol Oncol. 2008 Aug; 110(2):123-4. PMID: 18649408.
      View in: PubMed
    384. Absolom K, Eiser C, Turner L, Ledger W, Ross R, Davies H, Coleman R, Hancock B, Snowden J, Greenfield D. Ovarian failure following cancer treatment: current management and quality of life. Hum Reprod. 2008 Nov; 23(11):2506-12. PMID: 18664468.
      View in: PubMed
    385. Ottewell PD, Deux B, Mönkkönen H, Cross S, Coleman RE, Clezardin P, Holen I. Differential effect of doxorubicin and zoledronic acid on intraosseous versus extraosseous breast tumor growth in vivo. Clin Cancer Res. 2008 Jul 15; 14(14):4658-66. PMID: 18628481.
      View in: PubMed
    386. Hwang JY, Mangala LS, Fok JY, Lin YG, Merritt WM, Spannuth WA, Nick AM, Fiterman DJ, Vivas-Mejia PE, Deavers MT, Coleman RL, Lopez-Berestein G, Mehta K, Sood AK. Clinical and biological significance of tissue transglutaminase in ovarian carcinoma. Cancer Res. 2008 Jul 15; 68(14):5849-58. PMID: 18632639.
      View in: PubMed
    387. Lipton A, Cook R, Saad F, Major P, Garnero P, Terpos E, Brown JE, Coleman RE. Normalization of bone markers is associated with improved survival in patients with bone metastases from solid tumors and elevated bone resorption receiving zoledronic acid. Cancer. 2008 Jul 01; 113(1):193-201. PMID: 18459173.
      View in: PubMed
    388. Coleman RL. The Gynecologic Oncology Group's role in the treatment of recurrent cervix cancer: current clinical trials. Gynecol Oncol. 2008 Sep; 110(3 Suppl 2):S77-80. PMID: 18584855.
      View in: PubMed
    389. Coleman R, Brown J, Terpos E, Lipton A, Smith MR, Cook R, Major P. Bone markers and their prognostic value in metastatic bone disease: clinical evidence and future directions. Cancer Treat Rev. 2008 Nov; 34(7):629-39. PMID: 18579314.
      View in: PubMed
    390. Reid DM, Doughty J, Eastell R, Heys SD, Howell A, McCloskey EV, Powles T, Selby P, Coleman RE. Guidance for the management of breast cancer treatment-induced bone loss: a consensus position statement from a UK Expert Group. Cancer Treat Rev. 2008; 34 Suppl 1:S3-18. PMID: 18515009.
      View in: PubMed
    391. Coleman RE, Body JJ, Gralow JR, Lipton A. Bone loss in patients with breast cancer receiving aromatase inhibitors and associated treatment strategies. Cancer Treat Rev. 2008; 34 Suppl 1:S31-42. PMID: 18486346.
      View in: PubMed
    392. Ramirez PT, Schmeler KM, Milam MR, Slomovitz BM, Smith JA, Kavanagh JJ, Deavers M, Levenback C, Coleman RL, Gershenson DM. Efficacy of letrozole in the treatment of recurrent platinum- and taxane-resistant high-grade cancer of the ovary or peritoneum. Gynecol Oncol. 2008 Jul; 110(1):56-9. PMID: 18457865.
      View in: PubMed
    393. Fallowfield L, Jenkins V, Coleman R. Which bisphosphonates do oncologists prescribe for women with metastatic breast cancer and why? Results of a UK survey. Breast. 2008 Oct; 17(5):459-63. PMID: 18455921.
      View in: PubMed
    394. Brufsky A, Bundred N, Coleman R, Lambert-Falls R, Mena R, Hadji P, Jin L, Schenk N, Ericson S, Perez EA. Integrated analysis of zoledronic acid for prevention of aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole. Oncologist. 2008 May; 13(5):503-14. PMID: 18515735.
      View in: PubMed
    395. Lu C, Thaker PH, Lin YG, Spannuth W, Landen CN, Merritt WM, Jennings NB, Langley RR, Gershenson DM, Yancopoulos GD, Ellis LM, Jaffe RB, Coleman RL, Sood AK. Impact of vessel maturation on antiangiogenic therapy in ovarian cancer. Am J Obstet Gynecol. 2008 Apr; 198(4):477.e1-9; discussion 477.e9-10. PMID: 18395047.
      View in: PubMed
    396. Bundred NJ, Campbell ID, Davidson N, DeBoer RH, Eidtmann H, Monnier A, Neven P, von Minckwitz G, Miller JC, Schenk NL, Coleman RE. Effective inhibition of aromatase inhibitor-associated bone loss by zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: ZO-FAST Study results. Cancer. 2008 Mar 01; 112(5):1001-10. PMID: 18205185.
      View in: PubMed
    397. Eastell R, Adams JE, Coleman RE, Howell A, Hannon RA, Cuzick J, Mackey JR, Beckmann MW, Clack G. Effect of anastrozole on bone mineral density: 5-year results from the anastrozole, tamoxifen, alone or in combination trial 18233230. J Clin Oncol. 2008 Mar 01; 26(7):1051-7. PMID: 18309940.
      View in: PubMed
    398. Hirsh V, Major PP, Lipton A, Cook RJ, Langer CJ, Smith MR, Brown JE, Coleman RE. Zoledronic acid and survival in patients with metastatic bone disease from lung cancer and elevated markers of osteoclast activity. J Thorac Oncol. 2008 Mar; 3(3):228-36. PMID: 18317064.
      View in: PubMed
    399. Spannuth WA, Sood AK, Coleman RL. Angiogenesis as a strategic target for ovarian cancer therapy. Nat Clin Pract Oncol. 2008 Apr; 5(4):194-204. PMID: 18268546.
      View in: PubMed
    400. Liu WL, Coleman RA, Grob P, King DS, Florens L, Washburn MP, Geles KG, Yang JL, Ramey V, Nogales E, Tjian R. Structural changes in TAF4b-TFIID correlate with promoter selectivity. Mol Cell. 2008 Jan 18; 29(1):81-91. PMID: 18206971.
      View in: PubMed
    401. Frumovitz M, Gayed IW, Jhingran A, Euscher ED, Coleman RL, Ramirez PT, Levenback CF. Lymphatic mapping and sentinel lymph node detection in women with vaginal cancer. Gynecol Oncol. 2008 Mar; 108(3):478-81. PMID: 18190952.
      View in: PubMed
    402. Gatcliffe TA, Coleman RL. Tumor board: more than treatment planning--a 1-year prospective survey. J Cancer Educ. 2008; 23(4):235-7. PMID: 19058072.
      View in: PubMed
    403. Schmeler KM, Sun CC, Bodurka DC, Deavers MT, Malpica A, Coleman RL, Ramirez PT, Gershenson DM. Neoadjuvant chemotherapy for low-grade serous carcinoma of the ovary or peritoneum. Gynecol Oncol. 2008 Mar; 108(3):510-4. PMID: 18155273.
      View in: PubMed
    404. Kamat AA, Merritt WM, Coffey D, Lin YG, Patel PR, Broaddus R, Nugent E, Han LY, Landen CN, Spannuth WA, Lu C, Coleman RL, Gershenson DM, Sood AK. Clinical and biological significance of vascular endothelial growth factor in endometrial cancer. Clin Cancer Res. 2007 Dec 15; 13(24):7487-95. PMID: 18094433.
      View in: PubMed
    405. Coleman RE. Emerging strategies in bone health management for the adjuvant patient. Semin Oncol. 2007 Dec; 34(6 Suppl 4):S11-6. PMID: 18068485.
      View in: PubMed
    406. Coleman RE. Preserving skeletal wellness throughout the continuum of care in patients with cancer. Introduction. Semin Oncol. 2007 Dec; 34(6 Suppl 4):S1-3. PMID: 18068484.
      View in: PubMed
    407. Isonishi S, Coleman RL, Hirama M, Iida Y, Kitai S, Nagase M, Ochiai K. Analysis of prognostic factors for patients with leiomyoma treated with uterine arterial embolization. Am J Obstet Gynecol. 2008 Mar; 198(3):270.e1-6. PMID: 17997392.
      View in: PubMed
    408. Coleman RL. Gemcitabine plus carboplatin compared with carboplatin alone for platinum-sensitive recurrent ovarian cancer. Curr Oncol Rep. 2007 Nov; 9(6):469-71. PMID: 17991354.
      View in: PubMed
    409. Coleman RE. The benefits and costs of bisphosphonates. J Support Oncol. 2007 Nov-Dec; 5(10):483-4. PMID: 18240670.
      View in: PubMed
    410. Pajk B, Cufer T, Canney P, Ellis P, Cameron D, Blot E, Vermorken J, Coleman R, Marreaud S, Bogaerts J, Basaran G, Piccart M. Anti-tumor activity of capecitabine and vinorelbine in patients with anthracycline- and taxane-pretreated metastatic breast cancer: findings from the EORTC 10001 randomized phase II trial. Breast. 2008 Apr; 17(2):180-5. PMID: 17976988.
      View in: PubMed
    411. Saad F, Lipton A, Cook R, Chen YM, Smith M, Coleman R. Pathologic fractures correlate with reduced survival in patients with malignant bone disease. Cancer. 2007 Oct 15; 110(8):1860-7. PMID: 17763372.
      View in: PubMed
    412. Ramirez PT, Landen CN, Coleman RL, Milam MR, Levenback C, Johnston TA, Gershenson DM. Phase I trial of the proteasome inhibitor bortezomib in combination with carboplatin in patients with platinum- and taxane-resistant ovarian cancer. Gynecol Oncol. 2008 Jan; 108(1):68-71. PMID: 17905421.
      View in: PubMed
    413. Kim TJ, Ravoori M, Landen CN, Kamat AA, Han LY, Lu C, Lin YG, Merritt WM, Jennings N, Spannuth WA, Langley R, Gershenson DM, Coleman RL, Kundra V, Sood AK. Antitumor and antivascular effects of AVE8062 in ovarian carcinoma. Cancer Res. 2007 Oct 01; 67(19):9337-45. PMID: 17909042.
      View in: PubMed
    414. Brown JE, Ellis SP, Lester JE, Gutcher S, Khanna T, Purohit OP, McCloskey E, Coleman RE. Prolonged efficacy of a single dose of the bisphosphonate zoledronic acid. Clin Cancer Res. 2007 Sep 15; 13(18 Pt 1):5406-10. PMID: 17875770.
      View in: PubMed
    415. dos Reis R, Frumovitz M, Milam MR, Capp E, Sun CC, Coleman RL, Ramirez PT. Adenosquamous carcinoma versus adenocarcinoma in early-stage cervical cancer patients undergoing radical hysterectomy: an outcomes analysis. Gynecol Oncol. 2007 Dec; 107(3):458-63. PMID: 17854872.
      View in: PubMed
    416. Lipton A, Steger GG, Figueroa J, Alvarado C, Solal-Celigny P, Body JJ, de Boer R, Berardi R, Gascon P, Tonkin KS, Coleman R, Paterson AH, Peterson MC, Fan M, Kinsey A, Jun S. Randomized active-controlled phase II study of denosumab efficacy and safety in patients with breast cancer-related bone metastases. J Clin Oncol. 2007 Oct 01; 25(28):4431-7. PMID: 17785705.
      View in: PubMed
    417. Lipton A, Cook RJ, Major P, Smith MR, Coleman RE. Zoledronic acid and survival in breast cancer patients with bone metastases and elevated markers of osteoclast activity. Oncologist. 2007 Sep; 12(9):1035-43. PMID: 17914073.
      View in: PubMed
    418. Woodward JK, Holen I, Coleman RE, Buttle DJ. The roles of proteolytic enzymes in the development of tumour-induced bone disease in breast and prostate cancer. Bone. 2007 Dec; 41(6):912-27. PMID: 17945547.
      View in: PubMed
    419. Ramirez PT, Frumovitz M, Dos Reis R, Milam MR, Bevers MW, Levenback CF, Coleman RL. Modified uterine manipulator and vaginal rings for total laparoscopic radical hysterectomy. Int J Gynecol Cancer. 2008 May-Jun; 18(3):571-5. PMID: 17692091.
      View in: PubMed
    420. Smith MR, Cook RJ, Coleman R, Brown J, Lipton A, Major P, Hei YJ, Saad F. Predictors of skeletal complications in men with hormone-refractory metastatic prostate cancer. Urology. 2007 Aug; 70(2):315-9. PMID: 17826496.
      View in: PubMed
    421. Lu C, Kamat AA, Lin YG, Merritt WM, Landen CN, Kim TJ, Spannuth W, Arumugam T, Han LY, Jennings NB, Logsdon C, Jaffe RB, Coleman RL, Sood AK. Dual targeting of endothelial cells and pericytes in antivascular therapy for ovarian carcinoma. Clin Cancer Res. 2007 Jul 15; 13(14):4209-17. PMID: 17634550.
      View in: PubMed
    422. Coleman R. Potential use of bisphosphonates in the prevention of metastases in early-stage breast cancer. Clin Breast Cancer. 2007 Jul; 7 Suppl 1:S29-35. PMID: 17683651.
      View in: PubMed
    423. Daley AJ, Crank H, Mutrie N, Saxton JM, Coleman R. Determinants of adherence to exercise in women treated for breast cancer. Eur J Oncol Nurs. 2007 Dec; 11(5):392-9. PMID: 17524796.
      View in: PubMed
    424. Li Y, Finkel KW, Hu W, Fu S, Liu J, Coleman R, Kavanagh JJ. Pegylated liposomal doxorubicin treatment in recurrent gynecologic cancer patients with renal dysfunction. Gynecol Oncol. 2007 Aug; 106(2):375-80. PMID: 17512575.
      View in: PubMed
    425. Daley AJ, Crank H, Saxton JM, Mutrie N, Coleman R, Roalfe A. Randomized trial of exercise therapy in women treated for breast cancer. J Clin Oncol. 2007 May 01; 25(13):1713-21. PMID: 17470863.
      View in: PubMed
    426. Martin J, Coleman R, Mundy G. VIth meeting on cancer-induced bone disease. Expert Rev Anticancer Ther. 2007 Apr; 7(4):461-4. PMID: 17428166.
      View in: PubMed
    427. Daley AJ, Crank H, Mutrie N, Saxton JM, Coleman R. Patient recruitment into a randomised controlled trial of supervised exercise therapy in sedentary women treated for breast cancer. Contemp Clin Trials. 2007 Sep; 28(5):603-13. PMID: 17433791.
      View in: PubMed
    428. Lipton A, Cook RJ, Coleman RE, Smith MR, Major P, Terpos E, Berenson JR. Clinical utility of biochemical markers of bone metabolism for improving the management of patients with advanced multiple myeloma. Clin Lymphoma Myeloma. 2007 Mar; 7(5):346-53. PMID: 17562244.
      View in: PubMed
    429. Eiser C, Absolom K, Greenfield D, Snowden J, Coleman R, Hancock B, Davies H. Follow-up care for young adult survivors of cancer: lessons from pediatrics. J Cancer Surviv. 2007 Mar; 1(1):75-86. PMID: 18648947.
      View in: PubMed
    430. Milam MR, Sood AK, King S, Bassett RL, Lu KH, Slomovitz BM, Coleman RL, Ramirez PT. Supracervical hysterectomy in patients with advanced epithelial ovarian cancer. Obstet Gynecol. 2007 Mar; 109(3):641-6. PMID: 17329515.
      View in: PubMed
    431. Saucier JM, Yu J, Gaikwad A, Coleman RL, Wolf JK, Smith JA. Determination of the optimal combination chemotherapy regimen for treatment of platinum-resistant ovarian cancer in nude mouse model. J Oncol Pharm Pract. 2007 Mar; 13(1):39-45. PMID: 17621566.
      View in: PubMed
    432. Lu C, Bonome T, Li Y, Kamat AA, Han LY, Schmandt R, Coleman RL, Gershenson DM, Jaffe RB, Birrer MJ, Sood AK. Gene alterations identified by expression profiling in tumor-associated endothelial cells from invasive ovarian carcinoma. Cancer Res. 2007 Feb 15; 67(4):1757-68. PMID: 17308118.
      View in: PubMed
    433. Crotzer DR, Sun CC, Coleman RL, Wolf JK, Levenback CF, Gershenson DM. Lack of effective systemic therapy for recurrent clear cell carcinoma of the ovary. Gynecol Oncol. 2007 May; 105(2):404-8. PMID: 17292461.
      View in: PubMed
    434. Coleman RL. 7th annual International Conference on Ovarian Cancer. Expert Rev Anticancer Ther. 2007 Feb; 7(2):119-21. PMID: 17288523.
      View in: PubMed
    435. Coleman RE, Banks LM, Girgis SI, Kilburn LS, Vrdoljak E, Fox J, Cawthorn SJ, Patel A, Snowdon CF, Hall E, Bliss JM, Coombes RC. Skeletal effects of exemestane on bone-mineral density, bone biomarkers, and fracture incidence in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES): a randomised controlled study. Lancet Oncol. 2007 Feb; 8(2):119-27. PMID: 17267326.
      View in: PubMed
    436. Smith I, Procter M, Gelber RD, Guillaume S, Feyereislova A, Dowsett M, Goldhirsch A, Untch M, Mariani G, Baselga J, Kaufmann M, Cameron D, Bell R, Bergh J, Coleman R, Wardley A, Harbeck N, Lopez RI, Mallmann P, Gelmon K, Wilcken N, Wist E, Sánchez Rovira P, Piccart-Gebhart MJ. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet. 2007 Jan 06; 369(9555):29-36. PMID: 17208639.
      View in: PubMed
    437. Bhattacharya A, Watts NB, Gordon J, Shukla R, Waters T, Bartels S, Coleman R. Bone quantity and quality of youths working on a farm-a pilot study. J Agromedicine. 2007; 12(4):27-38. PMID: 19042677.
      View in: PubMed
    438. Coleman RL, Gordon A, Barter J, Sun S, Rackoff W, Herzog TJ. Early changes in CA125 after treatment with pegylated liposomal doxorubicin or topotecan do not always reflect best response in recurrent ovarian cancer patients. Oncologist. 2007 Jan; 12(1):72-8. PMID: 17227902.
      View in: PubMed
    439. Kamat AA, Kim TJ, Landen CN, Lu C, Han LY, Lin YG, Merritt WM, Thaker PH, Gershenson DM, Bischoff FZ, Heymach JV, Jaffe RB, Coleman RL, Sood AK. Metronomic chemotherapy enhances the efficacy of antivascular therapy in ovarian cancer. Cancer Res. 2007 Jan 01; 67(1):281-8. PMID: 17210709.
      View in: PubMed
    440. Landen CN, Merritt WM, Mangala LS, Sanguino AM, Bucana C, Lu C, Lin YG, Han LY, Kamat AA, Schmandt R, Coleman RL, Gershenson DM, Lopez-Berestein G, Sood AK. Intraperitoneal delivery of liposomal siRNA for therapy of advanced ovarian cancer. Cancer Biol Ther. 2006 Dec; 5(12):1708-13. PMID: 17106249.
      View in: PubMed
    441. Naumann RW, Coleman RL. The use of adjuvant radiation therapy in early endometrial cancer by members of the Society of Gynecologic Oncologists in 2005. Gynecol Oncol. 2007 Apr; 105(1):7-12. PMID: 17187847.
      View in: PubMed
    442. Morales L, Canney P, Dyczka J, Rutgers E, Coleman R, Cufer T, Welnicka-Jaskiewicz M, Nortier J, Bogaerts J, Therasse P, Paridaens R. Postoperative adjuvant chemotherapy followed by adjuvant tamoxifen versus nil for patients with operable breast cancer: a randomised phase III trial of the European Organisation for Research and Treatment of Cancer Breast Group. Eur J Cancer. 2007 Jan; 43(2):331-40. PMID: 17134892.
      View in: PubMed
    443. Biganzoli L, Coleman R, Minisini A, Hamilton A, Aapro M, Therasse P, Mottino G, Bogaerts J, Piccart M. A joined analysis of two European Organization for the Research and Treatment of Cancer (EORTC) studies to evaluate the role of pegylated liposomal doxorubicin (Caelyx) in the treatment of elderly patients with metastatic breast cancer. Crit Rev Oncol Hematol. 2007 Jan; 61(1):84-9. PMID: 17116400.
      View in: PubMed
    444. Coleman RL. Intraperitoneal chemotherapy for frontline ovarian cancer therapy: vindicated or vilified? Curr Oncol Rep. 2006 Nov; 8(6):439-440. PMID: 17091543.
      View in: PubMed
    445. Brown JE, Ellis SP, Silcocks P, Blumsohn A, Gutcher SA, Radstone C, Hancock BW, Hatton MQ, Coleman RE. Effect of chemotherapy on skeletal health in male survivors from testicular cancer and lymphoma. Clin Cancer Res. 2006 Nov 01; 12(21):6480-6. PMID: 17085662.
      View in: PubMed
    446. Coleman RL, Sood AK. Historical progress in the initial management of ovarian cancer: intraperitoneal chemotherapy. Curr Oncol Rep. 2006 Nov; 8(6):455-64. PMID: 17040624.
      View in: PubMed
    447. Lipton A, Berenson JR, Body JJ, Boyce BF, Bruland OS, Carducci MA, Cleeland CS, Clohisy DR, Coleman RE, Cook RJ, Guise TA, Pearse RN, Powles TJ, Rogers MJ, Roodman GD, Smith MR, Suva LJ, Vessella RL, Weilbaecher KN, King L. Advances in treating metastatic bone cancer: summary statement for the First Cambridge Conference. Clin Cancer Res. 2006 Oct 15; 12(20 Pt 2):6209s-6212s. PMID: 17062702.
      View in: PubMed
    448. Coleman RE. Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin Cancer Res. 2006 Oct 15; 12(20 Pt 2):6243s-6249s. PMID: 17062708.
      View in: PubMed
    449. Frumovitz M, Bodurka DC, Broaddus RR, Coleman RL, Sood AK, Gershenson DM, Burke TW, Levenback CF. Lymphatic mapping and sentinel node biopsy in women with high-risk endometrial cancer. Gynecol Oncol. 2007 Jan; 104(1):100-3. PMID: 16963111.
      View in: PubMed
    450. Han LY, Landen CN, Trevino JG, Halder J, Lin YG, Kamat AA, Kim TJ, Merritt WM, Coleman RL, Gershenson DM, Shakespeare WC, Wang Y, Sundaramoorth R, Metcalf CA, Dalgarno DC, Sawyer TK, Gallick GE, Sood AK. Antiangiogenic and antitumor effects of SRC inhibition in ovarian carcinoma. Cancer Res. 2006 Sep 01; 66(17):8633-9. PMID: 16951177.
      View in: PubMed
    451. El-Helw LM, Naik JD, Chester JD, Joffe JK, Selby PJ, Coleman RE. High-dose chemotherapy with haematopoietic stem-cell support in patients with poor prognosis, relapsed or refractory germ cell tumours. BJU Int. 2006 Sep; 98(3):519-25. PMID: 16925746.
      View in: PubMed
    452. Halder J, Kamat AA, Landen CN, Han LY, Lutgendorf SK, Lin YG, Merritt WM, Jennings NB, Chavez-Reyes A, Coleman RL, Gershenson DM, Schmandt R, Cole SW, Lopez-Berestein G, Sood AK. Focal adhesion kinase targeting using in vivo short interfering RNA delivery in neutral liposomes for ovarian carcinoma therapy. Clin Cancer Res. 2006 Aug 15; 12(16):4916-24. PMID: 16914580.
      View in: PubMed
    453. Gershenson DM, Sun CC, Lu KH, Coleman RL, Sood AK, Malpica A, Deavers MT, Silva EG, Bodurka DC. Clinical behavior of stage II-IV low-grade serous carcinoma of the ovary. Obstet Gynecol. 2006 Aug; 108(2):361-8. PMID: 16880307.
      View in: PubMed
    454. Thaker PH, Han LY, Kamat AA, Arevalo JM, Takahashi R, Lu C, Jennings NB, Armaiz-Pena G, Bankson JA, Ravoori M, Merritt WM, Lin YG, Mangala LS, Kim TJ, Coleman RL, Landen CN, Li Y, Felix E, Sanguino AM, Newman RA, Lloyd M, Gershenson DM, Kundra V, Lopez-Berestein G, Lutgendorf SK, Cole SW, Sood AK. Chronic stress promotes tumor growth and angiogenesis in a mouse model of ovarian carcinoma. Nat Med. 2006 Aug; 12(8):939-44. PMID: 16862152.
      View in: PubMed
    455. Ramirez PT, Slomovitz BM, McQuinn L, Levenback C, Coleman RL. Role of appendectomy at the time of primary surgery in patients with early-stage ovarian cancer. Gynecol Oncol. 2006 Dec; 103(3):888-90. PMID: 16806436.
      View in: PubMed
    456. Cook RJ, Coleman R, Brown J, Lipton A, Major P, Hei YJ, Saad F, Smith MR. Markers of bone metabolism and survival in men with hormone-refractory metastatic prostate cancer. Clin Cancer Res. 2006 Jun 01; 12(11 Pt 1):3361-7. PMID: 16740758.
      View in: PubMed
    457. Gossner G, Coleman RL, Mutch DG, Horowitz NS, Rader JS, Gibb RK, Powell MA, Herzog TJ. CA-125 response in patients with recurrent ovarian or primary peritoneal cancer treated with pegylated liposomal doxorubicin or topotecan. Gynecol Oncol. 2006 Oct; 103(1):212-8. PMID: 16677696.
      View in: PubMed
    458. Coleman RL, Frumovitz M, Levenback CF. Current perspectives on lymphatic mapping in carcinomas of the uterine corpus and cervix. J Natl Compr Canc Netw. 2006 May; 4(5):471-8. PMID: 16687095.
      View in: PubMed
    459. Santini D, Vincenzi B, Hannon RA, Brown JE, Dicuonzo G, Angeletti S, La Cesa A, Coleman RE, Tonini G, Budillon A, Caraglia M, Holen I. Changes in bone resorption and vascular endothelial growth factor after a single zoledronic acid infusion in cancer patients with bone metastases from solid tumours. Oncol Rep. 2006 May; 15(5):1351-7. PMID: 16596210.
      View in: PubMed
    460. Coleman R, Huggett KN, Lofgreen AS. Behaviour change project for second-year medical students. Med Educ. 2006 May; 40(5):462-3. PMID: 16635128.
      View in: PubMed
    461. Herzog TJ, Coleman RL, Guerrieri JP, Gabriel K, Du W, Techner L, Fort JG, Wallin B. A double-blind, randomized, placebo-controlled phase III study of the safety of alvimopan in patients who undergo simple total abdominal hysterectomy. Am J Obstet Gynecol. 2006 Aug; 195(2):445-53. PMID: 16626607.
      View in: PubMed
    462. Cross SS, Yang Z, Brown NJ, Balasubramanian SP, Evans CA, Woodward JK, Neville-Webbe HL, Lippitt JM, Reed MW, Coleman RE, Holen I. Osteoprotegerin (OPG)--a potential new role in the regulation of endothelial cell phenotype and tumour angiogenesis? Int J Cancer. 2006 Apr 15; 118(8):1901-8. PMID: 16287088.
      View in: PubMed
    463. Costa L, Lipton A, Coleman RE. Role of bisphosphonates for the management of skeletal complications and bone pain from skeletal metastases. Support Cancer Ther. 2006 Apr 01; 3(3):143-53. PMID: 18632488.
      View in: PubMed
    464. Frumovitz M, Coleman RL, Gayed IW, Ramirez PT, Wolf JK, Gershenson DM, Levenback CF. Usefulness of preoperative lymphoscintigraphy in patients who undergo radical hysterectomy and pelvic lymphadenectomy for cervical cancer. Am J Obstet Gynecol. 2006 Apr; 194(4):1186-93; discussion 1193-5. PMID: 16580331.
      View in: PubMed
    465. Coleman NM, Smith-Zagone MJ, Tanyi J, Anderson ML, Coleman RL, Dyson SW, Reed JA. Primary neuroendocrine carcinoma of the vagina with Merkel cell carcinoma phenotype. Am J Surg Pathol. 2006 Mar; 30(3):405-10. PMID: 16538063.
      View in: PubMed
    466. Slomovitz BM, Ramirez PT, Frumovitz M, Soliman PT, Bevers M, Coleman RL, Levenback C. Electrothermal bipolar coagulation for pelvic exenterations. Gynecol Oncol. 2006 Sep; 102(3):534-6. PMID: 16483643.
      View in: PubMed
    467. Body JJ, Facon T, Coleman RE, Lipton A, Geurs F, Fan M, Holloway D, Peterson MC, Bekker PJ. A study of the biological receptor activator of nuclear factor-kappaB ligand inhibitor, denosumab, in patients with multiple myeloma or bone metastases from breast cancer. Clin Cancer Res. 2006 Feb 15; 12(4):1221-8. PMID: 16489077.
      View in: PubMed
    468. Ramirez PT, Slomovitz BM, Soliman PT, Coleman RL, Levenback C. Total laparoscopic radical hysterectomy and lymphadenectomy: the M. D. Anderson Cancer Center experience. Gynecol Oncol. 2006 Aug; 102(2):252-5. PMID: 16472844.
      View in: PubMed
    469. Saxton JM, Daley A, Woodroofe N, Coleman R, Powers H, Mutrie N, Siddall V, Crank H. Study protocol to investigate the effect of a lifestyle intervention on body weight, psychological health status and risk factors associated with disease recurrence in women recovering from breast cancer treatment [ISRCTN08045231]. BMC Cancer. 2006 Feb 09; 6:35. PMID: 16469108.
      View in: PubMed
    470. Herzog TJ, Coleman RL, Markman M, Cella D, Thigpen JT. The role of maintenance therapy and novel taxanes in ovarian cancer. Gynecol Oncol. 2006 Aug; 102(2):218-25. PMID: 16460787.
      View in: PubMed
    471. Gallion H, Christopherson WA, Coleman RL, DeMars L, Herzog T, Hosford S, Schellhas H, Wells A, Sevin BU. Progression-free interval in ovarian cancer and predictive value of an ex vivo chemoresponse assay. Int J Gynecol Cancer. 2006 Jan-Feb; 16(1):194-201. PMID: 16445633.
      View in: PubMed
    472. Burkinshaw R, Coleman R. Bisphosphonates as adjuvant therapy for breast cancer. Womens Health (Lond). 2006 Jan; 2(1):115-26. PMID: 19803932.
      View in: PubMed
    473. Coleman RE. The role of bone markers in metastatic bone disease. Cancer Treat Rev. 2006; 32 Suppl 1:1-2. PMID: 16680830.
      View in: PubMed
    474. Coleman RE. Conclusion: Bone markers in metastatic bone disease. Cancer Treat Rev. 2006; 32 Suppl 1:27-8. PMID: 16680836.
      View in: PubMed
    475. Albain KS, de la Garza Salazar J, Pienkowski T, Aapro M, Bergh J, Caleffi M, Coleman R, Eiermann W, Icli F, Pegram M, Piccart M, Snyder R, Toi M, Hortobagyi GN. Reducing the global breast cancer burden: the importance of patterns of care research. Clin Breast Cancer. 2005 Dec; 6(5):412-20. PMID: 16381624.
      View in: PubMed
    476. Rao GG, Kurien A, Gossett D, Griffith WF, Coleman RL, Muller CY. A case-control study of methylenetetrahydrofolate reductase polymorphisms in cervical carcinogenesis. Gynecol Oncol. 2006 May; 101(2):250-4. PMID: 16297972.
      View in: PubMed
    477. Coleman RL, Broaddus RR, Bodurka DC, Wolf JK, Burke TW, Kavanagh JJ, Levenback CF, Gershenson DM. Phase II trial of imatinib mesylate in patients with recurrent platinum- and taxane-resistant epithelial ovarian and primary peritoneal cancers. Gynecol Oncol. 2006 Apr; 101(1):126-31. PMID: 16271384.
      View in: PubMed
    478. Goldstein MK, Lavori P, Coleman R, Advani A, Hoffman BB. Improving adherence to guidelines for hypertension drug prescribing: cluster-randomized controlled trial of general versus patient-specific recommendations. Am J Manag Care. 2005 Nov; 11(11):677-85. PMID: 16268751.
      View in: PubMed
    479. Woodward JK, Neville-Webbe HL, Coleman RE, Holen I. Combined effects of zoledronic acid and doxorubicin on breast cancer cell invasion in vitro. Anticancer Drugs. 2005 Sep; 16(8):845-54. PMID: 16096432.
      View in: PubMed
    480. Coleman RE. Supportive care in oncology. Support Care Cancer. 2005 Dec; 13(12):959-60. PMID: 16133072.
      View in: PubMed
    481. Hassadia A, Gillespie A, Tidy J, Everard R G N J, Wells M, Coleman R, Hancock B. Placental site trophoblastic tumour: clinical features and management. Gynecol Oncol. 2005 Dec; 99(3):603-7. PMID: 16085293.
      View in: PubMed
    482. Holen I, Cross SS, Neville-Webbe HL, Cross NA, Balasubramanian SP, Croucher PI, Evans CA, Lippitt JM, Coleman RE, Eaton CL. Osteoprotegerin (OPG) expression by breast cancer cells in vitro and breast tumours in vivo--a role in tumour cell survival? Breast Cancer Res Treat. 2005 Aug; 92(3):207-15. PMID: 16155791.
      View in: PubMed
    483. Coleman RE, Major P, Lipton A, Brown JE, Lee KA, Smith M, Saad F, Zheng M, Hei YJ, Seaman J, Cook R. Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid. J Clin Oncol. 2005 Aug 01; 23(22):4925-35. PMID: 15983391.
      View in: PubMed
    484. Martin M, Pienkowski T, Mackey J, Pawlicki M, Guastalla JP, Weaver C, Tomiak E, Al-Tweigeri T, Chap L, Juhos E, Guevin R, Howell A, Fornander T, Hainsworth J, Coleman R, Vinholes J, Modiano M, Pinter T, Tang SC, Colwell B, Prady C, Provencher L, Walde D, Rodriguez-Lescure A, Hugh J, Loret C, Rupin M, Blitz S, Jacobs P, Murawsky M, Riva A, Vogel C. Adjuvant docetaxel for node-positive breast cancer. N Engl J Med. 2005 Jun 02; 352(22):2302-13. PMID: 15930421.
      View in: PubMed
    485. Sood AK, Coleman RL, Wolf JK, Gershenson DM. Selected highlights from the 5th International Conference on Ovarian Cancer. Houston, TX, USA, 1-4 December 2004. Expert Opin Pharmacother. 2005 Jun; 6(7):1269-75. PMID: 15957979.
      View in: PubMed
    486. Evans TR, Yellowlees A, Foster E, Earl H, Cameron DA, Hutcheon AW, Coleman RE, Perren T, Gallagher CJ, Quigley M, Crown J, Jones AL, Highley M, Leonard RC, Mansi JL. Phase III randomized trial of doxorubicin and docetaxel versus doxorubicin and cyclophosphamide as primary medical therapy in women with breast cancer: an anglo-celtic cooperative oncology group study. J Clin Oncol. 2005 May 01; 23(13):2988-95. PMID: 15860854.
      View in: PubMed
    487. Lester J, Dodwell D, McCloskey E, Coleman R. The causes and treatment of bone loss associated with carcinoma of the breast. Cancer Treat Rev. 2005 Apr; 31(2):115-42. PMID: 15847981.
      View in: PubMed
    488. Fujiwara K, Markman M, Morgan M, Coleman RL. Intraperitoneal carboplatin-based chemotherapy for epithelial ovarian cancer. Gynecol Oncol. 2005 Apr; 97(1):10-5. PMID: 15790431.
      View in: PubMed
    489. Lester J, Coleman R. The use of bisphosphonates in breast cancer. J Br Menopause Soc. 2005 Mar; 11(1):12-7. PMID: 15814057.
      View in: PubMed
    490. Dark GG, Calvert AH, Grimshaw R, Poole C, Swenerton K, Kaye S, Coleman R, Jayson G, Le T, Ellard S, Trudeau M, Vasey P, Hamilton M, Cameron T, Barrett E, Walsh W, McIntosh L, Eisenhauer EA. Randomized trial of two intravenous schedules of the topoisomerase I inhibitor liposomal lurtotecan in women with relapsed epithelial ovarian cancer: a trial of the national cancer institute of Canada clinical trials group. J Clin Oncol. 2005 Mar 20; 23(9):1859-66. PMID: 15699482.
      View in: PubMed
    491. Reed SD, Radeva JI, Glendenning GA, Coleman RE, Schulman KA. Economic evaluation of zoledronic acid versus pamidronate for the prevention of skeletal-related events in metastatic breast cancer and multiple myeloma. Am J Clin Oncol. 2005 Feb; 28(1):8-16. PMID: 15685028.
      View in: PubMed
    492. Neville-Webbe HL, Rostami-Hodjegan A, Evans CA, Coleman RE, Holen I. Sequence- and schedule-dependent enhancement of zoledronic acid induced apoptosis by doxorubicin in breast and prostate cancer cells. Int J Cancer. 2005 Jan 20; 113(3):364-71. PMID: 15455384.
      View in: PubMed
    493. Brown JE, Cook RJ, Major P, Lipton A, Saad F, Smith M, Lee KA, Zheng M, Hei YJ, Coleman RE. Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors. J Natl Cancer Inst. 2005 Jan 05; 97(1):59-69. PMID: 15632381.
      View in: PubMed
    494. Woodward JK, Coleman RE, Holen I. Preclinical evidence for the effect of bisphosphonates and cytotoxic drugs on tumor cell invasion. Anticancer Drugs. 2005 Jan; 16(1):11-9. PMID: 15613899.
      View in: PubMed
    495. Rao GG, Rogers P, Drake RD, Nguyen P, Coleman RL. Phase I clinical trial of weekly paclitaxel, weekly carboplatin, and concurrent radiotherapy for primary cervical cancer. Gynecol Oncol. 2005 Jan; 96(1):168-72. PMID: 15589596.
      View in: PubMed
    496. Bhoola SM, Coleman RL, Herzog T, Morris R, Bryant C, Estes JM, Alvarez RD. Retrospective analysis of weekly topotecan as salvage therapy in relapsed ovarian cancer. Gynecol Oncol. 2004 Dec; 95(3):564-9. PMID: 15581964.
      View in: PubMed
    497. Coleman RE. The role of bisphosphonates in breast cancer. Breast. 2004 Dec; 13 Suppl 1:S19-28. PMID: 15585379.
      View in: PubMed
    498. Moschos E, Coleman RL. Acquiring laparoscopic skill proficiency: does orientation matter? Am J Obstet Gynecol. 2004 Nov; 191(5):1782-7. PMID: 15547564.
      View in: PubMed
    499. Munkarah AR, Coleman RL. Critical evaluation of secondary cytoreduction in recurrent ovarian cancer. Gynecol Oncol. 2004 Nov; 95(2):273-80. PMID: 15491746.
      View in: PubMed
    500. Coleman R, Heidenreich A, Bell R. Managing metastatic bone disease: three case studies. Semin Oncol. 2004 Oct; 31(5 Suppl 10):83-6. PMID: 15490382.
      View in: PubMed
    501. Conte P, Coleman R. Bisphosphonates in the treatment of skeletal metastases. Semin Oncol. 2004 Oct; 31(5 Suppl 10):59-63. PMID: 15490377.
      View in: PubMed
    502. Rao GG, Skinner E, Gehrig PA, Duska LR, Coleman RL, Schorge JO. Surgical staging of ovarian low malignant potential tumors. Obstet Gynecol. 2004 Aug; 104(2):261-6. PMID: 15291997.
      View in: PubMed
    503. Drake RD, Lin WM, King M, Farrar D, Miller DS, Coleman RL. Oral dexamethasone attenuates Doxil-induced palmar-plantar erythrodysesthesias in patients with recurrent gynecologic malignancies. Gynecol Oncol. 2004 Aug; 94(2):320-4. PMID: 15297168.
      View in: PubMed
    504. Leonard RC, Lind M, Twelves C, Coleman R, van Belle S, Wilson C, Ledermann J, Kennedy I, Barrett-Lee P, Perren T, Verrill M, Cameron D, Foster E, Yellowlees A, Crown J. Conventional adjuvant chemotherapy versus single-cycle, autograft-supported, high-dose, late-intensification chemotherapy in high-risk breast cancer patients: a randomized trial. J Natl Cancer Inst. 2004 Jul 21; 96(14):1076-83. PMID: 15265969.
      View in: PubMed
    505. Bottomley A, Biganzoli L, Cufer T, Coleman RE, Coens C, Efficace F, Calvert HA, Gamucci T, Twelves C, Fargeot P, Piccart M. Randomized, controlled trial investigating short-term health-related quality of life with doxorubicin and paclitaxel versus doxorubicin and cyclophosphamide as first-line chemotherapy in patients with metastatic breast cancer: European Organization for Research and Treatment of Cancer Breast Cancer Group, Investigational Drug Branch for Breast Cancer and the New Drug Development Group Study. J Clin Oncol. 2004 Jul 01; 22(13):2576-86. PMID: 15226325.
      View in: PubMed
    506. Daley AJ, Mutrie N, Crank H, Coleman R, Saxton J. Exercise therapy in women who have had breast cancer: design of the Sheffield women's exercise and well-being project. Health Educ Res. 2004 Dec; 19(6):686-97. PMID: 15198998.
      View in: PubMed
    507. Brown JE, Neville-Webbe H, Coleman RE. The role of bisphosphonates in breast and prostate cancers. Endocr Relat Cancer. 2004 Jun; 11(2):207-24. PMID: 15163299.
      View in: PubMed
    508. Coleman RE. Hormone- and chemotherapy-induced bone loss in breast cancer. Oncology (Williston Park). 2004 May; 18(5 Suppl 3):16-20. PMID: 15202583.
      View in: PubMed
    509. Sartor O, Reid RH, Hoskin PJ, Quick DP, Ell PJ, Coleman RE, Kotler JA, Freeman LM, Olivier P. Samarium-153-Lexidronam complex for treatment of painful bone metastases in hormone-refractory prostate cancer. Urology. 2004 May; 63(5):940-5. PMID: 15134985.
      View in: PubMed
    510. Delin JB, Miller DS, Coleman RL. Other primary malignancies in patients with uterine corpus malignancy. Am J Obstet Gynecol. 2004 May; 190(5):1429-31. PMID: 15167859.
      View in: PubMed
    511. Cuzick J, Buzdar A, Baum M, Bianco R, Coleman R, Constenla M, Distler W, Dowsett M, Forbes J, Guastalla JP, Houghton J, Williams N, Howell A, Locker G, MacKey J, Sainsbury R, Tobias J. Adjuvant use of anastrozole in breast cancer. J Clin Oncol. 2004 Apr 15; 22(8):1524-6; author reply 1526-7. PMID: 15084628.
      View in: PubMed
    512. Coombes RC, Hall E, Gibson LJ, Paridaens R, Jassem J, Delozier T, Jones SE, Alvarez I, Bertelli G, Ortmann O, Coates AS, Bajetta E, Dodwell D, Coleman RE, Fallowfield LJ, Mickiewicz E, Andersen J, Lønning PE, Cocconi G, Stewart A, Stuart N, Snowdon CF, Carpentieri M, Massimini G, Bliss JM, van de Velde C. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med. 2004 Mar 11; 350(11):1081-92. PMID: 15014181.
      View in: PubMed
    513. Schorge JO, Lea JS, Elias KJ, Rajanbabu R, Coleman RL, Miller DS, Ashfaq R. P16 as a molecular biomarker of cervical adenocarcinoma. Am J Obstet Gynecol. 2004 Mar; 190(3):668-73. PMID: 15041997.
      View in: PubMed
    514. Santoso JT, Cannada T, O'Farrel B, Alladi K, Coleman RL. Subjective versus objective nutritional assessment study in women with gynecological cancer: a prospective cohort trial. Int J Gynecol Cancer. 2004 Mar-Apr; 14(2):220-3. PMID: 15086719.
      View in: PubMed
    515. Santoso JT, Schwertner B, Coleman RL, Hannigan EV. Tumor board in gynecologic oncology. Int J Gynecol Cancer. 2004 Mar-Apr; 14(2):206-9. PMID: 15086716.
      View in: PubMed
    516. Lea JS, Coleman R, Kurien A, Schorge JO, Miller DS, Minna JD, Muller CY. Aberrant p16 methylation is a biomarker for tobacco exposure in cervical squamous cell carcinogenesis. Am J Obstet Gynecol. 2004 Mar; 190(3):674-9. PMID: 15041998.
      View in: PubMed
    517. Coleman RL. Primary vaginal melanoma: a rare and problematic clinical entity. Ann Surg Oncol. 2004 Jan; 11(1):4-6. PMID: 14699024.
      View in: PubMed
    518. Coleman RE. Bisphosphonates: clinical experience. Oncologist. 2004; 9 Suppl 4:14-27. PMID: 15459426.
      View in: PubMed
    519. Rosen LS, Gordon DH, Dugan W, Major P, Eisenberg PD, Provencher L, Kaminski M, Simeone J, Seaman J, Chen BL, Coleman RE. Zoledronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesion. Cancer. 2004 Jan 01; 100(1):36-43. PMID: 14692022.
      View in: PubMed
    520. Lea JS, Coleman RL, Garner EO, Duska LR, Miller DS, Schorge JO. Adenosquamous histology predicts poor outcome in low-risk stage IB1 cervical adenocarcinoma. Gynecol Oncol. 2003 Dec; 91(3):558-62. PMID: 14675676.
      View in: PubMed
    521. Rosen LS, Gordon D, Kaminski M, Howell A, Belch A, Mackey J, Apffelstaedt J, Hussein MA, Coleman RE, Reitsma DJ, Chen BL, Seaman JJ. Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial. Cancer. 2003 Oct 15; 98(8):1735-44. PMID: 14534891.
      View in: PubMed
    522. Schorge JO, Lea JS, Farrar DF, King MR, Coleman RL, Miller DS. Management of low-risk gestational trophoblastic neoplasia in indigent women. J Reprod Med. 2003 Oct; 48(10):780-4. PMID: 14628732.
      View in: PubMed
    523. Corton MM, Wai CY, Vakili B, Boreham MK, Schaffer JI, Coleman RL. A comprehensive pelvic dissection course improves obstetrics and gynecology resident proficiency in surgical anatomy. Am J Obstet Gynecol. 2003 Sep; 189(3):647-51. PMID: 14526284.
      View in: PubMed
    524. Santoso JT, Lucci JA, Coleman RL, Schafer I, Hannigan EV. Saline, mannitol, and furosemide hydration in acute cisplatin nephrotoxicity: a randomized trial. Cancer Chemother Pharmacol. 2003 Jul; 52(1):13-8. PMID: 12719883.
      View in: PubMed
    525. Schorge JO, Lea JS, Garner EO, Duska LR, Miller DS, Coleman RL. Cervical adenocarcinoma survival among Hispanic and white women: a multicenter cohort study. Am J Obstet Gynecol. 2003 Mar; 188(3):640-4. PMID: 12634634.
      View in: PubMed
    526. Chan SY, Gordon AN, Coleman RE, Hall JB, Berger MS, Sherman ML, Eten CB, Finkler NJ. A phase 2 study of the cytotoxic immunoconjugate CMB-401 (hCTM01-calicheamicin) in patients with platinum-sensitive recurrent epithelial ovarian carcinoma. Cancer Immunol Immunother. 2003 Apr; 52(4):243-8. PMID: 12669249.
      View in: PubMed
    527. Djulbegovic B, Coleman R, Stahel R, Singh D, Lyman G. Evidence-based oncology in cancer treatment reviews. Cancer Treat Rev. 2003 Feb; 29(1):45-50. PMID: 12633579.
      View in: PubMed
    528. Coleman RE. Current and future status of adjuvant therapy for breast cancer. Cancer. 2003 Feb 01; 97(3 Suppl):880-6. PMID: 12548590.
      View in: PubMed
    529. Body JJ, Greipp P, Coleman RE, Facon T, Geurs F, Fermand JP, Harousseau JL, Lipton A, Mariette X, Williams CD, Nakanishi A, Holloway D, Martin SW, Dunstan CR, Bekker PJ. A phase I study of AMGN-0007, a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma related bone metastases. Cancer. 2003 Feb 01; 97(3 Suppl):887-92. PMID: 12548591.
      View in: PubMed
    530. Biganzoli L, Cufer T, Bruning P, Coleman RE, Duchateau L, Rapoport B, Nooij M, Delhaye F, Miles D, Sulkes A, Hamilton A, Piccart M. Doxorubicin-paclitaxel: a safe regimen in terms of cardiac toxicity in metastatic breast carcinoma patients. Results from a European Organization for Research and Treatment of Cancer multicenter trial. Cancer. 2003 Jan 01; 97(1):40-5. PMID: 12491503.
      View in: PubMed
    531. Vlahou A, Schorge JO, Gregory BW, Coleman RL. Diagnosis of Ovarian Cancer Using Decision Tree Classification of Mass Spectral Data. J Biomed Biotechnol. 2003; 2003(5):308-314. PMID: 14688417.
      View in: PubMed
    532. Coleman RE. Efficacy of zoledronic acid and pamidronate in breast cancer patients: a comparative analysis of randomized phase III trials. Am J Clin Oncol. 2002 Dec; 25(6 Suppl 1):S25-31. PMID: 12562048.
      View in: PubMed
    533. Coleman RE. Future directions in the treatment and prevention of bone metastases. Am J Clin Oncol. 2002 Dec; 25(6 Suppl 1):S32-8. PMID: 12562049.
      View in: PubMed
    534. Coleman RE. Bisphosphonates for the prevention of bone metastases. Semin Oncol. 2002 Dec; 29(6 Suppl 21):43-9. PMID: 12584694.
      View in: PubMed
    535. Coleman RL. Vulvar lymphatic mapping: coming of age? Ann Surg Oncol. 2002 Nov; 9(9):823-5. PMID: 12417500.
      View in: PubMed
    536. Lea JS, Shin CH, Sheets EE, Coleman RL, Gehrig PA, Duska LR, Miller DS, Schorge JO. Endocervical curettage at conization to predict residual cervical adenocarcinoma in situ. Gynecol Oncol. 2002 Oct; 87(1):129-32. PMID: 12468353.
      View in: PubMed
    537. Brown JE, Coleman RE. Assessment of the effects of breast cancer on bone and the response to therapy. Breast. 2002 Oct; 11(5):375-85. PMID: 14965699.
      View in: PubMed
    538. Romanska HM, Polak JM, Coleman RA, James RS, Harmer DW, Allen JC, Bishop AE. iNOS gene upregulation is associated with the early proliferative response of human lung fibroblasts to cytokine stimulation. J Pathol. 2002 Jul; 197(3):372-9. PMID: 12115884.
      View in: PubMed
    539. Coleman RE. The clinical use of bone resorption markers in patients with malignant bone disease. Cancer. 2002 May 15; 94(10):2521-33. PMID: 12173317.
      View in: PubMed
    540. Barranger E, Grahek D, Cortez A, Uzan S, Darai E. Laparoscopic sentinel node procedure in patients with cervical cancer. J Clin Oncol. 2002 May 15; 20(10):2602-3; author reply 2603. PMID: 12011139.
      View in: PubMed
    541. Muller CY, Coleman RL, Toler K, Gibbons D, Ashfaq R, Voet RL. Adequacy of oophorectomy at the time of gynecologic surgery. Int J Gynaecol Obstet. 2002 Apr; 77(1):23-9. PMID: 11929652.
      View in: PubMed
    542. Coleman RL, Muller CY. Effects of a laboratory-based skills curriculum on laparoscopic proficiency: a randomized trial. Am J Obstet Gynecol. 2002 Apr; 186(4):836-42. PMID: 11967517.
      View in: PubMed
    543. Coleman RL, Mahoney NM, Hatch KD. Laparoscopic management of urolithiasis in a continent urostomy. Gynecol Oncol. 2002 Mar; 84(3):473-8. PMID: 11855892.
      View in: PubMed
    544. Levenback C, Coleman RL, Burke TW, Lin WM, Erdman W, Deavers M, Delpassand ES. Lymphatic mapping and sentinel node identification in patients with cervix cancer undergoing radical hysterectomy and pelvic lymphadenectomy. J Clin Oncol. 2002 Feb 01; 20(3):688-93. PMID: 11821449.
      View in: PubMed
    545. Coleman RL. Emerging role of topotecan in front-line treatment of carcinoma of the ovary. Oncologist. 2002; 7 Suppl 5:46-55. PMID: 12324633.
      View in: PubMed
    546. Lea JS, Sheets EE, Wenham RM, Duska LR, Coleman RL, Miller DS, Schorge JO. Stage IIB-IVB cervical adenocarcinoma: prognostic factors and survival. Gynecol Oncol. 2002 Jan; 84(1):115-9. PMID: 11748986.
      View in: PubMed
    547. Ashford RU, McCloskey EV, Purohit OP, Ingram CE, Grimer RJ, Coleman RE. Ten-Year Follow-Up of a Patient with Metastatic Ewing's Sarcoma of the Pelvis. Sarcoma. 2002; 6(4):131-3. PMID: 18521349.
      View in: PubMed
    548. Brown JE, Coleman RE. The present and future role of bisphosphonates in the management of patients with breast cancer. Breast Cancer Res. 2002; 4(1):24-9. PMID: 11879556.
      View in: PubMed
    549. Levenback C, Coleman RL, Burke TW, Bodurka-Bevers D, Wolf JK, Gershenson DM. Intraoperative lymphatic mapping and sentinel node identification with blue dye in patients with vulvar cancer. Gynecol Oncol. 2001 Nov; 83(2):276-81. PMID: 11606084.
      View in: PubMed
    550. Schorge JO, Mahoney NM, Miller DS, Coleman RL, Muller CY, Euhus DM, Tomlinson GE. Germline BRCA1-2 mutations in non-Ashkenazi families with double primary breast and ovarian cancer. Gynecol Oncol. 2001 Nov; 83(2):383-7. PMID: 11606101.
      View in: PubMed
    551. Gore M, ten Bokkel Huinink W, Carmichael J, Gordon A, Davidson N, Coleman R, Spaczynski M, Héron JF, Bolis G, Malmström H, Malfetano J, Scarabelli C, Vennin P, Ross G, Fields SZ. Clinical evidence for topotecan-paclitaxel non--cross-resistance in ovarian cancer. J Clin Oncol. 2001 Apr 01; 19(7):1893-900. PMID: 11283120.
      View in: PubMed
    552. O'Boyle JD, Coleman RL, Bernstein SG, Lifshitz S, Muller CY, Miller DS. Intraoperative lymphatic mapping in cervix cancer patients undergoing radical hysterectomy: A pilot study. Gynecol Oncol. 2000 Nov; 79(2):238-43. PMID: 11063651.
      View in: PubMed
    553. Von Gruenigen VE, Coleman RL, Li AJ, Heard MC, Miller DS, Hemsell DL. Bacteriology and treatment of malodorous lower reproductive tract in gynecologic cancer patients. Obstet Gynecol. 2000 Jul; 96(1):23-7. PMID: 10862836.
      View in: PubMed
    554. Muller CY, Coleman RL, Adams WP. Laparoscopy in patients following transverse rectus abdominis myocutaneous flap reconstruction. Obstet Gynecol. 2000 Jul; 96(1):132-5. PMID: 10928902.
      View in: PubMed
    555. Levenback C, Coleman RL, Ansink A, van der Zee AG. Re: Terada et al.: Sentinel node dissection and ultrastaging in squamous cell cancer of the vulva. Gynecol Oncol 76:40-44, 2000. Gynecol Oncol. 2000 Jun; 77(3):484-5. PMID: 10831370.
      View in: PubMed
    556. Coleman RL, Santoso JT. Vulvar carcinoma. Curr Treat Options Oncol. 2000 Jun; 1(2):177-90. PMID: 12057056.
      View in: PubMed
    557. Santoso JT, Canada T, Latson B, Aaaadi K, Lucci JA, Coleman RL. Prognostic nutritional index in relation to hospital stay in women with gynecologic cancer. Obstet Gynecol. 2000 Jun; 95(6 Pt 1):844-6. PMID: 10831978.
      View in: PubMed
    558. Powell JL, Joseph DB. Abdominal sacral colpopexy in patients with gynecologic cancer and "Burch" not "Birch". Gynecol Oncol. 2000 Jun; 77(3):483-4. PMID: 10831367.
      View in: PubMed
    559. Lin WM, Michalopulos EA, Dhurander N, Cheng PC, Robinson W, Ashfaq R, Coleman RL, Muller CY. Allelic loss and microsatellite alterations of chromosome 3p14.2 are more frequent in recurrent cervical dysplasias. Clin Cancer Res. 2000 Apr; 6(4):1410-4. PMID: 10778971.
      View in: PubMed
    560. Coleman RL, Lindberg G, Muller CY, Miller DS, Hameed A. Ectopic production and localization of beta-human chorionic gonadotropin in lymphoepithelioma-like carcinoma of the cervix: a case report. Int J Gynecol Pathol. 2000 Apr; 19(2):179-82. PMID: 10782417.
      View in: PubMed
    561. Hameed A, Coleman RL. Fine-needle aspiration cytology of primary granulosa cell tumor of the adrenal gland: a case report. Diagn Cytopathol. 2000 Feb; 22(2):107-9. PMID: 10649522.
      View in: PubMed
    562. von Gruenigen VE, Coleman RL, King MR, Miller DS. Abdominal compartment syndrome in gynecologic surgery. Obstet Gynecol. 1999 Nov; 94(5 Pt 2):830-2. PMID: 10546746.
      View in: PubMed
    563. Hameed A, Miller DS, Muller CY, Coleman RL, Albores-Saavedra J. Frequent expression of beta-human chorionic gonadotropin (beta-hCG) in squamous cell carcinoma of the cervix. Int J Gynecol Pathol. 1999 Oct; 18(4):381-6. PMID: 10542948.
      View in: PubMed
    564. Coleman RL, Whitten CW, O'Boyle J, Sidhu B. Unexplained decrease in measured oxygen saturation by pulse oximetry following injection of Lymphazurin 1% (isosulfan blue) during a lymphatic mapping procedure. J Surg Oncol. 1999 Feb; 70(2):126-9. PMID: 10084657.
      View in: PubMed
    565. Santoso JT, Lucci JA, Coleman RL, Hatch S, Wong P, Miller D, Mathis JM. Does glutamine supplementation increase radioresistance in squamous cell carcinoma of the cervix? Gynecol Oncol. 1998 Dec; 71(3):359-63. PMID: 9887231.
      View in: PubMed
    566. von Gruenigen VE, Santoso JT, Coleman RL, Muller CY, Miller DS, Mathis JM. In vivo studies of adenovirus-based p53 gene therapy for ovarian cancer. Gynecol Oncol. 1998 Jun; 69(3):197-204. PMID: 9648587.
      View in: PubMed
    567. Santoso JT, Coleman RL, Voet RL, Bernstein SG, Lifshitz S, Miller D. Pathology slide review in gynecologic oncology. Obstet Gynecol. 1998 May; 91(5 Pt 1):730-4. PMID: 9572220.
      View in: PubMed
    568. Coleman RL, Miller DS. Topotecan in the treatment of gynecologic cancer. Semin Oncol. 1997 Dec; 24(6 Suppl 20):S20-55-S20-63. PMID: 9425962.
      View in: PubMed
    569. Coleman RL. Prediction of residual neoplasia in hysterectomy specimens among women previously treated by cervical conization. Gynecol Oncol. 1997 Aug; 66(2):336-7. PMID: 9264588.
      View in: PubMed
    570. Bulusu VR, Allerton R. Paclitaxel in advanced ovarian cancer: too much optimism? Gynecol Oncol. 1997 Aug; 66(2):335-6. PMID: 9264587.
      View in: PubMed
    571. Coleman RL, Bagnell KG, Townley PM. Carboplatin and short-infusion paclitaxel in high-risk and advanced-stage ovarian carcinoma. Cancer J Sci Am. 1997 Jul-Aug; 3(4):246-53. PMID: 9263631.
      View in: PubMed
    572. ten Bokkel Huinink W, Gore M, Carmichael J, Gordon A, Malfetano J, Hudson I, Broom C, Scarabelli C, Davidson N, Spanczynski M, Bolis G, Malmström H, Coleman R, Fields SC, Heron JF. Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer. J Clin Oncol. 1997 Jun; 15(6):2183-93. PMID: 9196130.
      View in: PubMed
    573. Burke TW, Levenback C, Coleman RL, Morris M, Silva EG, Gershenson DM. Surgical therapy of T1 and T2 vulvar carcinoma: further experience with radical wide excision and selective inguinal lymphadenectomy. Gynecol Oncol. 1995 May; 57(2):215-20. PMID: 7729737.
      View in: PubMed
    574. Coleman RL, Keeney ED, Freedman RS, Burke TW, Eifel PJ, Rutledge FN. Radical hysterectomy for recurrent carcinoma of the uterine cervix after radiotherapy. Gynecol Oncol. 1994 Oct; 55(1):29-35. PMID: 7959262.
      View in: PubMed
    575. Lynch HT, Lynch J, Conway T, Watson P, Coleman RL. Familial aggregation of carcinoma of the endometrium. Am J Obstet Gynecol. 1994 Jul; 171(1):24-7. PMID: 8030707.
      View in: PubMed
    576. Coleman RL, Burke TW, Morris M, Eifel PJ, Hallum AV, Wallace S, Tornos C. Intraoperative radiographs to confirm the adequacy of lymph node resection in patients with suspicious lymphangiograms. Gynecol Oncol. 1993 Dec; 51(3):362-7. PMID: 8112646.
      View in: PubMed
    577. Coleman RL, Schink JC, Miller DS, Bauer KD, August CZ, Rademaker AW, Lurain JR. DNA flow cytometric analysis of clinical stage I endometrial carcinomas with lymph node metastases. Gynecol Oncol. 1993 Jul; 50(1):20-4. PMID: 8349159.
      View in: PubMed
    578. Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1). The Lancet Oncology. 18:75-87.
    579. Lower extremity lymphedema. Women's Oncology Review. 2:269-276.
    580. Vaginal reconstruction in gynecologic oncology. Women's Oncology Review. 2:13-18.
    581. PTEN loss is a context-dependent outcome determinant in obese and non-obese endometrioid endometrial cancer patients. Molecular Oncology. 9:1694-1703.
    582. Topotecan in the treatment of gynecologic cancer. Seminars in Oncology. 24.
    583. Radical hysterectomy for recurrent carcinoma of the uterine cervix after radiotherapy. ACOG Current Journal Review. 8:32.
    584. Moving beyond the platinum sensitive/resistant paradigm for patients with recurrent ovarian cancer. Gynecologic Oncology.
    585. PTEN expression as a predictor of response to focal adhesion kinase inhibition in uterine cancer. Molecular Cancer Therapeutics. 14:1466-1475.
    586. A pilot study of laparoscopic extraperitoneal lymph node dissection in patients with locally advanced cervical cancer. Clinical Ovarian Cancer. 3:113-117.
    587. Characteristics of 10-year survivors of high-grade serous ovarian carcinoma. Gynecologic Oncology.
    588. Continuous anti-angiogenic therapy after tumor progression in patients with recurrent high-grade epithelial ovarian cancer. Oncotarget. 7:35132-35143.
    589. Neoadjuvant chemotherapy for newly diagnosed, advanced ovarian cancer. Journal of Clinical Oncology. 34:3460-3473.
    590. Should dose-dense paclitaxel in combination with carboplatin be the new standard for treatment for suboptimally debulked patients or patients treated with neoadjuvant chemotherapy?. Clinical Ovarian and other Gynecologic Cancer. 5:51-52.
    591. Evaluation of rucaparib and companion diagnostics in the PARP inhibitor landscape for recurrent ovarian cancer therapy. Future Oncology. 12:1439-1456.
    592. Anti-angiopoietin therapy with trebananib for recurrent ovarian cancer (TRINOVA-1). Obstetrical and Gynecological Survey. 69:661-662.
    593. Molecular pathways. Clinical Cancer Research. 21:955-961.
    594. Folate receptor-targeted therapeutics for ovarian cancer. Drugs of the Future. 41:137-143.
    595. Virologic versus cytologic triage of women with equivocal Pap smears. Women's Oncology Review. 4:107-108.
    596. SGO guidance document for clinical trial designs in ovarian cancer. Gynecologic Oncology. 135:3-7.
    597. Randomized phase II trial of seribantumab in combination with paclitaxel in patientswith advanced platinum-resistant or -refractory ovarian cancer. Journal of Clinical Oncology. 34:4345-4353.
    598. Effects of music relaxation video on pain and anxiety for women with gynaecological cancer receiving intracavitary brachytherapy. Journal of Research in Nursing. 20:129-144.
    599. Addition of bevacizumab to paclitaxel/carboplatin in first-line management of advanced ovarian cancer. Clinical Ovarian Cancer. 3.
    600. Extensive cutaneous metastases of ovarian cancer after prolonged response to liposomal doxorubicin. Gynecologic Oncology Case Reports. 5:64-66.
    601. Neoadjuvant chemotherapy for newly diagnosed, advanced ovarian cancer. Obstetrical and Gynecological Survey. 71:717-718.
    602. Erratum. Gynecologic Oncology. 130:252-253.
    603. Targeted Therapy and Molecular Genetics. 539-560.
    604. Ovarian Cancer Staging. Operative Techniques in General Surgery. 9:53-60.
    605. Current challenges and future directions in the management of ovarian cancer. Clinical Ovarian Cancer. 3:81-97.
    606. Randomized phase II evaluation of bevacizumab versus bevacizumab plus fosbretabulin in recurrent ovarian, tubal, or peritoneal carcinoma. Journal of Clinical Oncology. 34:2279-2286.
    607. Invasive Cancer of the Vagina. 245-259.
    608. Pelvic irradiation with concurrent chemotherapy versus pelvic for high-risk cervical cancer. Women's Oncology Review. 4:127-128.
    609. Targeting angiogenesis. Translational Cancer Research. 4:70-83.
    610. Final results of a phase 3 study of trebananib plus weekly paclitaxel in recurrent ovarian cancer (TRINOVA-1). Gynecologic Oncology. 143:27-34.
    611. Preclinical and clinical development of siRNA-based therapeutics. Advanced Drug Delivery Reviews.
    612. Ovarian cancer. 85-96.
    613. Sequencing of mutational hotspots in cancer-related genes in small cell neuroendocrine cervical cancer. Gynecologic Oncology.
    614. Dll4 Inhibition plus Aflibercept markedly reduces ovarian tumor growth. Molecular Cancer Therapeutics. 15:1344-1352.
    615. Corrigendum to "Sequencing of mutational hotspots in cancer-related genes in small cell neuroendocrine cervical cancer" [Gynecol. Oncol. 141 (2016) 588-591]. Gynecologic Oncology.
    616. Dual metronomic chemotherapy with nab-paclitaxel and topotecan has potent antiangiogenic activity in ovarian cancer. Molecular Cancer Therapeutics. 14:2677-2686.
    617. Efficacy of intraperitoneal adenovirus-mediated p53 gene therapy in ovarian cancer. International Journal of Gynecological Cancer. 9:365-372.
    618. Gynecologic malignancy. 447-452.
    619. Ovarian Cancer. 667-674.
    620. Role of video-assisted thoracoscopy in advanced ovarian cancer. International Journal of Gynecological Cancer. 26:801-806.
    621. Gynecologic cancer. Journal of Gynecologic Oncology Nursing. 21:18-21.
    622. Carcinoma of the uterine cervix. Clinical Consultations in Obstetrics and Gynecology. 7:141-146.
    623. Saving the best treatment for last?. Annals of Oncology. 27:1656-1658.
    624. Intraperitoneal chemotherapy. American Journal of Oncology Review. 5.
    625. PRO. Clinical Ovarian Cancer. 4:1-3.
    626. Editorial. Women's Oncology Review. 6:119.
    627. Olaparib monotherapy in patients with advanced relapsed ovarian cancer and a germline BRCA1/2 mutation. Annals of Oncology. 27:1013-1019.
    628. Preface. Cancer Metastasis - Biology and Treatment. 21.
    629. Equivalency challenge. Gynecologic Oncology. 141:357-363.
    630. Venous thromboembolism (VTE) rates following the implementation of extended duration prophylaxis for patients undergoing surgery for gynecologic malignancies. Obstetrical and Gynecological Survey. 68:439-440.
    631. Neoadjuvant chemotherapy for newly diagnosed, advanced ovarian cancer. Gynecologic Oncology. 143:3-15.
    632. XPO1/CRM1 inhibition causes antitumor effects by mitochondrial accumulation of eIF5A. Clinical Cancer Research. 21:3286-3297.
    633. Validation of a second-generation multivariate index assay for malignancy risk of adnexal masses. American Journal of Obstetrics and Gynecology.
    634. Erratum. Cancer Journal from Scientific American. 3:314.
    635. Gynecologic Oncology. 144:448.
    636. Surgical cytoreduction for ovarian cancer. Oncology. 22.
    637. Bowel complications of gynecologic surgery. Clinical Consultations in Obstetrics and Gynecology. 8:91-99.
    638. Anti-vascular therapies in ovarian cancer. Cancer and Metastasis Reviews. 34:19-40.
    639. Health-related quality of life in women with recurrentovarian cancer receiving paclitaxel plus trebananib orplacebo (TRINOVA-1). Annals of Oncology. 27:1006-1013.
    640. The emerging role of laparoscopy in bowel surgery. Operative Techniques in Gynecologic Surgery. 6:105-112.
    641. Combination therapy with topotecan, paclitaxel, and bevacizumab improves progression-free survival in recurrent small cell neuroendocrine carcinoma of the cervix. Gynecologic Oncology. 144:46-50.
    642. Sister Society Meeting on Global Education Development and Collaboration. International Journal of Gynecological Cancer. 26:1186-1188.
    643. International Gynecologic Cancer Society (IGCS) 2014. Gynecologic Oncology. 136:185-188.
    644. Invasive Cancer of the Vagina and Urethra. 265-281.
    645. Clinical impact of selective and nonselective beta-blockers on survival in patients with ovarian cancer. Cancer. 121:3444-3451.
    646. The 41st annual meeting on women's cancer conducted by the society of gynecologic oncologists. Clinical Ovarian Cancer. 3:9-13.
    647. Diagnosis of Ovarian Cancer Using Decision Tree Classification of Mass Spectral Data. Journal of Biomedicine and Biotechnology. 2003:308-314.
    648. Individualized Medicine in Ovarian Cancer. Gynecologic Oncology. 144:229-231.
    649. Editorial. Women's Oncology Review. 3:1.
    650. Erythropoietin Stimulates Tumor Growth via EphB4. Cancer Cell. 28:610-622.
    651. Introduction. Operative Techniques in Gynecologic Surgery. 6:49.
    652. Is it equivalent? Evaluation of the clinical activity of single agent Lipodox® compared to single agent Doxil® in ovarian cancer treatment. Journal of Oncology Pharmacy Practice. 22:599-604.
    653. Stress and the spread of ovarian cancer in mice. Cancer Biology and Therapy. 5:898.
    654. Depression, correlates of depression, and receipt of depression care among low-income women with breast or gynecologic cancer. Women's Oncology Review. 5:227-228.
    655. Targeting the tumour microenvironment in ovarian cancer. European Journal of Cancer. 56:131-143.
    656. Obesity and endometrial cancer. Alternative Therapies in Womens Health. 8:70.
    657. Making of a Phase III study in recurrent ovarian cancer. Clinical Ovarian Cancer. 1:78-80.
    658. Anti-angiogenic agents in ovarian cancer. Annals of Oncology. 27:i33-i39.
    COLEMAN's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    _
    Co-Authors Expand Description
    _
    Similar People Expand Description
    _
    Same Department Expand Description